var title_f40_6_41056="Skin biopsy Stills dermis";
var content_f40_6_41056=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F72353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F72353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skin biopsy of adult Still's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 367px; height: 245px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD1AW8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDjZ4zLMAAfSteYLZWCRxfecgn6UyERxRSzP0QZqD7Wbm3cyEeYj7cf7J6f1ritd3fQ+rb5rJFm6jAEUiAmaIBXX1HrWpaTedbsIiUkAyoPrVC1YSXkbuAW6fQ1ZicW18yv9zdkH0qLfgZyV9CNV+1SrcQKqzZ+dF4/EVNHqM8cmwqGYdmWkKGDezLlScqRVO9h+1IxiLC4LZBz7cU0lezFZNGwL4tIUnjCH1p8tuXztYH6GsTwSmpNZXEOtI7BG/dvJ1I7jNbNuyQ3EgAwCAOtTJWbS6GUXpdaGfdwyxzBAeCMjA5q/b3QliAbbknGDUl66GISFsBcHPpWekcU16pAKr5q428dQadurL+JajCQZpCp4IKn65quNsd3bs4wPMx+ef8AGtXU7aOCQSR8I+Tis28BaEvjlHzT0ZrB8yNOefyZVUDdub7vsKzNeJU+WFUyOdxHp7GrELtJrLtnKou7HbJAp/2YXV7M7/MMck9z/hRoiUuVlPQI5wX2nCDgn1bvW8qxxIVZgGY5JJ61kjUrK31KHTjuWXJVSv3d2On1qe4TyThkyeoxSae8iG+d6E88W0EkH65qO1UnfgNsHOT6060G2OR2ZWBAO30pLW5Sa5MfmL8i5ZQfypajvoTWsaArJKNrc4B7jNYurBZb13Ug884rSvGRbmN5CcKuABWW9pMzGQAhGJpx03Lp78xcilNvGY5C0YJCmQDpVDU4pdrtG7ShGyGrSt9zQ3Cyg5EYByc5qlYb0kikILpgbl7EVS0V0Ut2y/E88+lExKQ4wcjjdVa2gmiETtEWld/lUnp3rRivpjO8K2hSNT8rAcYqO/Mkb5SU5fkAn7v0pIhNp2LZktzKSXCynqp6jtUV0odY0ddyE4b8e9YosZ7S+jnuAWM5CjnOMn/9VbkgcGdSPmKghaGl0ElaxmybWuhGpIRFwAfWnWEQfzTIQF3YHPWqOlmU3j7xkYPJ65xV3YwijiPU5yfc1XkavsSLdXLW7SyMBGPkQdyfWnqipoznP76UbuewziorpfstlFAVJ25O49zUscbOhdgVTaFUHvRJ9SbK2gzSN8EG/H/LTk/hWjcwtJKxb5Yx1Y1HHBmxKKxDZ3Y7H/69J9sk3GNdx5xj8KnVkN3k7D7aRTcKsK/u1ByT9KbdySfYDIXb/WcdsinpI6nIQD2NQavdmG0hRkDbzu+mP/10rPoJK8ihpkyxSTM+TtxwPfNXjeTTIscZCSE8A5+761kWkmwSyD1B/HNTRo/mhnc7pDtBPp3qnuaSgtWxxKQzi4kHmYOFB/io1Tzp2F0VKlhyAeo/+tRrd/8A2ZYiSG386QNsUYzU7StLFbyvHtZ4wzKe3HIotZcxHPrZEOmNIqMVIMinco7MPStjcNm9vTPNYjwywskkIzDtyx6Ec9KvJOSuDjPUejClJKRM1fUfs+0NlzmNiDz2qhrLxxFCwCqePrV4jdIsiS/KuAFA9RSaharcxrHgZYYGeg/yKnRMIuzMyEqU8yNegDH2FWpZYpbYcruPHIqGxZILyWIKyqUCqSM1NINsYGFweA6HIP4VTKluV1jJKh3VmxhR681beK53EIibCMYB/pVW0ZI50Py/OdpyemO9TXFupnJYtg8ja1D3E9zBnctbSIORwSPUUmmRg2szg5bIB/pUdszFywAOAWIPsKs6NcW8lxKYDuimXkf3SK115TWUktCwjFJE5wUbHSr12xaUHsyg/SovscgkPcdj61bltvMiUZ2sOuayurktrRkVjc7jscggZBB70t7bm3AktycZyPUH0oitQJFUHDoOfetFolaF4nbGRw3oexqb6kSkk7omsbsXFgJAfm6HPrVJV3SylnUFsBRnms6O4bTrtknUiN/vgf8AoQqxcwM7b4/nRsFSpzQkloLks35kyXGyQxvjB4Hem3LPDAYyR5+4Slh0GDjAprwSrIGkjBYcbj1qHUSfOnJJLeXwfyNUikk2aurkNBCB2zj8qzbgZhbphiKt3TM1mjDrgEflVdk+WIdckEe9StkENECQubtmjbDfMv8AL+lXYoWhYupIOD8uetVG3G7uUAwPmI9+KzzcsmGizkHjPUmqauPlciW40K0u9Qiuy7x3SneVR+M+uK2ZZSUChBvIzsbviqkO2PUYiQ29kLZPUZ7VLcEs7KiMccZBpNtvVmTWpGblpD5ZiCZGCfSsfRtJg0me4umunmklBRVY5x3zWw9tIy85XH945FRx2LMxNxICo5IXvT5rKxVo7lTUdSjt42uriMsFA4x3qHRdfl1K2m8yFBGjYVlPFWbmCKeRo5kBjAyQ3p6VUtYYYYpUhiCQLyFHp6GqvG1ralKN2mLFPLI8nIC85FXNOdAsSbxyCpB4qnFCBdAjISRePpSutul0qiUoqcAEdKJPoa2TOo8siJBnaAOfasrUQBGsnmEjOPpTrC5WaWSJ5VkRuU55BqO9gFtAzOSRvAX6VmlYyirPUvW6oYIPKJeNFyCeTnnNQCR0lMkjMyq2NvUsTVXTtzW9xDGeUZXTHsR/SnXeVhV2z/Ef5VfUajqO0cIdTYEcMxNVb1ntboxnOEYEZpLN2GpwFTkH5s1q6xAjut03zFc8epo2ZTfLIr6rmR7fcf4AT9auJB50nnlz5eAuwdqqbWmtjKy/vF+Yj0FW7SYRxHsO9Jky2sh+oSGNVW32qMZJPNZ0btHcL5eCwPfvxS3t6bpiIYmHHXPXFSSXlvAqNFGJJX6kngewpq6RMYtaWJru7BwsILZOBxjcaz9d8xYLVZmPmAsT9MitGT/VC4jGBs+UehrJ11maW2EhO/yhuz6kmhF01qrEWnwyTRbUAO5jmte2WJNQijzu8pOvvis7Q7kxyyKBkKpDN/dqzYsftsfmgLJIAMZ6CnJWCpdtmiYA7F5xnaM4HcVlw38s1ypKjyycbSvCiugPynHQd6xdRhcXoSEhIuGJHGPXPrWUWZQabsyvFqcdzPJDs/dscYxx9aJEMGVlk3hhhfb0rOvGjtpQsRBPVnxg/SrF63m6Z5m/JI6e/rWltmauNtjR0/H/AAIfKeOv+c1POcPhvkRRuLnvVHQpfOEoOCcZx68U3Ur2DzBp8lwFuJlyIv8ACk4tuxk9JalF5/N1AMmBEMBQR1Petm3Hm8nG3qp71jxw+VOo7hsc9+K0drtdNtbC7eP0ptJoup5EN5b+Rch48FSclT2NKpKbikaFl4yT8o+hNXbgq1s8x4JYAn0rJmzcOkYfCDJx7etJBHXcrWtsAXGRkrj8xVPR9PNneN5e7epyUPQe1aMUq5HIOfu+w961LQLNN5m75sc8dapycYtCnvdl2Jo1gLyfKiLk5rkNU1Od7gmJyig8LXU6xGf7Nl8vIOQSB3HeuMuk2ruYYY8gGphorlYeCldnQ6HqBuosSAeYDzWk5O7kmub8NhvtIVerDI/Cuqx8uHA3VD0dhVUoy0KOoQC4s/mxvUEqT/L6VX8OvIBLH1UcgehrUK7gRkUyxtlt5G2/xHNNv3SebRofco7xtlgrFTwfWsfMksVuJh+9x5TfUd/yrS1STahwe9ZyXCyodvVWL8++Bj8KtJ2Kgna5qkq2y3bugIPrUItn82MNyqt27ilJURWcxOSeCRU630C4MuUbcVIPtUa9CdVsRRHebplH7wOdh+g6VRuJ7ZUS4QlZG6RgdD3FXoMLcTruGRISPcHBz+tUNVghA85SPn5x2z3q93YqO5oDbI0dwuT8uMdxVe8muPsMrWnEoOF9zU2nSBrUEEYA/MVQ0/VUudRudOAaOaEZzjj/APXSinv2M5aaGZpVrq0M5udSvPLQk5Rjn8Oa15JZHIQSfeGEYDOD7+1ZutW322ZZLqWVY4FOUXqwAz+fGKXw1cS3ltK5g8lUPyDHIXHTJrWTuuYlK3us2NHkmmheK9jCFWwDn7wqZkt4IWjOcMfTmsrRP7Qtoy+rFSxkIQ7uQvY1rpHHckOARtbuOaxlo2VHQ5HxjNeaO1tNbNgR4GSOGHoa1YrddSsoNStvlEoGUPY1oaxEbzzoxGZNoBAx0qnpUg+xT26A7EwwUcEetW5Xil1RrHmvzXI4IHhlZhgshwcGta/u1YLBcxBo2A+YHnPqKyYrlorqNGOQ55bGM1tXi2pSCa5wSPuDtUvQqb1VyroCgTTMSSCdvIx0qbWZTHPAqAHaDkdqngkTzVYSq7FeABjFZ97ci5vgojKsmQW67sUlvclJyncbZDzZ/MAA4OABiql5NNsUl2YLwfzqfT3ZLhsNgZzmqr3TGRops+UW54q0tTVLU2NFZjbSNJyT696fFG0ivFEpbccew/GlskSFSUbejABSf5VtW8aRoFUAD2qG7HPOdm7HN3UbW8wWMqrAZ4GR+NVrMJIT9p+ULyMHlvYVr3sDpqTSom5TjrWXrEOFuJbONm8vBVM9WPUfhVxd1Y0jK6Nm5lR4IioxGSBgdvasHXHD6lJzwmE/Kk0e/nSx/wBJjXzQxIBzxWXqVz5NpLO3zNtL/U0+XWxVOPLqzR09BGzSOfkYb8f3j6VaX97rsRXoCDxVPQlku9BtnuA0cp6D1FXtIA/thlODtyufpTlu0K6cXI6G5dYozI5xiqExSYmaMqxXpkZwfpU2rOPsLsfXAHrVLSGDWU7p9/PfmsUjCKsuYwr0u0wiWOMNkfMgwTUt7OHi8pEJVMZbpk96sECaWRrjIkRsqyrjj+tY+qXE6XyW9nFui3b3f0rWKvodEpJWNTQt63DJkAFcmovEmgtqJhu7Zx9st+RjjK56fhUdhctFeRgDLZxx3Ga3Zp2a6DiNwmNpOOP8ihtxkmjGceZlC03SLbNL94s2TjocDBp9zdomqQ2qFzJKTnaOBgdTWgbdMs6Nv4wFU9KjS1AZpWaONs8lvX0Gam66ibuVLnfHHJE/Kk8nFJYQtA5mkjYgjCDHb1NWicZcjp0z3qlOXwFUkbjkKDmki1qrGPC+YuPUg1raVMFLL19KzY4jHDG+cMRhgfUVPZS7ZypA55qmro0kro6GdgbYgmuM1FjLMxX1xXWMw+z/ADEAHvXLXA2kjjrRBaBhla5c8Mcapbg+jfyrd1C4Vbgcn5eTXP8AhgkaoCeiIxFa108clyzHt396i2rFVV6ly9E4dVdWGzqSfSmrvN51OzGcVlvcMtjcRhQ2MMoAxxmtmylWWKIt94qOT3PelJWMZLlKmoI7MG/gXrxWQUMTl1/1blsewOP8K6e4VXiZV4bGRWCIt6GPOHfIU+lXF3Nac9CtDcTTWkCj7u9gPw7VfSGSeKN2ADkFWBH5GoZVS2W0tojkqjMfUEHP9DW0NsVv5qKQpAIGOD6U5NilPsZyxSQTgODuZAevpx/hT76My2LbsbkcH8DUhna4hildQrRtjj0PFWCpaznU45U4/Kl1E2+pV07y/sIwdo7n0xUJEM+6704QSyE4eSPnp2PvUelqWV4T/EG/lWH8PDOl7qVtLlI0Xcy46HOKpRXK5djOq3GVjr/syOvmSoCzD5huH8qRAqrshTaPQf1rlF0K7j1l7qXUJUtEbdGNxJb2x6Vovqb3UrLaSbGjOGyOKUqavo7kx5mtTKXSNbm11r3UWiWBMhFWT7w7KB/jXYGYwWkDnIJXHTvVZT9ot1SZSO+Q9LfiUaRbxhd3zYPHI60pSc2rjhDl0G2txM9yzZDxNwcdV+vtWbfO9nqbSRcqVyP8KWaG6hSZrfLTbPlKn731rAsbnU5JsalGw+bAJ700tG7nRGylY0o2aW5i34BJyMV0t0YLq1WFmUMh2gHsa56dPIkhAGMpn8e1bS2a3yC6glVWIyyEd+4pPuVUtoylMs1jLhV6gAHqP/r1csma5R2uG5xgErg1fsVxCq3KAyISFye1VJV85cr8vJBoV2Z899ClGqhjt5C9an08xTWZMsSSFVzhhnNMukNpvQrjIyDTLK5NnCshG7d8qg9Caq1ypXa0NiT97DGyAAKeAB0FXNNm8+BXBBB/T61iT6xFbafNc3PIiIXao5JPQVpaK8LWaXUEIh+0AMRWcou1znn2E1i9jglig8xVuJOUBGc+tU5CBGY1ycDjPv3q7Mkct2s7qN8a7d/oD2rE1G5JGxGJ3dSey1UdrF0o30Kl3MoDRxEnP3m9fYVmX8c04gRELCWQJj/Z71r2Ni1zMB0XGSfQVeD7b7yljxbovy5GD9au9mdMmkuVEcMqs8YUYSM424xj2q3YW/l3Mt2VIDscfjUZjBu4tgAGwE471qQOu4hmG0DGMdKhsxnLTQgkYzsIfKDRj5iW7VHe3X9mhfLhUoy5PFWxIssUrwHcVyv4ilEaXMC/dLjkAjODUGaa6mI+plc5jVo26p6H2PeopL+3h3BLJcScMxPr6VPcWMkZPytJ6jHFZ93DEJG5JbjKn+GtFZ9DdRi9iBLbyZ9/m8DBXnnrXR3DMm2bOUdcY9/XFc7BhR+8G9Cpxnt6VeupnTS9+fu7WA7n1P0q5a2YpRsTzTyRyqYSR3PNPMrXDoxwxPA471BakTxKzRkEjk5q15YTasSsZG647Cot3E7IR1Ks6n5iBhR1NSRQgWe4OBJnDMe1Ikh8osQGmUkL6/WoSZI2eJyS7DcR09KlkasYbFJ7JfMXbKoqhAFFwEVCuDgn2q5qV6tm0PPDckUkc0dzdBoduAvI9aNeXUcW9bmmsCXERTqrf3fWuUulxMRz1x+NdPHcx26EllUqMjNZMcH2yB3IxLyTz1NOOi1HRlyt3INCVY9QB/vAr+dXmiMt2Y+VGefpVGzB8xgOGHINdDAI5/32NshXaT60S0ZVV8ruUYY0kumiYfK6449qJrxrCfyEjOw9MVeESW5aZhwoptwI5xFcKm/YCCox09CKE9TK6b12IIrnzgduQ2NwB74piIssjKDtZgSDVWWNQfPsXIkVv9We3tU9xGY50IOwuu4f7LelV6GlktiO5hYzpMfvKcMO/NaEbMLHyXOfLOAe5HaqbXGJEMw25OD6H3rQgkWT515B65/lUsmSaRlSiSFw6j5T1Q/xCtmydJ7ZZM54IOOhNYGp3cjMADjnIAq5plwqXBRchZAGAxxnoacl1KnFuNxbNDb6lgg9yv0pbO1+x/bZnVAzkksByw9TVkITfZ54bj6VZ+SdmA2jZkZpX6Gc3c5HUHuNURJdMmeMxthgcqfw9q37eS3+wojtbtdSKBI2AN7VWjXUV1xlWKN9PPy5GMqak1awR4Gkh+VxypHU47GrbTaRCtuZesm+gs1ezLK8b/Nt5OKq6rrGpwHTn2sEmUF0C9WPc1vRXwjtluXyWC4Ygc5HWpbbVU1FFMEJ8sDPzjn3pqTW8dgaux/np5EcrIRKV4HeqgSO4tZG3FpFIJ3Dmn6mCl4jDhWAxntU9vbB2Z4/k3jEgx1FZLRGqslcpX9v9pKNF2QAY9qqWs9zp7sFjJU+vStJbco8ihsMDwRxn0NWrR90LR3I35HXFU2ac9lbcisLl7qcLKdhxkjNTAMZ/LUfeJPsKlhtIgW8kFWPc1HarcRXwDKdrA5468VNzK99jP1Bvtk+FbJ6/gKrb4rl4UUFtgx8vI/OtC1gRZLpn52KRUItEktkWzVUVWzV301NE1sRaPEbzSb4XK4L3B+U87R2/lWrb3W+eO2Cqi4wMe1TWqJbwwxxrGHnY+YB19zWcIQbpXUkywvjAPX3NJu7MopO9y5eTyRW06EKCzYX3HSsCQEzHP3j29BXTXFsspjV2wA241kiNZL9AgGGbJPsDSiy6UkkzYjVdPslRCBK43OxGfwqiL1JGMV6ozggOlPvySJDgkHkVl2kgy6TLkE5B9KEEY3V2aKhYYy5GX3bPqOoP60yDfKXwyq2dwycc9gKhj850kiI+ZGHB9On8qmMUTwx20bgSoPMLEc+hFOwPsWrZs2AeRjC5J3DGQKqXU0kLLtk/dkZVh0/OrULxyskokbYqtHJuGMnqGqFbUP59vwHPzxn3pbO5MbJ6jrK+3yFbjICpv3dQcVSuLiC4uHARiZSCVb6dBUUc8kQkjcExHMb46f/AK6WxWSO/UPJ+5jwQ/qPTFP0L5UrspyxBJ3iiJKD17H0raa0ie2XncwRQQen0qjfwMl0wU7VDbmA7jNX4J1+ySGNcsuOT6029LhJt2HO8drwY2+XjGP0onljtQ9w5PnkYCE8AkdKzLWe7adwZDjlmHXk9KdJE004aVsgfeJ7mlYXJrqWbeV4oojlA7fMxY+9MaOSeZ2LfP3PSnzNG23bGWKsMkj8qkt3+y3P7wlg6k5Jz39aRN+pgeJOsDDoUArO0+R4Z45UOMHH1q7rrbhsP8AxUmhWwnickZwwNVLRI2i0oakvi3TpL+O28lyrA7iAO1adjlIAjKVmiXJz3FWEu0BZGBBXIGe9U76U58y3ZjlccDrzU3ckk+hzxXQZNCEuBInSQZx6VctGKHI/HFQxN59vGedyqKswocf1oeu5bemo3VZswKgzgnn61BZfPbSQZw7Elfyq3d25kQbcZzmm/ZR5ayZIePLfKeo9KF0EpJRsZ8MTOzLcMwYjAfP3T70Rb5IDBLnzodxwfSpppobi2FzFlXYnO3pn39KZaOZLpJDggnbu9cjpVM0u2rkdu5bdBNhl/hJ/hNMt53tZCpJ25xz2FR3KmG5cD7gbH0B6VJO4mRmP+tUY/wB4U0i7XRbubWO6t1nToxIbHZqy5JPKkTaRuTj8Kv6TMywzRdQRuxVSeGOeR1A2s4yp7g+lC8xRbTcWb9nILiJZ05JyDmmiGNj8h7/N9RVfQpD9hKPlTkrn0NXYk8uF3P8AACxrN6Oxg9GyKFxHORK3Lc7DTNQkKRIFALkZ46g1VtLl7i5/fBXK85FWb5GZQ8JDkHcBjmi2oONnqUJHjtGigbbvVcsD6nk1Bea7baRqlvafZfluj87/AN0HjiorWU3VzMbvBdTlGPT6VLcaZBqFxYySJuaJ8Zz71s+VP3iWm0bNxELorHtO5R8pP8qqRXH2aVlfIUkL071fjIXU2BOMMcD04602Qnad6K7Iw8wnr+FYXLXYhgullYbxymRknqR0H9a0LWJlDu+PLIyM1jwKDqm7BRCc4q5qdyftMNuh/wBpv6U2tQlHohbvUxAJFhUblH61Ba6tNIAWQMq/fxxgU+/tY0jibALFgWPfH+TWdfxRW0G+3mIUttZMcmml2KjGLRvXEMbRExdJzkn8OKp2MC2rqs8nzuchFNNs7kHTNwYvtdTnGO9VrpiNT87BIU9M9u1JLoEYvVFy7DC5hcZ3ITnHfk8flSWaCPVpiwGXHmK3oKs3Sh2V8BlbDcfT/EVXnt5bhoAq4dkZflOOKdxaWsGp3DIVmTkjg88GpbY2wtHnjycnkdx7VHqFqttpkayHc+7B9yaoaZE8cEgOeWA+tK10CSa0NaER3NhPI+QwJz2xWNEAJVDE4ZgPpW1ZLG0MyNJxvJZfaq81kknz2wKEcjccg072YRaV0K8wilKkjyySr5HPNZsNq9nfi9VxKgJDDPJHtWpPaS3EauFUTEYdB0J9jVJbW4iLefFIEHIxyKadhppluaJY45owGkMwyAOgHWqctyfMjlQbXRcY9D6VZ06WUu8Mzq8W3CkDnFUtRVogZUYMM9QOv196QRWtmXr9hPYpIkYZc/Ov9axLrcSJIgxi6Ef3TWtp0hudOcjKyxgke4qqtv8AaiGjchsZK9jT2Y4vlGxTfa9+7qsYyKnmLC0MaEDzHyfp2qutt9maXcT5jgkc9vSr9ugk+zE4CMMlj2703sK6vcdaWyWliGY5ZxuJ7nNVYSsrs07bYxkBRUU8st1nYWWJTgfyqNoIwGDuQFHf1FLzHbuXkHaM7gcYrG0/VBqeo3MDRMj2zEZPAYdPzrY09l+zbhnKjP4VBgRtI4jhErH5iq4z7E96Fpchp8xz985kxj5if1rotItxZ2qRv/rWG4/jWRpEIkuTM4ysYyB71sRyNJOSBjB55pTu2VVd/dRTXcb0K3zIrNux1FNlunnuE2rsRSNoHH+TV2aDynaZThRk8nFNhWOYK64ZCOOOhpt9RRkty4OIQVBBPWiN8jANSwL+72nsaZNb7RvRgFHGKi5CtexLCcqRwaq29z5UpSQ4GSue1PiJBKh18wjgZqNLGbGZyspxjcBjP4U0kCsnqWrC1ggSZFAaOU5KtzVa8njSW2ihRVSOTnHQVLFvTaD2qO7VXkYbDvZQwbJ7e34U99WNb6keowj7WrMBskXBFUbmCSEq6/MP5ituTZc2cTfeI6VGYw9thuxzQn3LjUtoZFq/2ZjcJyoOSv8Asng1LPbsCJVwV+9uHamyLGZZYx0ZSMVnGc/YM723g7GXP9Ku1zW13dFjUGaPSJ7iF2Vgc/L3q74Yupr7To2kdvmABJHao9CgS8sZLe43bCe3UVs6fDHbBYYlCxrwB+NJyTjYwqaMrajJBp8Ek9wFhSM8EDGRmqF7qj29sl7p0JuYs7XTuM+op2rxnV7aWyuTjccowH3COn1FQ+FNIm0sXRublJDId2F5AI+tP3Yq73Id9mUJoEsNFuNXsoZhM4A8uQ/cyeuO+Km8JzMmnQzzOzSyvk7vrXSpJHeAxfKyHjCnP51mQxJbq8ewBQeB2X2FNz5k09xQWpN4kn+wWs05j8zzSFA3Y9zz+FT21wJvKnjU5kUHYfp3pZI7bVtPa0vUygxz61NaIiPEIVR0UbCw4246Cs9LeZV7bmZKksV1LMqnC8AY71V0/wA+7vo5JAVaR8D2ronEUkyRn5WLZYHuMUywRYrp4gBhCWB9BScmkWp6EWpyRgSxSEglQFNVYrRdQthEzBZV5ViOv1qW8RJriRpyRt+6B3plovlYl3gMMgKOv41XQpK0dNwWJLO3lgY4kKHIHrUthbwahah5g25B1U4yPeq9yXczycGNlyjAdfr71e8LAfZZRik9EKbajzCBHZFhtExGgwC3BP40zzDZLKm8NckcY5CD0rY4EgHvXOaulwsoacDe+cbcdPSlHUiDUnZjnmaaZSfm2jHrWmIUi2QMrKSNykjgn0rN0xoraSN7kgs3C8cLU+oGRbllkOejq1NrWxUtXZF2KNBNJhQGbv8ApTLm2lkjKxuVwfzqS03SYJGD1PvWjt+T2qG7GTlZmBEXsy4ubjazjanOTn1xUwknLCRySqgAkHg+9Y12ryas5YHZnaDnpitNFRlEcU2CRlDnIBq7GrWlx2o2iyRm4tcJKoyyjuPXHrVSza3nUedwxbcRnhjWpbOAxA3Bgec8Vi6pbC385lUptbehHQg9RST6Ci7+6y7aRtZ3TK6ARTA4weBUFjGXWf7ITuwdu/oD2/CrFtK15phSMbpAMYzgkGsuW4uNOjbarKcdGX0p21sNK9+5T0Wx8ue5e91FJ72Y5EecBB7Z/LitqMBrX7KCQ55DEdCK5HVowbnTtUh/dFpwrA9BmusuDtunKY3Lzn61rPVJsiCs3FEFsQm5SflKgg+hzU19JCgMkm0BSWbPAIPWmzxbhbiE/u3x09qdrNlb3lnJBICBGVGfXv8AzrP1Lb6orabcJJBL5fMZ+XNPuzhk/ugn+WKZpVtFaqFjPGC3t0qN2zZwscEvkt7Gm7N6FdSPRQUDbu4xirsUgkmkAwoBGeOtUrOfy7vZJGVXPBHINXAXRX8uIAbufepfUifxXLqNuO1h17GpILWOM/KAAewqOBhnng+mKW4uHWUKoAOM5qGY63sil4h1EWKeXAcyH9K5+y1e5bzYpZSwbnmrviZEkIuBKNx4ZGPP4Vz7ocBl4z0NaWslY7aMIuPmdvpU9s8QZx5cnQnPB+lXrq8SK2LxlX7KAe9c1oDM9rJiPe4Odv8AWrkDmCKRJGUyynhG6f8A1qlJXMp09Sez1M3E/kyoik5wRV+ZEnBWOQCZDkAHBqrbxW96xeJRHLGRkr0zVDWAsd0HDFX9RTWrEopystCeWWS1fbJ8hc52N1+tXrSUvAwzk4rOSUzxgTENIq4Vn+8B9as2sscaEDqaGVKJnXGYp1bBJI6+9ZVrj7Q6S/dfr7VuakqlQwxWRMg8mR0/1i87fX1rSOqNou6NPw5N/p8sak4xx+Fb4B3uSMqc8d64rwddM2qS7/8AVu3HtxXZXspiEZiYbS3zY7ipnG0rHLJ8zKVyFScCMHc2Nw9Aao+I7W5OgstiQHD85bHB6nNak6tLH5qriXGPwrE8d2tzdaUGtC5QgNIi9cdzVU/iQqj90h8GaGbC5+3y3jSOVOFVsqf8a3LUC5vJY2Odw5zwQaz/AAXpiaVpNupLyXV0vm7SeIxjgYqnqMk0GpxNC7ffDHB68807OcnqZ09FtY37csoO4bjGwq1PbmAMIS7lwGAxwD1qnYyJPeTRq480DO3NX7aXcEZTvY8Ljt6isZaM0uU45JZJUbbjD/NxirZBXUwvQlSCK5tfEu7WLmyntdkkZIjlBxkg9CK2L6/gMsLl2ErKCVUU5QlHca9/Yv3VtuBQNtZvfBrKubYW0kcau2HBG/GOf8KWS7a44KEBeUYnkH61PDJ9qEcdxIWmDZQNx/8ArppWLSlFah5HlaU6Mcs2OnrV3w9xHKo9jVTV4JLewyO/T2pdEuBFC8roQ+3getJ6rQUvegzV1BioCIwEjcA+nvWFrA8qKFA2+RT823k1btri5vFLbFWQ9WxyB6VXDMVRICjKcmVj1+gpRVhQXKSRQNEkNzI6rFyWRuSR2AFUbiVpJQz7syc4J6CrFixu7eRbmULHG4Kk9QPSq93GH1BCrAxyD5fcVSepa31Om0pBHZpkjc3OPaq+s6uNNT5k3FquQMiIgkYKcDg8VyPip3udRhVfmjHp0zWcY3lqc8VzSM25vZLq8aXGSeoB7VaS6njjBKgoD6cirOkJY27NLdHe/ZcU7UbqOdxLBb7M+h4Na9bHXdbWNK31OPyo/OI3dmxUN0gv3LwyI0UgxycEH+tVbJiQzSINqjOCO1S6dbtLOWkU/ZxkjHH5YqbWZk4qLbRHaRyRSBDHIsg4DAEAitB7iaCAZHmxL13DkU1r9Uco3Qfjg09XZl8sNjPKkjII9CKT1E7vVoyNTWO+tlyE8svkAj7pFWrtwszTIvmERpuHrjiqMEO6edYxhQ2VGfzq1ckEsORtVVOD35q+hdkmWtJ8kxGREKRhiQpOee9RSwTm1cy/K8w5x2OeBTo2a2tIcodxO7B4wM1X1HTbm5vEv7e6YoCB5WeAPX+tJWb1M27O4yxndbdYJIxklhnv04/WokQEiPJwCQRU+q2/2iNpLaUx3I5yvTPrioURY7NHkykpHzn1PqKafUtO7FtJEW4CzcFs7fQVfFxCxcBgoQ454xVRLCQu8hIDk8c8EUsVrOLjeAEQk5OetQzN8sne5fihJcODn6VYli3QsuA3HQ9DUkKAKMYqXaCCM49/Ss763MHJtnm3juKaW4jjiSQNGm4BTxn0qKy86WzUXETI6jBOOCa7CV8XKLqcUZ28B88H/wCtUd7Y7dMnVHykTmWMdTt7iujnulA6qb5Jc3cz/D7qLkwnGJVKg+hqO4kmtrhonjTrglhzVSJzFOjr1BrqdQmt3jhluIFlBTKn39KS0djep7sr9ypZ3RsNP8wqpkd+MdxWgsi31qJYMK3Q7kBwayJWi1CNIbcCOSPOEJwMe1XLO3aKz/dTkyo+7HQMO4pNWtYyklv1IpoZCS4UFlyGbGKoNMY2yM471s6hdNbGKRlJiYfMPWqU0MUxzGfl68U07lwfcptcrLGQDkg1Fp5WaaSGXoRgf40l/GojAgAWTqxFV7Dc06sOHAx+VV0NLaFm2ij0955Cm7Yhb69qq+FtV1G91uUTLI0BXOMcL6AVd1OznvbadInWJpMAZPHvSyRX+h+FHjsGM1yTlpEHKj2rRWcbdWctVu9zrIE5wAQvXn+VBiJhIZgGUk8DtXPfD+51O+WWTUTIQB8pcc11ckeHBzg98d65prlfL2MeY5LxPqj6JcWl0i+YhIVsdh3FaQtrfU1gu7V1lhc5Ur29jWN42S7aJLa1sUnjkbcQeT+HpWxoNrFpMapHujyoyjHNatWimtwTdx2l6ELHVZ79pmd5eFjIwFHf+VZ/hOGe2+3xO+6NZ9yf1P8AKtx5ZHyWGGU5A9RTopLKzkEYlRZJvmCnrmpc3Zp67DSMu80u3uNWhvmjYSAHd6ce1JJY7pUlc7eMBl5yPpW28gkguArZLKSB7VnReZ9mgkiUsACvA96lNs1hIrtCWIS3mRiR06VRvY7i2KM/IJyrA962khWKVTn98Tk5HB9qdqNpHDppiTp5hce3tTvrY0VSz1Kbaibu28mcgswwCRVyxnEUgt1QtgjORnHvWTYpsvEWTgHGKvKHXV54Q+x2IKknjpS6ClFbI1fOeSRsDag9sZNZxk8ye58pFXMeCR0JPFaVu9vI0yrIWCffx0464rLhmSGOaaYgJI2enYdhSSMonNavb31xcx29uTDbKRvlbjd7Cum1C3NxBC0YyIxt3DjjtVODV7XV7jyYkBjTOMHnjvitKSaO2eONg7fLuBB45PTFaSbsk1sNPXmW5VXVFhQLfCR1XjcTnFNa4t7mQjYMKcEEYNTaxpa3kIeErFISGIccH8Kht7CZbTddeWWzgbT1HrUable7uXIrHT5EDBCdvVQ1XIo7dDtWEIBwMisso64kR/LK4yfWnz6zHH8pTf64qWricZPYuXmnxy25+ynZIB0PQiqttFO2VDLGv90MTz7VNa38U8ExtuSAQARznFRIfJdWlbaSOQBTSaJV9mQtDKA7TxBUUFgevFJbOrqUHzcZU470G8ntyXIR4xxjOQa0LKSGaEtDGIR3AGBQy22lqYumkRhgRtkLhTntzU0nlNfXC7S2RuUBsdDUV+qrcyMMeYp+ZfUetUxPiW3kI+XzMHnsa0WpVr6o1Ls/2naNHZTxfaIgQVDcj2qr4Y86z0x7afDOjlsn36iuf07ztH8cXFuitNHeNnew+YA8/lXY6nwwjj4lY4DHt+NElyqy2Zzxd9GVL672gGMAd2OP0qrsaSESSZIA79Ks6gAs6xuCoUA4POTSSFJrKOEbtzcnjpio6XN1ZJWGacZQqo5OBTmkM85YM428cnAqeCWIRNLn5AOTVW3u1nlIXBLdCVwfpxS6NkWu7pGzZsSACSatkfSqVoCDyCKukZHPFZGE9GY+paVHPMZlLFjyU9aqW9wVIjkAVOjcdBXQ7eetUdStbeTEkz7OeSO9UpX3NIVPss5C+tjbTyRdQrYB9u1bemFLrSmjlYgRg5PpUWvwKkqtGMoyDFN0IKpdHPytxWzeikdTfNTuU4rFZbqPZdJtz05BrqPsi2lq0ihpJMcD1NY1zof78PbzbFHzcjgfjVy71LyvKt45chAN8h9amWrM5tztysju5JG0gfaVAYtx7Vm2MyJvBYcqDn8K19TjaSxZkCtHtDAjue/6VyyxmWfaCQp6009LmtJJpons2M88rHJDHJ+lQIfJmVgcY5/Wri3CRQm3twB2Zu5qEQeY+T2GcfjV9TXZFzUcuYnQn7vb3ptjJc28gMbEr3UnINMllMlsPkK7eOlWdNk+QMvODyp6GhrTUyurWOgsNQSRU3jaehHoat3kkyoGjCtF/FjqBWTJFFcRF4eGAyQKt6ZOZIzG7fMvrWTVtTnlBfEivq8oitBcMwQx8hjXBvrFxrdzsgZ1vUbhSfvAf3a7zVbD7bp81s74Eq/KT/CQciuM8K2YsdVuDdRbLiNDtY9D9PeuijZRb6oyk22ktjrtS8yG1t5ncIURTKAR+NZUlj/aOvQahZTrJaD5gUOenVTWW73N9dXNu0jNHJGT1rU8BaHPpYnlklV4JiNig+nVj+eKTjyR31/zHqrdhkOsTR+LJNPlTajL+67ds4/HmuhtJTDvt5ceXuDDI7VS1SALLHPNGss8L5D7cYX0z3ps2oQXGE3BJx6cYqJWlayLinbU2b1AMEcHsabcIJbQiRsFRkHHWs+P7T9iDXEnmZbCn2xWku02URLD5l5IqLDtZIyXPmqucCSLp70l5IZw08ZImU88c7cVoXUcU8YeNNj/AHSQfvfX3rGljZw0ZDBhkBwcEVSNYu+ptaKgktZJFOTIhB471n6tB5sKwnOOhPv3FavhaEjTsv1yRn196rXro1+Ik+6hJPualOzMk/eaOZ07SjotlcPZRGa7l4AJydue1bF08ylbiTYk8iqAB2OOav3Vz5EduIFHmSggsR0XPSm2FrFeDNxkFWOATg4qpTctWOKUdehWtLeVkMkkoY9SSTxUl63m2luok2M0mFOfvfSrV8vlTIYmEcEX8IJ5Pv61RvXlLq2eg+U4AwD6VK7lL39gvg0bRF23DpsHG2q6WiSqzudidB7mnW7pISk5ZoxgnnJqV7xfMX9yFQfKqfSmVqlYZYQGz3SAjEhIBFatw9vIUjlba44V/T1rNjuYjK0Lh9g/ebgOQc0XsRaVpVbdG3zBhyP/AK1Jq7uS1d6li60qJN0yq8mMfKlWrqdLK3hijjyWAAVvSstprhYFeGbdt4IHHHvVKfUddfX7a3tIoRZOAfMaPO0d8n1pqLloZzvFLm1JJI3+0M6gqJTghuTuzzWfdqYbnyCQTuD4rf1XJnLRjY7YRcDO36Vh3dv5N/JvJPbJ+lVE2hK5tW8Ex8m4PAX5g7dQO9Sy3RuC2Qk0Gf4VIK/XNT3MkkVjFsTcu0duKhEn2i1zBGFlX5igx06Go13Mb31KOoD/AImbAco23A9sVLbuIkYyjPGMevNOkjzqAn/hxjB+mMU+VPIwxBcr0Uevel0SL5tEjMt4yLK6QnG4g/oMVq6JYeTCXmCl2OQfasrZLNBE6SKm0ZwejVr2F4zIqvjPTg1MrtEzbs0jUAC9Kdk00EEegpRxWW5zCN9zjk1z2smV5UVwAoztOa6M/pWPrWmPeFXhOHHqaum1c0pNKWpj2LtcrJazMCU5jPp7VDATb3UZfpvwRUOro+kTGZThkGSR3q06G9hhuEwGkGSB6it0tDsTW3c0769RUJBCoMAZ6E1TsreBUaS4G5XPygH71Q3ULz21sF5UHDn0+tNmuIo2VAcxqMA5/OlbQSjpZG1JMGi2hcDG0AVzGoZtNyL988Z9BXRaYRIoIHy56kc1TvdPM17IW4GTyaE7JhBqLsYViHZ/lU4rpdN099gZ1PPJNR20VrZYd2B+vNWZ9Yj8srEBx60tblTlKWkUNubVWBTIH9aoQAW1wBxgnvWdNezvdEu5yTxg0l/csEUsfm9aryHGk0joZg0RWaAkZ/zililG4XMfy4O2RfT/AOtUejv9rsyp6kcfXFQSgrnBw3Qj1pLXQhK+jN+9BdI1GQpAaiVIDbqsyZOcDjnNQ28xltUkmJBRNpx7c1574u1jVbi9T7GZo7eMbuPfiqp03PRHLP3Uauu+H76HUmnsZQsEi55OMdsVo/2beSeGZbSOYhy4+cc5HcVzN3r+oaRpsKSbmuGGTv5AFdroF7Lf6BHMybN67sCtajnFJsUXG/KS21sbPS4rdy0hRPLYnrXN6po13JeQS2bDap+fPBxXSaddTyo8chIYHCO3Oc+tSW95bG9Nn5+blVJZemCKyjJptmj0VmRQ28smlxxs4wG4XHarLwsY4re3UnAxjNLaSB9xfKojbQDRrVvLqVnPZ2c3k7xhnU/PjuB9and2ByaI5hHDayokvmTxgMcDgfSmzJ5tnLcp8oICj8azNM09NOAtIxNkq29pDkscVbZ3GlRQ4yHmA+gxn+lO2uhaTtdm3preRZ8emQPauat7xI54ppnCvK/BPc10FtOPIMUm2SRlbhB2FcL45gYJp0kRZCJWGFHTpg1VOPNKxHNy8zOqltnvb59pCxgnHPAFWQsj+VIp2j365xTtKL/YgXXEyqBg9+OtR3Uhhi2vwS+QCfuis+thtt6FdrdpMwzkurgkkHk1Gt1aWVoLfU0YtEPkY91+tWrb92kmSNyqTk+vWqN4pu4Ld8K56SL/AA5PrTTu9R2ux0k8DtHKI/LEqZB9B2xUMaSGbzZPniIJDDnJroIoLdrULJHG7JGAcjp7VzcreTI6u37pfuxJ0/E0lK5VOV9EJaQPdTm2yQW+ZyOwq42nxWEwVLpwX5C7M5qONWhtmjI/0icgt2Kr6VoWlvd+WQ8u2N12qG5Ofahsc31uZ97YyJGZEQh16lcj8xTbG7ZUjDMArNhSegrZ3xWCKksu8ZwQeoPrislIQrXEQUFPPwPbg0J3Epcysy7Cwa4WUj0Nc7qO57yeZmDAyHbj0Fa1jvKMSQvyt+nU/pVS7tybd5ANqMcjnvVrRjirM1bRpZtNjeOVldRtOOentUEd2Ucec/OcHC4OfXiotGv4YbeUSkL5Q3MT6UWt3HqDi4aRTD/AVHDZqWtWyLJNokmG4l04Qjt6+1SO2QgK5kA4x2HvVfyisbEuCiswIz0x3p11M32eKRRuUgbV/D9aVhWMYu6WhU5Bi4PPapZbhLbUFdGzE6KQw6EmqeoSvFKJGUHdyRng1HBBJPGogzLH1VSOVOeRmrsrGnLrd7HfQsHiVlI5HWpBVPT1MdvGhPOB1q1kA8niuS3c45bj+1A4+tJkY4p1AjnPEdqkzkSYIdePxGP51S8OSrNpckC8TW58s49uhrqLq2SdfmAyK5u5057GWea2LRlvnyp4J9xXRGSkrdTeEuZJF6wMEzSIPlY/NKrDj6iodY0+2k8mS1IG5thx0z2q1DAk2lzT24IklTPpz3rO0PbFFM0pJjT5gD60X6mqeraexeyLKKOBBmZhn6CszU7hywRPv5wTmpPPZ5fNkJy3T1P/ANao2iCYBxvPPJ6VUVY0jHq9zMu0lMWS5Y1T0uafdN5seUHG6t2WL91knI7VEfJXSwyf8tHzz61aslqVLVqxlJGTMre9V9TlMlwFU/d4FbEUKsm84+UE1mtb75hxzU2OhM6Lwa54Rs4B4OOlamp2YW7YIeG+YLVfR4vJijCLgsNzMOwq7cRrdu8yOwdPmU+oHaoSszim7TuhlhHs09llBJEuSCcZB4rMvrS2hklZEO8MPlJ5IqjqvieTRjDE9uJ1lbJJJGAPT3rasYYbmb7a+QLhQSp7VavFXfUzb95+RzepatpDQPdXlnvjR/LKAfNu/wAK6XRtStbu1jewCrAFwqDgD2xVPXPDtrqFlc2cREUhIkVgO+Kr+F9FfR7Yo7hjnccciqk4uOjMVzX1Nm8uFso5XVSdnAC9TVDRo4bq7/tSWJYZiuNxOM9sVbu4/NQg9euaxtd0y51ZY1spPJjgOSg4z71Me2xtJaXN/UGAtCcFfn+8D1FM8+OGZZopwuQDggk49xVCVLmxishcsGtSRHI2MlT2/Wt86XCbppmP7s8gHoBipeiGpJLUgkvnmtHkhhVnHy5bjg9cVSBWOxXzTg+YCP1q7czxtIILcDdkBUXp+NYXiR7v7RYwWwBjUgykd+en0qoK7sLZaFy417T9NujaXbyR55BCZxnpmrZZHl8xovNKkbHI4A9fem32nWd7exPf29uxROC/UN9e4q3HGTbAkBcZUgDgCk3HRrchXW40O4jkdMFFU4Hcn/CqjDN8sc3QRhz+PWq8l/b6VEZbm5CbyYwJOi8/rTdVtptUby7dyDJHt3qcfL1HNCjr5FLqXbya2SGRYD5qkYLBs9exNR6YgS2+VciWTaMnoF71nPZRaDoyW8z+ZNM4BOe9aenx7x5jHbFAxOT05AzQ4q2mw18JQ1Oa8gZ42LEFuAq8E+1WbK2S3tftFwC0x5UYzird4tsbiKZg4kJJWP29T6VnS3yxahJbTL8pXK1K10Rd21YntrWO7TzfOZZixyXHUd6tRSwxziJZJLh2IyccKaq3cBRIpbZGMTL8pGTj61j3bzPf2tlAlzukO6SRVIVR0HNNR5hSatds05YZDNK8kgUKTu3feqxZxo8kyMSFDxsOe+O9WGkNsYYpIhNARgSFgSfrVNMppyu+PNnl3jHtSvoO9yxLD5cNyznLsuSw4VBnhar6mn+hxqr/ACbOcUy8Y/YxEh/1rbyc0kLefaSRsQHQ5BY4HoadtAiramdb6fDdfaba4kMUckRTf6HsatW+lR6LZxWdqR5eQfOduSx68dhTYT+/eFxufHBq/NbyM0bMwKABd2Op9qbbSt0CaXNzMbezQxRsbl0CH92ASFyemaq6nFK0i/Zn2JEAAAM5BHasjxfay6lpVtFaxtJNuyFB5z0/xrSUSWVlbJNlpI4kVwDn5gOf0qkrJSM1fm5Tn9AMV9pUH2qdUbc2S3Xk10Mq/wBlW+20AycfvG5z9Kw7gx25CJAsaepGK2Ut21HSI2RgJV5HuKmT97XZmlrRXM9C3DqEkgRYwGdvXpWo8jDHPJrG0qyeEFiwaTGB6Kav2ImMQ88EODjnqayZnNRvoaVuxI5FT+3So4QAKlHSsmc73Eb5Rms6/ad1P2Z9rDqMdavsfUcVC8Klt3b0qo6blRaTM+xebJ8+QFCuCuOc1Rlt2tbYLKFIdvlVT19z7VtGKPdvHyt3x3rE1G733HHIXgY71pE6YPmehWmZony5UzdOBgKPQUx1J29FLcZp1vC0p3SjCjk5NVdTuXsYxdmMvAnBHf61rFNuyNnJRWpZUOpwuCq9Aao6sJI44gAAnJAA70/Q9Vt75g8LNjPIYYxV7xMUFohAGd1N6OwQabVjJtXkMfbBNWYkZZgxAxUVrIoijHcmrud1tI46A8+3NJGstLnQ2Ekcts0SPtkC88cj6UiiSNc7XXGMVDoV1vtiuxWlixz3K1al1MgEpD8vTJNZvc42pczRSvrCznZJrqL5EJcqfp+lc5easHvBMZBFbW5wqDv2rtZRHcrscAwTR+mCM1w/iDwq4iD2Mm2BeqtyWPvW9HllpJkSk+xvT6jGg06UyFkuMgv2FQ+IfEH2DU47ZADEyhmNZNpFJJoX9lzJ+8VS8bAfdOeKuaJZReIdGje6Oy7t2MZPTIHY1XJGOstv6sTd3N5JVdRNt3KI9wApunXDXKxzhCgb5ckY6063iWAm3wYysQCse1JDFdKD5kium4YOc4rnfY0b1LqgubqOVQykZBboTTLq+jWLy+SwA4/pUc9wyRjaDsfjA9fam21sm5heykkHcpH8YpJaAkt2UoriZbuWWJAqouAcdCe5q1bSmGzklvSZGkyIgOCB6+1Okm33BEcRSIfMy45YfSnx+ZLb+fBEzSu+zDAYUVTZo7MrSo87bpg+xYwRvGeO36046hkxrKrGNQVyhwfxrQ824Rikk6lwPugZxSzPtIKom8gZbAzycUrk36WMjVNJstT8o3MRliVty87SD/kVefFvtaPhFG0ewp9oDNZzSMC21zgA/eNVXEkdrJJKyEEEEA9PQU7t6EW1Kmv25vJbaTGQhyfpWk25YHk+URW6AqvYuR1P0rMtpilmocklH6+x6VtyRB7edXH+jOqkFMZzRJ2sgasYoD3V3GwIYnqxNM1OyBuZJ93QbcVoyi0tFD7XMmOFZuKqTyNcQI2xVAYkhTw1CfY1Tu0+g7Sp5vIeOBg2XPybsHGO1SrcT22IWLCIk/e64PasnRv+QiFLFdp3A+vtW4sUkkkckw3x7sjcc/lQ0rimknqRRTpMDE+0wrwhB5B+tVL4uGjVVLpET0GeDViWzeJi33YQckLyR3p7XMcd3GQHKSLj/wDXQg0+yYNvfNdq4Q8Mx4+lXI5go3nDcAMD3qf+xilxJJbxsPnIG0Y461nXOYZyvcZ/GqVnsXF8xdW2P24eS5G8ZjJ5/Crl5cnMSx84XcM8Amq+nuPtUBbjYCc1atoHCOJH+UqFUAfdHWpZE3Z6lVAjXBuZMpEAEGDgMc1Bfti5bDBlzkEDqcVrNGsUCblHyDIFYshxJ5kh3Y5bA6k0r3Yob3MY2F1e3II3MM8segrolC2Vl5Mb5cJnNVNWvJLOLyoflJHJ71kW88kUsckhZoznIPfNNpvVmlnNJ9DpEuFi02OVTkng49c1fs5hIowcisu1EAtXWQ/un+bGelNe7+wsIofnBG5ievPas7XWhk43ujpoyOoqTt6VRsHMsav6irbHBrI5pKzsJKwRCWIA9TVZLhXJwflBqjqUzXF6IYjmOLG761Wkm4ZVO0Z5rRRNYw0uy7qd4iJsRvmb0rLtrNrl22qx7/L2HuansrJ7ybfJ8sY6Vc1MObVra0+WJfvY6tVqy91GsXy6Iwr2eSIGAzK5H91f5mprZEXTmN2wIkOBvGc1Ys9MiWIT3ZI9R3z6UmuW8Vzp6z26svlkAqT0qr3aSNHJPRFa20uwh/eWkYRic8HjPtVXxC7Axwkdeal02byoC0uTsPygnjNN8SsJbuJlBAMa8U023qVCLjJIzoo2+UjjA61vaekfkGFskPwx96pXELRWsDjgFcGrujri1klftQtjSbuh2nlbbV1jDfuycZBxg1ev+LqTfGGJ6Y4/E+tZdpCZLhn5BU7mPpiteHUTMsUnlAyM5QkL94Y/Sh6PQwqaO5OZwLa0kC/eXaB0/GqKa1bzatcackbvNGxJc/d+lM8TX32CbTVdOZJFXaOijNRx6aljqOo3pJLXLHGR05yaIxVrv5HPu9Cvd6paW980Tn9/J8h9qsaOghmlBT/WEMR2b1rm7zSkvtYF7E/7ksCwJ5BFaGkXDXniyR1dvs0KbMZ4JxWsorl0fTUpX6m/e5mlDBgqYIO7gDFc3H4k8y9+wWMRndn2mXOAB3I/CuqNupLmQeYuckN0+n5Vzmo2w0rVXmtbdEVwAMD86mnyu99wbeiTNnU/O/s3yrXPmryv4gVmaJLf21skF+X8yUk/N1A9q6BA00G6MiOQx4U/3ff+tc9omjXNpLPNeXr3UsrlRuJ4I6n+VKDXK7lJ3lsdG9lc3EMbQSeW38WDyasym4htkCsJJFbEm1RUmkgLZKFGGwcg+tUYGnt7hllD5B6KOtY7huySFfMmM8e5VP8ArEPt3FDXQkkRyCIVOcDv6VNER9tlwTukT5c/59aaYktofL34kbpgf0ouBV0ot5slo42rg/rU62llDO6yFSh4Ck9/WozI5uNqeYD5ZxIFGOvNNuYvMuWiJiZsjv8AMR9Kp3uG7ILm0KM0SnIZcL7jqKvRvIdGJt8eYi9CM1XvXMkitEGKwnGcdu5pmi3EtpJLHcIWTd98HIOaTu1cUk2jOMU9wCm09eSa0Z1WE+UMZij59zS2+mumqTX814zQctHEvAGeuapyFpLZ7g53Suxx6DNPyRanzMzIQ8UsEgBG7Ib8811KILTT/tDklQN4X3PGPpmsi2KyajDFtGXjLYrfRlS1EFz90jH4UpsVV3ZkW9zKZNm1mLjczOcY/wDrVTud0splh5hA2IPXHf8AnVu6Mc90LSy3BDgO+c59vpUj2FnbBXu5WZ1/hHT8qLpFJpEsU8/2byI3VbhQCT147gVz1xumveQS2eB3NaTXUCyzS5fDMAGI5XjpVRVb+0HkBLFBwfWqjYqC5R1vIYJpWIywTYB9etX4lSLUWWW43TBF+QnBGR+tUjh72IHqyfrTfFtlIZo76xkQXsAG6MjO5f8A61NK7SM6poatLuYKThNuT6/Ss+BN4jZhjkjH4VduY2ls45WwW6OR2PWs9JcPt6A/NUxXQcF7uhmTFGv7gamWUgn5l6VY1wRNpdq2nxb1RtrZbGAe9Zt9fPfKC4UEDnH8R9avaahn0uSPdyQce1U3qmaOLtcLUsLe2I6FtpBrSvbSJbxp55AYuCIweSaoWaGO3jdmCuCdqEc/Wq0txLJKVOS5OWOaQ2nJ6HZWF1HKoCAKMcCrUjY2muYt7+O1CRj537kGtq1uDcRkYwQM4rBqxyzp2d+hXhQCaZ8gl2JPtVW2gWVzIxwm7qTWokcYRnbp3rOaCW6cPMvkWkfROhIFaJ72HHUty6pb2ljM8I8xoiFKjuag8OnzY5riVgRJyGz/AEqrFtkuneTCQDLSccY7VoafdQtPJa2+wxIMr2P/ANehq0bDlGyaRSupt9w4nkVgvC+XytVrdvkntkyUl6EjnPWprq209dUW5YyBgNrID8h98VrQxWsh3RBRtxyDwBTbSK5rLVHLTptuolYN5YOSAOtS68yS6iAvGEXj/P1rpVjtjK0uQULZU1zuuQFdTaQrjoMVSknsa0580kaEqI+lxxnl8VDbfLZGFMlweadYt5rRp61qL5H242sKM5PLMo4zReysEnysqadbsLe4LDLFSMH0NJb6vp1nKLaErJcKcMinJFT3U01hekAK8HAPHr3rn9I8J416W8M4Matv69e+DTSTT5mY1G3r0L3iGyk1PU7GZHG2CXLDpitG7cPO6sfmEeQPYnrVm6j8g5K8uevauc8TXklnqtlKn+ruo/KyP4SD/wDqojedo9iFaOpJYWwUSjPGS2Kis4TBNJJCoXLfnWRZajc2+rLDOx8okgiunt8Onmf8s3rWacd+ppFp7FnT5d87JJ95VLc1ZubcTptYArg4as681K00i3e6ulLLIQg2fe5//VWrY3EcvCHehAdSR2I71g7rVIhvU56za7TW5QZSbdYvljzz6VoWknm29wi/ejfdn8OatP5MF4dyhdwIU+maztOJg1CVGb5JAQT2qm76o1im1c11vW3ReTzk/PkEn6Cnvf3EYeS6g8pB90dGNVkiSK2EwuFiYkqdxwG/GlRhcRxRTTqcAqkjHO4/WoaQuVbl17jzbOOeBRvPqOcd6rahbLLfw3K7/MiGdueCfem3MctpYRRxODOjEkLzwfSmReZNBMjukkOzCzDO8c9MULQnbVFy6VzEs4bCqpBQDPJ71BbMZ8wysFk6JIBhh7U+KWOCxZA2DjC9ufWstIrp8tDHIzDkEfzzQlccVo7lq4a3jgaOPzX9STgVlSX4ivoIdzJ5ykevA/rWndwyNb5aNlduXyeBWLrckcaWlwiYWA+UmOCxbgn+tXBXdmN25bo6aG6iaXY8gExXaqY6+/1rOsm8mwQNtLjcQm7kjPXFQ6IyavZIY12SQuUd264Han6bErwC4njLC1DMh7YI/wD10uW17matZ2Ksbul+t5LtXAOQo7Vdl1b7bYy7kCgHBbt61Ba7brzSVJ2x8jHXI6CpdMtozbGB8bEboeCadl1NZWvcn0yaO3tRMpz5hIBPcVcuPJaGK4aMFyQBu7j6VTkijji8sDCqxK/j1FWIfKyZrglUQYAJ/pUSXUh66ix6XaGaU/wuu5gTwMVmXLD7S5RfkYbQR7GrYuobhZMbo7dBg8/e9PzrL+1PJ5i+WAincAvoO1NJ9S4RfUbZFjqceBuxwfpV/WCf7TLhd2AMVj2NywvFZl2ndjHbHtXTSrayu8yNvdMblzxTfRjqO0iG6OyIlfuSru2+hxWGuXTpz3rSupsRE87UGD789BWBZajFeanJaxAsEGWZTxmiEW3oSmorUfLpUf2nBc7TxjFXtIiW2tJpB8xQE896KKctUvkW5OxiyTvcTF2OCWxx2pJpCmBH8pPU96KKTep0pKxWt5pA5UNwa6jw7K7SEMcjaaKKifUxrL3Tbtf3kW5uRycfQ1n6hcNJN5fRR196KKUVqzmpq8htlCkyXCyDKnbkVb0mzghaSZEw6AqDmiinJvYdRvVFC0tBeXR81zjPIHeptTPlXnkRfLEgChR7jmiin1LTvJJkAmYTDOGWPkAjvSXz/bLeO4cYZjyKKKpJWuUviK+kOUvsddp4/KrsUzwW1xJEdsh2jcOuD1ooosrlsZpLvLeuJHZg65OT1Na2lyi4875FRs7dy9cCiik9jOqtx7KS+zcdueh5FZuq6XFeWQaRiDbzB1x39RRRTi+Vpow33Me5s4ZLs3uCG8pm2jpnpUGmahKbW0T+F2YEZ96KK6VrDX+txvSWhekt4db+02F2hCwgOkgPIIH/ANetbw3lISmciNdq8dhRRWM3o16Da3ZNrSB7ZZsBWz0HSsox4njkBPzDp6UUVC2NaT0LWqnGgREcEMfxqvoA3XcKyfMo6A9AaKKH8Ja+Bm3cQpNPK2NsqLgOD2+lZloJ1viVuGGeuRnNFFVBJp3Mr2VjoFRccqp47gVDJanDyQSvEzYzjkce1FFYczMUAQ3EDQTMWO05foaytWsYGFpbspMceHHPU5PNFFXF21H9qxN4TtI4rK8A53Ttn6VbSJIdGkSNQF+YAenNFFOTvJkdTFsX2PKwHoa00XZqCpnIY55FFFDNpkOqErISMH1z3qjeTNKqKxIGB0oopo0prYqoxKvHn5QamvHWziW0VA27Ds56n2ooqn0LluYRkbzWOeOCB6V1ViAdPMmPmdSG96KKJbE1tjI1Ik2cqA4wN2R/n3qroulQ6ZZhoiWknG52PXHYUUU02oadWZtJtXP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this micrograph of a biopsy specimen from the involved skin from a patient with adult Still's disease, perivascular infiltration of inflammatory cells and edema separating collagen bundles in the dermis is apparent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lisa Mandl, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_6_41056=[""].join("\n");
var outline_f40_6_41056=null;
var title_f40_6_41057="Handheld Doppler";
var content_f40_6_41057=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F56662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F56662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Handheld Doppler",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Portable Doppler device.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleisher GR. Textbook of Pediatric Emergency Medicine, 5th Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_6_41057=[""].join("\n");
var outline_f40_6_41057=null;
var title_f40_6_41058="Map of epidemic dengue";
var content_f40_6_41058=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F60722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F60722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Global distribution of dengue virus activity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 445px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Map of the world highlighting the distribution of Aedes aegypti mosquitoes (orange) and areas of A. aegypti mosquitoes plus epidemic dengue virus activity in 2005 (red).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From the Centers for Disease Control and Prevention. www.cdc.gov/ncidod/dvbid/dengue/map-distribution-2005.htm.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_6_41058=[""].join("\n");
var outline_f40_6_41058=null;
var title_f40_6_41059="Dissection for occult left parathyroid gland";
var content_f40_6_41059=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F55184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F55184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Dissection for occult left parathyroid gland",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This illustrates the cross sectional anatomy at the second tracheal ring. The dotted line corresponds to the lateral approach for a reoperative case, exposing the prevertebral fascia behind the carotid sheath.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_6_41059=[""].join("\n");
var outline_f40_6_41059=null;
var title_f40_6_41060="Radial artery puncture site";
var content_f40_6_41060=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Radial artery puncture site",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 347px; height: 595px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The strongest radial pulse is typically located as shown.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Torrey SB, Saladino RA. Arterial puncture and catheterization. In: Textbook of Pediatric Emergency Procedures, 2nd edition, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_6_41060=[""].join("\n");
var outline_f40_6_41060=null;
var title_f40_6_41061="Abdominal hernias in continuous peritoneal dialysis";
var content_f40_6_41061=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Abdominal hernias in continuous peritoneal dialysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/6/41061/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/6/41061/contributors\">",
"     Michael Rocco, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/6/41061/contributors\">",
"     John M Burkart, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/6/41061/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/6/41061/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/6/41061/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/6/41061/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/6/41061/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal hernias can be a significant problem in patients treated with continuous peritoneal dialysis (PD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/1\">",
"     1",
"    </a>",
"    ]. A discussion of abdominal hernias in patients undergoing peritoneal dialysis will be presented in this topic review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the early 1980s, the incidence of abdominal hernia was approximately 10 to 15 percent per year. Historically, the incidence was lower with intermittent than with continuous ambulatory PD, with the former having an annual rate of less than 5 percent.",
"   </p>",
"   <p>",
"    A subsequent advance, the utilization of a paramedian approach to PD catheter insertion, has significantly reduced the incidence of exit site and incision hernias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Hernia rates are currently reported at a rate of 0.06 to 0.08 per patient per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR HERNIA FORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of risk factors for hernia formation have been identified. These include female gender, increasing age, longer time on PD, autosomal dominant polycystic kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/4,6\">",
"     4,6",
"    </a>",
"    ], increasing number of laparotomies, smaller body size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/7\">",
"     7",
"    </a>",
"    ], CAPD (versus cycler only) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/4,5\">",
"     4,5",
"    </a>",
"    ], and multiparity. From a pathophysiologic standpoint, these risk factors reflect anatomic, hydrostatic, or metabolic factors that can influence hernia formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Anatomic sites",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sites of anatomic weakness that predispose to hernia formation include the inguinal canals, umbilicus, linea alba, patent processus vaginalis, exit site, and site of a prior surgical incision. As an example, the testes descend into the scrotum via the processus vaginalis, which should then become obliterated. However, a patent processus vaginalis has been found in 90 percent of infants at birth and, at autopsy, in up to 37 percent of adults without hernias. Leakage of peritoneal fluid into a patent processus vaginalis can result in the formation of an indirect inguinal hernia.",
"   </p>",
"   <p>",
"    Previously, the most common location for hernia was the inguinal area (23 percent), followed by exit site (19 percent), umbilical (19 percent), and other incisional site hernias (10 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/1\">",
"     1",
"    </a>",
"    ]. Currently, the most common location for hernias is the umbilical area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/4,5\">",
"     4,5",
"    </a>",
"    ], with leaks most commonly located in the pericatheter area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/4,5,8\">",
"     4,5,8",
"    </a>",
"    ]. There is also an increase in hernia risk if the PD catheter is placed in an area of anatomic weakness, such as the midline. The incidence of catheter-related hernias has decreased since catheters have been placed in a paramedian location [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anatomic weakness also may account for the apparently higher risk of abdominal hernia in patients with autosomal dominant polycystic kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/9\">",
"     9",
"    </a>",
"    ]. The abdominal wall abnormality may be secondary to the same process that results in the increased incidence of cerebral aneurysms, valvular disease, and diverticulosis in these patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/33/30233?source=see_link\">",
"     \"Extrarenal manifestations of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hydrostatic pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The empty peritoneal cavity has an intraabdominal pressure of 0.5 to 2.2 cmH2O; this value rises in direct proportion to the amount of fluid infused into the peritoneal cavity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/10\">",
"     10",
"    </a>",
"    ]. In a review of 61 consecutive PD patients at a single center in Belgium, mean baseline intra-abdominal pressure was approximately 13.5 cmH2O with a two liter instilled volume and, as noted in other studies, intra-abdominal pressures rose as instilled volume increased, and were higher when ambulatory than when supine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there does not appear to be an increase in the rate of hernias in patients who are prescribed higher dwell volumes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/5,13,14\">",
"     5,13,14",
"    </a>",
"    ]. This indicates that hernias appear in sites of anatomic weakness and are not absolutely related to dwell volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/5,13,14\">",
"     5,13,14",
"    </a>",
"    ]. This suggests that such anatomic sites should be repaired if identified at the time of PD catheter placement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further elevations in intraabdominal pressure can be induced by increasing abdominal girth, changing from a supine to standing position, straining due to constipation, weight lifting, and leg lifting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The highest pressures, up to 30 cmH2O, have been recorded with coughing. The increase in hydrostatic pressures in the upright position may partially explain the higher incidence of hernia with CAPD when compared to cycler PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20761?source=see_link\">",
"     \"Abdominal compartment syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Metabolic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolic factors also may play a contributory role. Examples include the adverse effects of both malnutrition and uremia on wound healing and cellular proliferation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms associated with abdominal hernia in PD patients include painless swelling at different sites, discomfort or disfigurement, and problems related to a complication from the hernia. As an example, these patients may develop intestinal obstruction, incarceration, or strangulation and present with symptoms of peritonitis. Thus, underlying intestinal pathology should be considered in any patient with a hernia who develops peritonitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/11,17\">",
"     11,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The migration of peritoneal fluid into adjacent body structures can lead to either abdominal wall or genital edema. As an example, scrotal or labial swelling can be caused by dialysis flow through a patent processes vaginalis or by dissection through the peritoneal membrane, followed by tracing of the fluid inferiorly into the scrotal or labial wall. Dialysate fluid can also traverse the peritoneal membrane into the soft tissues of the anterior abdominal wall, leading to abdominal wall edema. Patients with this complication often present with increasing abdominal girth in conjunction with decreased peritoneal fluid drainage volume.",
"   </p>",
"   <p>",
"    More serious complications, such as small bowel obstruction or intestinal incarceration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    strangulation, are rare. Incarcerated hernias can be seen in the umbilical, inguinal or can be incisional in the area of the PD catheter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/18\">",
"     18",
"    </a>",
"    ]. They are most likely to occur with catheter and other incisional site hernias and least common with inguinal hernias. Incarceration and strangulation of the bowel are also more likely when the hernia is small, preventing the free movement of bowel into and out of the hernia sac. Presenting features of this complication are variable, ranging from tenderness at the site of the hernia sac to bowel perforation or obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF HERNIAS AND DIALYSATE LEAKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several methods can be used to detect either the presence of hernias or of leakage or peritoneal dialysate outside of the hernias or of leakage of peritoneal dialysate outside of the peritoneum. These are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/32/41477?source=see_link\">",
"     \"Modalities for the diagnosis of abdominal and thoracic cavity defects in peritoneal dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several measures can be taken in the preoperative and postoperative periods to reduce the risk of hernia formation and dialysis leaks. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Detection and repair of preexisting hernias [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Detection of a patent processus vaginalis by the surgeon during insertion of the peritoneal catheter.",
"     </li>",
"     <li>",
"      Paramedian versus midline catheter placement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Placement of the deep cuff of the peritoneal dialysis catheter in the subaponeurotic area (instead of rectus muscle) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Liberal use of agents in the early postoperative period to prevent constipation and coughing.",
"     </li>",
"     <li>",
"      Laparoscopic placement with rectal sheath tunneling [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A catheter break-in period of at least two weeks. If dialysis is needed in the interim, it can be provided with either the use of a low volume (1.0 to 1.5 L), supine, rapid cycling (six exchanges per day) PD regimen or with hemodialysis. The latter modality is preferred if there are concerns about inadequate dialysis by using low volume PD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Surgical repair of hernias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who develop a hernia after the initiation of PD should undergo elective repair, if possible. The use of a polypropylene mesh prosthesis appears to decrease the risk of hernia formation post-operatively and allows for the reinstitution of peritoneal dialysis within several days of the hernia repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. In a retrospective review of 58 hernia repairs in 50 patients, recurrence rates were 12 percent without use of mesh and 0 percent with mesh hernioplasty. There were two cases of peritonitis, and although unclear in manuscript, it appears that these resolved with antibiotics alone without need to remove mesh [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peritoneal dialysis may frequently be resumed within several days of the herniotomy, using low volume, supine, rapid cycling PD with gradual reinstitution of the former PD regimen in the subsequent two to four week period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/19,23,25\">",
"     19,23,25",
"    </a>",
"    ]. At the University of Toronto, intermittent peritoneal dialysis is begun 48 hours after surgery and PD is gradually reintroduced. In a retrospective study of 50 consecutive patients at this center, hemodialysis was not required in any patient, and leakage or early hernia recurrence was not observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Treatment of dialysate leaks with or without hernia",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with uncomplicated peritoneal leaks (ie, without an associated hernia) can initially be treated with either low volume, supine PD with a dry day or hemodialysis. In one study in which this technique was attempted for four weeks, the rate of relapse was 52 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/4\">",
"     4",
"    </a>",
"    ]; however, repeating this technique for an additional four weeks resulted in resolution of the leak in 86 percent of the remaining patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Abdominal wall or genital edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient with uncomplicated abdominal wall or genital edema (but without an associated hernia) should be treated conservatively with bed rest and temporary hemodialysis. A rest period of three to seven days may be sufficient for the tissue defect to heal and allow for the reinstitution of PD.",
"   </p>",
"   <p>",
"    Recurrent abdominal wall edema can be treated with a more prolonged course of hemodialysis (at least four to six weeks) or surgical repair. Surgery may be difficult if there is no obvious hernia present, since the site of the leak may not be defined. In this setting, imaging studies, as described above, may help localize the defect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, the treatment of recurrent genital edema is dependent upon the etiology of the edema:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A patent processus vaginalis should be surgically repaired. This anatomic defect can be detected by technetium scanning, CT with intra-peritoneal contrast, MRI scanning without gadolinium or by exploratory laparotomy.",
"     </li>",
"     <li>",
"      Migration of fluid via the anterior abdominal wall can be treated as previously described. This migration occurs via either small rents in the peritoneal membrane or pericatheter leak.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If it is unclear if genital wall edema is secondary to dialysate leakage, then confirmation of the leakage can be performed by imaging techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/17,27\">",
"     17,27",
"    </a>",
"    ]. Sequential imaging can be used to determine if dialysate fluid travels outside of the peritoneal cavity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41061/abstract/17,27,28\">",
"     17,27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abdominal hernias can be a significant problem in patients treated with continuous peritoneal dialysis (PD). Hernia rates among patients undergoing PD are currently reported at a rate of 0.06 to 0.08 per patient per year. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      From a pathophysiologic standpoint, the principal risk factors for the hernia formation reflect anatomic, hydrostatic, or metabolic factors. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors for hernia formation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms include painless swelling at different sites, discomfort or disfigurement, and problems related to a complication from the hernia. The migration of peritoneal fluid into adjacent body structures can lead to either abdominal wall or genital edema. More serious complications are rare but include small bowel obstruction and intestinal incarceration",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      strangulation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several measures can be taken in the preoperative and postoperative periods to reduce the risk of hernia formation and dialysis leaks including evaluation and repair of existing hernias, the location and procedures used for peritoneal dialysis catheter placement, and methods to decrease intra-abdominal pressure in the post-operative period. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who develop a hernia after the initiation of PD should undergo elective repair, if possible. The use of a polypropylene mesh prosthesis appears to decrease the risk of hernia formation post-operatively. Low-volume, supine peritoneal dialysis can often be resumed several days after surgical repair.",
"     </li>",
"     <li>",
"      Treatment of a dialysate leak varies in patients with or without an associated hernia. Treatment of an uncomplicated dialysate leak (that is, no associated hernia) can initially be treated by temporarily stopping PD, by changing to low volume, supine, or dry day PD, or by a short term transfer to hemodialysis. Treatment of recurrent leaks depends on the location and etiology of the leak (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41061/abstract/1\">",
"      Rocco, MV, Stone, WJ. Abdominal hernias in chronic peritoneal dialysis patients: A review. Perit Dial Bull 1985; 5:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41061/abstract/2\">",
"      Suh H, Wadhwa NK, Cabralda T, et al. Abdominal wall hernias in ESRD patients receiving peritoneal dialysis. Adv Perit Dial 1994; 10:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41061/abstract/3\">",
"      Spence PA, Mathews RE, Khanna R, Oreopoulos DG. Improved results with a paramedian technique for the insertion of peritoneal dialysis catheters. Surg Gynecol Obstet 1985; 161:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41061/abstract/4\">",
"      Del Peso G, Bajo MA, Costero O, et al. Risk factors for abdominal wall complications in peritoneal dialysis patients. Perit Dial Int 2003; 23:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41061/abstract/5\">",
"      Hussain SI, Bernardini J, Piraino B. The risk of hernia with large exchange volumes. Adv Perit Dial 1998; 14:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41061/abstract/6\">",
"      Modi KB, Grant AC, Garret A, Rodger RS. Indirect inguinal hernia in CAPD patients with polycystic kidney disease. Adv Perit Dial 1989; 5:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41061/abstract/7\">",
"      Tokg&ouml;z B, Dogukan A, G&uuml;ven M, et al. Relationship between different body size indicators and hernia development in CAPD patients. Clin Nephrol 2003; 60:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41061/abstract/8\">",
"      Leblanc M, Ouimet D, Pichette V. Dialysate leaks in peritoneal dialysis. Semin Dial 2001; 14:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41061/abstract/9\">",
"      Morris-Stiff G, Coles G, Moore R, et al. Abdominal wall hernia in autosomal dominant polycystic kidney disease. Br J Surg 1997; 84:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41061/abstract/10\">",
"      Twardowski ZJ, Prowant BF, Nolph KD, et al. High volume, low frequency continuous ambulatory peritoneal dialysis. Kidney Int 1983; 23:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41061/abstract/11\">",
"      Bargman JM. Complications of peritoneal dialysis related to increased intraabdominal pressure. Kidney Int Suppl 1993; 40:S75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41061/abstract/12\">",
"      Aranda RA, Rom&atilde;o J&uacute;nior JE, Kakehashi E, et al. Intraperitoneal pressure and hernias in children on peritoneal dialysis. Pediatr Nephrol 2000; 14:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41061/abstract/13\">",
"      Bleyer AJ, Casey MJ, Russell GB, et al. Peritoneal dialysate fill-volumes and hernia development in a cohort of peritoneal dialysis patients. Adv Perit Dial 1998; 14:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41061/abstract/14\">",
"      Dejardin A, Robert A, Goffin E. Intraperitoneal pressure in PD patients: relationship to intraperitoneal volume, body size and PD-related complications. Nephrol Dial Transplant 2007; 22:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41061/abstract/15\">",
"      Twardowski ZJ, Khanna R, Nolph KD, et al. Intraabdominal pressures during natural activities in patients treated with continuous ambulatory peritoneal dialysis. Nephron 1986; 44:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41061/abstract/16\">",
"      Colin JF, Elliot P, Ellis H. The effect of uraemia upon wound healing: an experimental study. Br J Surg 1979; 66:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41061/abstract/17\">",
"      O'Connor JP, Rigby RJ, Hardie IR, et al. Abdominal hernias complicating continuous ambulatory peritoneal dialysis. Am J Nephrol 1986; 6:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41061/abstract/18\">",
"      Cherney DZ, Siccion Z, Chu M, Bargman JM. Natural history and outcome of incarcerated abdominal hernias in peritoneal dialysis patients. Adv Perit Dial 2004; 20:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41061/abstract/19\">",
"      Garc&iacute;a-Ure&ntilde;a MA, Rodr&iacute;guez CR, Vega Ruiz V, et al. Prevalence and management of hernias in peritoneal dialysis patients. Perit Dial Int 2006; 26:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41061/abstract/20\">",
"      Winchester JF, Kriger FL. Fluid leaks: prevention and treatment. Perit Dial Int 1994; 14 Suppl 3:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41061/abstract/21\">",
"      Crabtree JH, Burchette RJ. Effective use of laparoscopy for long-term peritoneal dialysis access. Am J Surg 2009; 198:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41061/abstract/22\">",
"      Guzm&aacute;n-Valdivia G, Zaga I. Abdominal wall hernia repair in patients with chronic renal failure and a dialysis catheter. Hernia 2001; 5:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41061/abstract/23\">",
"      Tast C, Kuhlmann U, St&ouml;lzing H, et al. Continuing CAPD after herniotomy. EDTNA ERCA J 2002; 28:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41061/abstract/24\">",
"      Mart&iacute;nez-Mier G, Garcia-Almazan E, Reyes-Devesa HE, et al. Abdominal wall hernias in end-stage renal disease patients on peritoneal dialysis. Perit Dial Int 2008; 28:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41061/abstract/25\">",
"      Shah H, Chu M, Bargman JM. Perioperative management of peritoneal dialysis patients undergoing hernia surgery without the use of interim hemodialysis. Perit Dial Int 2006; 26:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41061/abstract/26\">",
"      Mandel P, Faegenburg D, Imbriano LJ. The use of technetium-99m sulfur colloid in the detection of patent processus vaginalis in patients on continuous ambulatory peritoneal dialysis. Clin Nucl Med 1985; 10:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41061/abstract/27\">",
"      Juergensen PH, Rizvi H, Caride VJ, et al. Value of scintigraphy in chronic peritoneal dialysis patients. Kidney Int 1999; 55:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41061/abstract/28\">",
"      Prischl FC, Muhr T, Seiringer EM, et al. Magnetic resonance imaging of the peritoneal cavity among peritoneal dialysis patients, using the dialysate as \"contrast medium\". J Am Soc Nephrol 2002; 13:197.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1865 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-A1F0AAE071-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_6_41061=[""].join("\n");
var outline_f40_6_41061=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS FOR HERNIA FORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Anatomic sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hydrostatic pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Metabolic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS OF HERNIAS AND DIALYSATE LEAKS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Surgical repair of hernias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Treatment of dialysate leaks with or without hernia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Abdominal wall or genital edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20761?source=related_link\">",
"      Abdominal compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/33/30233?source=related_link\">",
"      Extrarenal manifestations of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/32/41477?source=related_link\">",
"      Modalities for the diagnosis of abdominal and thoracic cavity defects in peritoneal dialysis patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_6_41062="Flumazenil: Drug information";
var content_f40_6_41062=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Flumazenil: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/60/36803?source=see_link\">",
"    see \"Flumazenil: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/58/38821?source=see_link\">",
"    see \"Flumazenil: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F172027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Romazicon&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F172028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Anexate&reg;;",
"     </li>",
"     <li>",
"      Flumazenil Injection;",
"     </li>",
"     <li>",
"      Flumazenil Injection, USP;",
"     </li>",
"     <li>",
"      Romazicon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F172071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidote",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F172031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Reversal of conscious sedation and general anesthesia:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial dose: 0.2 mg over 15 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Repeat doses (maximum: 4 doses): If desired level of consciousness is not obtained, 0.2 mg may be repeated at 1-minute intervals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maximum total cumulative dose: 1 mg (usual total dose: 0.6-1 mg). In the event of resedation: Repeat doses may be given at 20-minute intervals as needed at 0.2 mg per minute to a maximum of 1 mg total dose and 3 mg in 1 hour.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspected benzodiazepine overdose:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial dose: 0.2 mg over 30 seconds; if the desired level of consciousness is not obtained 30 seconds after the dose, 0.3 mg can be given over 30 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Repeat doses: 0.5 mg over 30 seconds repeated at 1-minute intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maximum total cumulative dose: 3 mg (usual total dose: 1-3 mg). Patients with a partial response at 3 mg may require (rare) additional titration up to a total dose of 5 mg (although doses &gt;3 mg do not reliably produce additional effects). If a patient has not responded 5 minutes after cumulative dose of 5 mg, the major cause of sedation is not likely due to benzodiazepines. In the event of resedation, repeat doses may be given at 20-minute intervals if needed, at 0.5 mg per minute to a maximum of 1 mg total dose and 3 mg in 1 hour.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F172050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/58/38821?source=see_link\">",
"      see \"Flumazenil: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Reversal of benzodiazepine when used in conscious sedation:",
"     </b>",
"     Children &ge;1 year: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Initial dose: 0.01 mg/kg over 15 seconds (maximum: 0.2 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Repeat doses (maximum: 4 doses): If desired level of consciousness is not obtained, 0.01 mg/kg (maximum: 0.2 mg) repeated at 1-minute intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum total cumulative dose: 1 mg or 0.05 mg/kg (whichever is lower)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mean total dose: 0.65 mg (range: 0.08-1 mg)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F172032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. No differences in safety or efficacy have been reported; however, increased sensitivity may occur in some elderly patients.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F172033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; however, pharmacokinetics are not significantly affected by renal failure (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute) or hemodialysis.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F172034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial reversal: No dosage adjustment necessary. Repeat doses: Reduce dose or frequency.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F172006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 0.1 mg/mL (5 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Romazicon&reg;: 0.1 mg/mL (10 mL [DSC]) [contains edetate disodium]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F171991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F172009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Administer in freely-running I.V. into large vein. Inject over 15 seconds for reversal of conscious sedation and general anesthesia and over 30 seconds for benzodiazepine overdose.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F172078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F172007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Benzodiazepine antagonist; reverses sedative effects of benzodiazepines used in conscious sedation and general anesthesia; treatment of benzodiazepine overdose",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7914344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Flumazenil may be confused with influenza virus vaccine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F172069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Vomiting (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Palpitation (3% to 9%), flushing (1% to 3%), vasodilation (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Ataxia (10%), dizziness (10%), vertigo (10%), agitation (3% to 9%), anxiety (3% to 9%), insomnia (3% to 9%), nervousness (3% to 9%), abnormal crying (1% to 3%), depersonalization (1% to 3%), depression (1% to 3%), dysphoria (1% to 3%), emotional lability (1% to 3%), euphoria (1% to 3%), fatigue (1% to 3%), headache (1% to 3%), malaise (1% to 3%), paranoia (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flashes (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (3% to 9%), nausea (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Pain at injection site (3% to 9%), injection site reaction (1% to 3%), rash (1% to 3%), skin abnormality (1% to 3%), thrombophlebitis (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Hypoesthesia (1% to 3%), paresthesia (1% to 3%), weakness (1% to 3%), tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (3% to 9%), abnormal vision (1% to 3%), lacrimation (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (3% to 9%), hyperventilation (3% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal hearing, altered blood pressure increased/decreased, arrhythmia, bradycardia, chest pain, confusion, coldness sensation, delirium, difficulty concentrating, dysphonia, fear, generalized seizure, hiccups, hyperacusis, hypertension, junctional tachycardia, panic attacks, rigors, seizure, shivering, somnolence, stupor, tachycardia, thick tongue, tinnitus, transient hearing impairment, ventricular tachycardia, withdrawal syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F172012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to flumazenil, benzodiazepines, or any component of the formulation; patients given benzodiazepines for control of potentially life-threatening conditions (eg, control of intracranial pressure or status epilepticus); patients who are showing signs of serious cyclic-antidepressant overdosage",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F171995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Amnesia: Does not consistently reverse amnesia; patient may not recall verbal instructions after procedure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving) for 24 hours after discharge.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Resedation: Occurs more frequently in patients where a large single dose or cumulative dose of a benzodiazepine has been administered along with a neuromuscular-blocking agent and multiple anesthetic agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory depression: Should not rely upon to reverse respiratory depression/hypoventilation. Flumazenil is not a substitute for evaluation of oxygenation. Establishing an airway and assisting ventilation, as necessary, is always the initial step in overdose management.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures:",
"     <b>",
"      [U.S. Boxed Warning]: Benzodiazepine reversal may result in seizures; seizures may occur more frequently in patients on benzodiazepines for long-term sedation or following tricyclic antidepressant overdose. Dose should be individualized and practitioners should be prepared to manage seizures.",
"     </b>",
"     Seizures may also develop in patients with concurrent major sedative-hypnotic drug withdrawal, recent therapy with repeated doses of parenteral benzodiazepines, myoclonic jerking or seizure activity prior to flumazenil administration. Use with caution in patients relying on a benzodiazepine for seizure control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head injury: Use with caution in patients with a head injury; may alter cerebral blood flow or precipitate convulsions in patients receiving benzodiazepines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic dysfunction; repeated doses of the drug should be reduced in frequency or amount.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Panic disorder: Use with caution in patients with a history of panic disorder; may provoke panic attacks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug/alcohol dependence: Use caution in drug and ethanol-dependent patients; these patients may also be dependent on benzodiazepines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intensive care patients: Should be used with caution in the intensive care unit because of increased risk of unrecognized benzodiazepine dependence in such settings.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Should not be used to diagnose benzodiazepine-induced sedation. Reverse neuromuscular blockade before considering use. Flumazenil does not antagonize the CNS effects of other GABA agonists (such as ethanol, barbiturates, or general anesthetics); nor does it reverse narcotics. Not recommended for treatment of benzodiazepine dependence.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Overdose use: Use with caution in patients with mixed drug overdoses; toxic effects of other drugs taken may emerge once benzodiazepine effects are reversed.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F172000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypnotics (Nonbenzodiazepine): Flumazenil may diminish the sedative effect of Hypnotics (Nonbenzodiazepine).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ramelteon.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F172002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F172014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not seen in animal reproduction studies. Embryocidal effects were seen at large doses. Use during labor and delivery is not recommended. In general, medications used as antidotes should take into consideration the health and prognosis of the mother (Bailey, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F172037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15962080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if flumazenil is excreted in breast milk. The manufacturer recommends that caution be used if administering to breast-feeding women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F15962118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol for the first 24 hours after administration or as long as the effects of benzodiazepines exist.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Flumazenil Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg/5 mL (5 mL): $8.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/10 mL (10 mL): $148.31",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F172004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for return of sedation, respiratory depression, and other residual effects of benzodiazepines for at least 2 hours and until the patient is stable and resedation is unlikely.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F172015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Anexate (AE, AT, AU, BE, BF, BG, BH, BJ, CH, CI, CL, CY, CZ, DE, EE, EG, ES, ET, FR, GB, GH, GM, GN, GR, HK, HN, HR, HU, ID, IE, IL, IQ, IR, IT, JO, JP, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, NO, NZ, OM, PK, PL, PT, QA, SA, SC, SD, SL, SN, SY, TH, TN, TR, TW, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Antabenz (MY);",
"     </li>",
"     <li>",
"      Lanexat (AR, BB, BM, BR, BS, BZ, CN, CO, DK, EC, FI, GY, JM, MX, PE, PY, SE, SR, TT, UY, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F171994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitively inhibits the activity at the benzodiazepine receptor site on the GABA/benzodiazepine receptor complex. Flumazenil does not antagonize the CNS effect of drugs affecting GABA-ergic neurons by means other than the benzodiazepine receptor (ethanol, barbiturates, general anesthetics) and does not reverse the effects of opioids",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F172011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 1-2 minutes; 80% response within 3 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: 6-10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Resedation occurs after ~1 hour (range: 19-50 minutes); duration related to dose given and benzodiazepine plasma concentrations; reversal effects of flumazenil may wear off before effects of benzodiazepine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Initial V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.5 L/kg; V",
"     <sub>",
"      dss",
"     </sub>",
"     : 0.9-1.1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~50% (~67% of which is bound to albumin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; dependent upon hepatic blood flow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Adults: Alpha: 4-11 minutes; Terminal: 40-80 minutes; Moderate hepatic dysfunction: 1.3 hours; Severe hepatic impairment: 2.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces; urine (&lt;1% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bailey B, \"Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?\"",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2003, 67(2):133-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/6/41062/abstract-text/12769509/pubmed\" id=\"12769509\" target=\"_blank\">",
"        12769509",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baktai G, Szekely E, Marialigeti T, et al, &ldquo;Use of Midazolam (Dormicum) and Flumazenil (Anexate) in Paediatric Bronchology,&rdquo;",
"      <i>",
"       Curr Med Res Opin",
"      </i>",
"      , 1992, 12(9):552-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/6/41062/abstract-text/1582237/pubmed\" id=\"1582237\" target=\"_blank\">",
"        1582237",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brammer G, Gilby R, Walter FG, et al, &ldquo;Continuous Intravenous Flumazenil Infusion for Benzodiazepine Poisoning,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 2000, 42(5):280-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/6/41062/abstract-text/11003118/pubmed\" id=\"11003118\" target=\"_blank\">",
"        11003118",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chern CH, Chern TL, Hu SC, et al, &ldquo;Complete and Partial Response to Flumazenil in Patients With Suspected Benzodiazepine Overdose,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1995, 13(3):372-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/6/41062/abstract-text/7755838/pubmed\" id=\"7755838\" target=\"_blank\">",
"        7755838",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chern CH, Chern TL, Wang LM, et al, &ldquo;Continuous Flumazenil Infusion in Preventing Complications Arising From Severe Benzodiazepine Intoxication,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1998, 16(3):238-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/6/41062/abstract-text/9596422/pubmed\" id=\"9596422\" target=\"_blank\">",
"        9596422",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clark RF, Sage TA, Tunget C, et al, &ldquo;Delayed Onset Lorazepam Poisoning Successfully Reversed By Flumazenil in a Child: Case Report and Review of the Literature,&rdquo;",
"      <i>",
"       Pediatr Emerg Care",
"      </i>",
"      , 1995, 11(1):32-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/6/41062/abstract-text/7739960/pubmed\" id=\"7739960\" target=\"_blank\">",
"        7739960",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ghouri AF, Ramirez Ruiz MA, and White PF, &ldquo;Effect of Flumazenil on Recovery After Midazolam and Propofol Sedation,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1994, 81(2):330-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Haverkos GP, Di Salvo RP, and Imhoff TE, &ldquo;Fatal Seizures After Flumazenil Administration in a Patient With Mixed Overdose,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1994, 28(12):1347-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/6/41062/abstract-text/7696723/pubmed\" id=\"7696723\" target=\"_blank\">",
"        7696723",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hojer J, Baehrendtz S, Magnusson A, et al, &ldquo;A Placebo-Controlled Trial of Flumazenil Given by Continuous Infusion in Severe Benzodiazepine Overdosage,&rdquo;",
"      <i>",
"       Acta Anaesthesiol Scand",
"      </i>",
"      , 1991, 35(7):584-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/6/41062/abstract-text/1686131/pubmed\" id=\"1686131\" target=\"_blank\">",
"        1686131",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jones RD, Lawson AD, Andrew LJ, et al, &ldquo;Antagonism of the Hypnotic Effect of Midazolam in Children: A Randomized, Double Blind Study of Placebo and Flumazenil Administered After Midazolam-Induced Anaesthesia,&rdquo;",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1991, 66(6):660-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/6/41062/abstract-text/2064881/pubmed\" id=\"2064881\" target=\"_blank\">",
"        2064881",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Massanari M, Novitsky J, and Reinstein LJ, &ldquo;Paradoxical Reactions in Children Associated With Midazolam Use During Endoscopy,&rdquo;",
"      <i>",
"       Clin Pediatr (Phila)",
"      </i>",
"      , 1997, 36(12):681-4.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mathieu-Nolf M, Bab&eacute; MA, Coquelle-Couplet V, et al, &ldquo;Flumazenil Use in an Emergency Department: A Survey,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 2001, 39(1):15-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/6/41062/abstract-text/11327221/pubmed\" id=\"11327221\" target=\"_blank\">",
"        11327221",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McDuffee AT and Tobias JD, &ldquo;Seizure After Flumazenil Administration in a Pediatric Patient,&rdquo;",
"      <i>",
"       Pediatr Emerg Care",
"      </i>",
"      , 1995, 11(3):186-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/6/41062/abstract-text/7651879/pubmed\" id=\"7651879\" target=\"_blank\">",
"        7651879",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reisner-Keller LA and Pham Z, &ldquo;Oral Flumazenil in the Treatment of Epilepsy,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1995, 29(5):530-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/6/41062/abstract-text/7655138/pubmed\" id=\"7655138\" target=\"_blank\">",
"        7655138",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Richard P, Autret E, Bardol J, et al, &ldquo;The Use of Flumazenil in a Neonate,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1991, 29(1):137-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/6/41062/abstract-text/2005661/pubmed\" id=\"2005661\" target=\"_blank\">",
"        2005661",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roald OK and Dahl V, &ldquo;Flunitrazepam Intoxication in a Child Successfully Treated With the Benzodiazepine Antagonist Flumazenil,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1989, 17(12):1355-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/6/41062/abstract-text/2512053/pubmed\" id=\"2512053\" target=\"_blank\">",
"        2512053",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shannon M, Albers G, Burkhart K, et al, &ldquo;Safety and Efficacy of Flumazenil in the Reversal of Benzodiazepine-Induced Conscious Sedation. The Flumazenil Pediatric Study Group,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1997, 131(4):582-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/6/41062/abstract-text/9386663/pubmed\" id=\"9386663\" target=\"_blank\">",
"        9386663",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spivey WH, &ldquo;Flumazenil and Seizures: Analysis of 43 Cases,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 1992, 14(2):292-305.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/6/41062/abstract-text/1611650/pubmed\" id=\"1611650\" target=\"_blank\">",
"        1611650",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sugarman JM and Paul RI, &ldquo;Flumazenil: A Review,&rdquo;",
"      <i>",
"       Pediatr Emerg Care",
"      </i>",
"      , 1994, 10(1):37-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/6/41062/abstract-text/8177806/pubmed\" id=\"8177806\" target=\"_blank\">",
"        8177806",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trujillo MH, Guerrero J, Fragachan C, et al, &ldquo;Pharmacologic Antidotes in Critical Care Medicine: A Practical Guide for Drug Administration,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1998, 26(2):377-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/6/41062/abstract-text/9468179/pubmed\" id=\"9468179\" target=\"_blank\">",
"        9468179",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wiley J and Wiley C, &ldquo;Benzodiazepine Ingestions in Children,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1995, 33(5):520.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8456 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-46FA143880-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_6_41062=[""].join("\n");
var outline_f40_6_41062=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708776\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172027\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172028\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172071\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172031\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172050\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172032\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172033\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172034\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172006\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171991\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172009\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172078\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172007\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914344\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172069\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172012\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171995\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299345\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172000\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172002\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172014\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172037\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962080\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962118\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323156\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172004\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172015\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171994\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172011\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8456\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8456|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/60/36803?source=related_link\">",
"      Flumazenil: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/58/38821?source=related_link\">",
"      Flumazenil: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_6_41063="Elevator under nail";
var content_f40_6_41063=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Nail elevator under the nail plate during partial nail avulsion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 418px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Elizabeth Billingsley, MD, Dept of Dermatology, Penn State Hershey.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_6_41063=[""].join("\n");
var outline_f40_6_41063=null;
var title_f40_6_41064="Surgical treatment of differentiated thyroid cancer";
var content_f40_6_41064=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgical treatment of differentiated thyroid cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/6/41064/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/6/41064/contributors\">",
"     R Michael Tuttle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/6/41064/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/6/41064/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/6/41064/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/6/41064/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/6/41064/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary therapy for differentiated (papillary and follicular) thyroid cancer is surgery. Considerable controversy exists about how much thyroid tissue should be removed at the initial operation, and there are no prospective randomized clinical trials to provide guidance for selection of the optimal operation.",
"   </p>",
"   <p>",
"    However, an increasing body of evidence suggests that most patients with papillary and follicular thyroid cancer are best served by total (or near-total) thyroidectomy.",
"   </p>",
"   <p>",
"    This topic will review the rationale behind selection of the most appropriate type of operation for these patients, the basic approaches to the operation, and management of the medical complications of surgery, particularly hypoparathyroidism. An overview of the management of differentiated thyroid cancer, radioiodine treatment, and external radiotherapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/17/44313?source=see_link\">",
"     \"Overview of the management of differentiated thyroid cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/13/34010?source=see_link\">",
"     \"Radioiodine treatment of differentiated thyroid cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/17/39191?source=see_link\">",
"     \"External beam radiotherapy in the treatment of thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IMPORTANCE OF PREOPERATIVE STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative ultrasonography of the central and lateral neck identifies abnormal lymph nodes in as many as 20 to 30 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]; these ultrasound findings may alter the planned surgical procedure in up to 20 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. However, ultrasonography can miss as many as 50 percent of the involved lymph nodes in the central neck because the overlying thyroid gland hinders adequate visualization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/5\">",
"     5",
"    </a>",
"    ]. While ultrasonography is the preferred modality for evaluation of the thyroid and cervical lymph nodes, alternative imaging modalities such as MRI, CT with contrast, laryngoscopy and endoscopy may be required to adequately stage locally invasive tumors presenting with rapid growth, fixation to surrounding structures or evidence of invasion into major neck structures. In these locally aggressive cases, the benefit of accurate surgical planning outweighs the delay in radioiodine administration that is necessary after the use of iodinated contrast.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SURGICAL OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two potential surgical approaches to differentiated thyroid cancer: total (or near-total) thyroidectomy and unilateral lobectomy and isthmusectomy. A third option, subtotal thyroidectomy, is considered to be an inadequate procedure and is not recommended.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Total thyroidectomy involves removal of all thyroid tissue while attempting to identify and preserve the recurrent laryngeal nerve, the superior laryngeal nerve, and the vascular supply to the parathyroid glands.",
"     </li>",
"     <li>",
"      Near-total thyroidectomy is identical except for a slightly more conservative approach to preserving the posterior thyroid capsule of the lobe contralateral to the thyroid tumor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The difference between these two procedures is primarily a semantic one, because most patients who undergo radioiodine imaging after total thyroidectomy have thyroid-bed uptake consistent with residual normal thyroid tissue. At our center, we recommend total thyroidectomy for most patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During a unilateral lobectomy and isthmusectomy, the surgeon removes one entire lobe and the isthmus, without entering the contralateral neck.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subtotal thyroidectomy, in which several grams of thyroid tissue are preserved along the posterior capsule bilaterally, is an",
"    <strong>",
"     inadequate",
"    </strong>",
"    procedure for patients with thyroid cancer. It is associated with a higher complication rate if subsequent surgery is required, and we do not recommend it [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Total thyroidectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend total thyroidectomy for most patients with thyroid cancer. Our approach is supported by the following arguments:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Foci of papillary cancer are found in both thyroid lobes in up to 36 to 85 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/9-12\">",
"       9-12",
"      </a>",
"      ]. Although some of these multifocal lesions may represent metastases via intrathyroidal lymphatics, one study demonstrated that at least half of multifocal tumors may have independent origins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/13\">",
"       13",
"      </a>",
"      ]. Multifocality in the ipsilateral lobe was the only variable that predicted contralateral tumor in one study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Between 5 and 10 percent of recurrences of thyroid cancer are in the contralateral lobe [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One-half of patients who die from recurrent thyroid cancer die from complications of central neck recurrence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Radioiodine ablation of thyroid bed remnants and treatment of metastatic disease is facilitated by resection of as much thyroid tissue as possible.",
"     </li>",
"     <li>",
"      The specificity of measurements of serum thyroglobulin as a tumor marker is facilitated by removal of nearly all normal thyroid tissue.",
"     </li>",
"     <li>",
"      During follow up, ultrasonography (US) often identifies nonspecific abnormalities in the remaining contralateral lobe that is a source of concern to both the clinician and the patient. While only a minority of these US-detected abnormalities proves to be thyroid cancer, they usually lead to additional testing and often additional surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Retrospective studies indicate that the risk of recurrence and death is reduced with a total thyroidectomy in patients whose primary tumors are 10 mm or more [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/16-20\">",
"     16-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of 52,173 patients in the National Cancer Data Base, 83 percent had a total thyroidectomy and 17 percent had a lobectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/20\">",
"     20",
"    </a>",
"    ]. The risk of recurrence or death was higher after a lobectomy for patients with tumors greater than 10 mm (HR 1.15 and 1.31 for recurrence or death, respectively). To minimize the influence of larger tumors, the subgroup with tumors between 10 and 20 mm were analyzed separately; the risk of recurrence or death was still higher with lobectomy compared to total thyroidectomy (HR 1.24 and 1.49).",
"   </p>",
"   <p>",
"    Additional evidence of benefit of total or near-total thyroidectomy came with publication of results from the National Thyroid Cancer Treatment Cooperative Study Group in 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/21\">",
"     21",
"    </a>",
"    ]. In a multicenter analysis of the outcomes of nearly 3000 patients with differentiated thyroid cancer, significantly worse overall survival was reported in the following groups of patients who underwent less than total or near total thyroidectomy (with risk ratios for all-cause mortality in subgroups ranging from 1.36 to 1.76):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Papillary cancer under age 45, with tumor greater than 4 cm, or in the presence of macroscopic extrathyroidal extension or extracervical metastases",
"     </li>",
"     <li>",
"      Papillary cancer at age &ge;45, with tumor of at least 1 cm, or in the presence of multifocal tumors, extrathyroidal extension, or metastases to locoregional nodes or distant sites",
"     </li>",
"     <li>",
"      Follicular cancer under age 45, with tumor greater than 4 cm, or in the presence of macroscopic multifocality, macroscopic invasion of either the tumor capsule or extrathyroidal tissues, poor differentiation, or extracervical metastases",
"     </li>",
"     <li>",
"      Follicular cancer at age &ge;45",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional data from the 2009 National Thyroid Cancer Treatment Cooperative Study Group demonstrated a lower recurrence rate in patients with multifocal microscopic papillary cancer who had a total or near-total thyroidectomy (6 versus 18 percent in those undergoing less than near-total thyroidectomy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether there is a clinically important difference between total thyroidectomy and near-total thyroidectomy is uncertain. This was illustrated by the results of an analysis of 23,605 patients from the NCI SEER (National Cancer Institute; Surveillance, Epidemiology, and End Results) database with median follow-up of 6.6 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/23\">",
"     23",
"    </a>",
"    ]. In a multivariate analysis adjusted for prognostic variables (ie, older age, larger tumors with extrathyroidal extension), there was a significantly lower 10-year overall survival and cause-specific survival in patients treated with near-total versus total thyroidectomy (overall survival 89.5 versus 90.4 percent, hazard ratio 1.21, 95% CI 1.03-1.41; cause-specific survival 96.6 versus 96.8, HR 1.39, 95% CI 1.06-1.82). The absolute difference in outcomes favoring total thyroidectomy (0.9 and 0.2 percent) is small and of uncertain clinical significance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Unilateral lobectomy and isthmusectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two arguments have been put forth to support a unilateral procedure in most patients: absence of a survival benefit with more extensive surgery, and fewer complications with unilateral surgery.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In some studies, survival was improved by total thyroidectomy only in patients with \"high-risk\" disease, ie, older patients with extrathyroidal papillary cancer, capsular invasion by follicular cancer, or a primary tumor greater than 5 cm in diameter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/24\">",
"       24",
"      </a>",
"      ]. However, one retrospective analysis found that, even in high-risk patients, the 10-year outcome was not affected by the extent of surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 1656 low-risk patients, ie, young adults with small tumors, treated at the Mayo Clinic by unilateral or bilateral thyroidectomy, the local recurrence rate was higher in the patients treated by unilateral thyroidectomy (14 percent versus 2 percent), but the 20-year rates of distant metastases and death from cancer were similar [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the analysis from the NCI SEER database described above, patients treated with lobectomy had a 10-year overall survival (90.8 percent) and cause-specific survival (98.6 percent) that was nearly identical to patients selected to receive total thyroidectomy (90.4 percent and 96.8 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/23\">",
"       23",
"      </a>",
"      ]. A greater proportion of patients who were treated with lobectomy had smaller tumor size &le;2 cm (65 versus 53 percent) without extrathyroidal extension, suggesting that the appropriate selection of candidates for lobectomy is important for achieving good outcomes.",
"     </li>",
"     <li>",
"      Postoperative hypoparathyroidism is rare following lobectomy because a unilateral procedure avoids the contralateral neck. Similarly, although hoarseness may result from damage to one recurrent laryngeal nerve in about 1 percent of cases, a unilateral procedure avoids the possibility of bilateral paralysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Choice of procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The publication of several consensus guidelines on management of thyroid cancer has helped to establish a general standard of surgical management for this disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. Given access to an experienced thyroid surgeon, we recommend the following procedures for patients with papillary or follicular cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Total thyroidectomy is recommended if the primary tumor is 1.0 cm in diameter or greater, there is extrathyroidal extension of tumor, or there are metastases. This operation should also be performed in all patients with thyroid cancer who have a history of exposure to ionizing radiation of the head and neck, given the high rate of tumor recurrence with lesser operations in these patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/32\">",
"       32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/49/1818?source=see_link\">",
"       \"Radiation-induced thyroid cancer\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      If an experienced thyroid surgeon is unavailable and it is impossible to refer the patient elsewhere, then the slightly more conservative \"near total\" procedure should be performed.",
"     </li>",
"     <li>",
"      Unilateral lobectomy and isthmusectomy can be considered if the tumor is less than 1.0 cm in diameter (or even up to 3 cm if entirely confined to thyroid in low risk patients) and confined to one lobe of the gland, because the 30-year survival rate for this subgroup of patients approaches 100 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/19\">",
"       19",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Since greater than 25 percent contact with the thyroid capsule on pre-operative ultrasound has a 71 percent positive predictive value for extrathyroid extension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/33\">",
"       33",
"      </a>",
"      ], this pre-op ultrasonographic characteristic would suggest that a total thyroidectomy may be warranted rather than a unilateral procedure. Furthermore, with the widespread use of neck ultrasonography in these low risk patients, minor abnormalities often develop in the contralateral lobe during long-term follow-up, which are worrisome for recurrence. Therefore, a total thyroidectomy is often considered, even in low risk patients, because of these practical follow-up issues.",
"      <br/>",
"      <br/>",
"      Alternatively, a surgeon intending to perform a total thyroidectomy for more extensive disease may choose to stop with a unilateral lobectomy and isthmusectomy if the recurrent laryngeal nerve has been damaged or intentionally sacrificed during the resection of the initial lobe. The patient should subsequently be referred to a specialist for completion of thyroidectomy.",
"     </li>",
"     <li>",
"      Node dissection should be performed if there is clinical evidence (on exam or ultrasound) of cervical or mediastinal node metastases due to the increased risk of neck recurrence and mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/19\">",
"       19",
"      </a>",
"      ]. If diseased nodes are found in the central compartment (the region bounded by the jugular veins, the hyoid bone, and the upper mediastinum), then all nodal groups in this area should be resected. The presence of diseased nodes lateral to the jugular vein indicates a need for a modified radical neck dissection, sparing the internal jugular vein, spinal accessory nerve, and sternocleidomastoid muscle. This topic is discussed in greater detail below. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Approach to neck dissection'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with a cytologically suspicious nodule, and not proven cancer, a unilateral lobectomy and isthmusectomy is usually performed. Because as many as 60 percent of these patients may prove to have benign disease, total thyroidectomy is usually not required as the initial procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/34\">",
"     34",
"    </a>",
"    ]. If the final pathologic diagnosis is cancer, a completion thyroidectomy can then be performed without significantly increased risk because the second surgery would avoid the first operative field [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. This occurs most commonly in patients with follicular cancer or the follicular variant of papillary cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     APPROACH TO THYROIDECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knowledge of the surgical technique of thyroidectomy allows the referring clinician to interpret operative reports and findings, to understand the particular risks of thyroidectomy, and to explain to the patient what lies ahead [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Identification and preservation of the recurrent and superior laryngeal nerves are the major technical challenges of this procedure. The technique of thyroidectomy is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/57/31642?source=see_link\">",
"     \"Initial and reoperative thyroidectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Parathyroid glands",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to identifying the recurrent and superior laryngeal nerves, normal variations in the location and number of the parathyroid glands must be appreciated to avoid postoperative hypoparathyroidism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/23/29045?source=see_link\">",
"     \"Surgical anatomy of the parathyroid glands\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most superior parathyroid glands are located within 1 cm of the intersection of the recurrent laryngeal nerve and the inferior thyroid artery, usually within the thyroid fascia. About 15 percent are located within the thyroid capsule, and the remainder are located in the retropharyngeal or retroesophageal spaces.",
"     </li>",
"     <li>",
"      The location of the inferior glands is far more variable, although they are usually anterior and lateral to the recurrent nerves. They may be just below the superior glands, posterolateral to the lower pole of the thyroid; immediately inferior or posterior to the thyroid; within or below the thymus; or in the posterior mediastinum.",
"     </li>",
"     <li>",
"      The arterial supply for the parathyroid glands is usually provided by branches of the inferior thyroid artery; compromise of these vessels is the most common cause of postoperative hypoparathyroidism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     APPROACH TO NECK DISSECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Nomenclature",
"    </span>",
"    &nbsp;&mdash;&nbsp;A frequently used nomenclature defines level I nodes as submental and submandibular, level II, III, and IV nodes as upper, middle, and lower jugular, respectively, level V nodes as posterior, and level VI nodes as anterior central compartment. A consensus group has defined the relevant anatomy of the central neck and associated terminology that should be used to describe the indication (prophylactic versus therapeutic neck dissection) and the specific lymph node levels involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Therapeutic",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is general agreement that therapeutic node dissection should be performed in patients with papillary cancer who have visibly involved nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/7,31\">",
"     7,31",
"    </a>",
"    ]. Preoperative cervical ultrasound can detect clinically nonpalpable, metastatic nodes in up to 20 percent of patients with papillary cancer, including those with primary tumors &lt;1 cm in diameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/4,38\">",
"     4,38",
"    </a>",
"    ]. Lateral compartment nodes containing metastases detectable by ultrasound are associated with a shortened relapse-free survival, whereas those only found by histologic examination do not predict altered outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/38\">",
"     38",
"    </a>",
"    ]. Thus, we recommend lateral node dissection strategies based upon intraoperative gross involvement or preoperative ultrasound detection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although cervical nodal metastases are rare in patients with follicular cancer, patients with the H&uuml;rthle-cell variant may have nodal disease (which predicts a worse outcome) and should have a therapeutic neck dissection if metastatic lymph nodes are identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Prophylactic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microscopic regional lymph node metastases of papillary cancer occur in up to 80 percent of patients. However, only about 35 percent have cervical or mediastinal node metastases that are detected at the time of initial surgery. Because microscopic nodal disease is rarely of clinical importance or subsequent radioiodine administration ablates these occult foci, and observational studies have not shown a clear benefit in reducing locoregional recurrence rates, many authors argue that prophylactic neck dissection of microscopic lymph node metastases that are not clinically identifiable at the time of surgery may not improve long-term outcome and could subject patients to more risk than benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. However, the precise role of prophylactic neck dissection for well differentiated thyroid cancer remains controversial because in experienced hands, this procedure can be done with minimal additional risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/44\">",
"     44",
"    </a>",
"    ], and some observational studies have suggested a survival benefit in selected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Since thyroid cancers harboring the BRAF mutation have the potential to be more clinically aggressive and less responsive to RAI adjuvant therapy, some authors have suggested that prophylactic central neck dissection be considered for these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/47\">",
"     47",
"    </a>",
"    ]. However, until additional data are available demonstrating a clinical benefit to this approach, we are not advocating prophylactic neck dissection on the basis of the molecular profile of the tumor at the current time.",
"   </p>",
"   <p>",
"    The American Thyroid Association (ATA) guidelines suggest that prophylactic central-compartment neck dissection may be performed for advanced primary tumors (&gt;4 cm",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    with extrathyroidal invasion) but was not necessary for small, noninvasive papillary and most follicular cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Others who routinely perform prophylactic neck dissection argue that the absence of involved nodes and adverse pathological features modifies the indication for radioiodine therapy in many patients. In a retrospective study of 115 patients with papillary thyroid cancers under 2 cm (without ultrasound evidence of cervical nodes) undergoing neck dissection, 13 of 115 patients were identified (11 percent) who were expected to receive adjunctive radioiodine therapy, but did not because of the surgical findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/48\">",
"     48",
"    </a>",
"    ]. Follow-up in this study was only one year, and any benefit of avoiding radioiodine therapy has to be balanced against the risk of complications of neck dissection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with papillary cancer, we perform a preoperative assessment of nodal status with ultrasound, followed by a regional neck dissection only if there is clinical evidence of nodal involvement in the central or lateral neck compartments. This approach is consistent with the National Comprehensive Cancer Network, which recommends central neck dissection only in the presence of grossly positive metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During the operation, the lymph nodes should be inspected, and any suspected of containing cancer should be biopsied.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If nodes in the central compartment are found to contain cancer, dissection of all lymphatic and areolar tissue in that compartment should be performed.",
"     </li>",
"     <li>",
"      If any nodes in the upper, middle, or lower jugular nodal groups are found to contain cancer, complete dissection of nodal tissue along the jugular and carotid vessels should be done. Radical dissection, with removal of the internal jugular vein, spinal accessory nerve, and sternocleidomastoid muscle, is rarely necessary.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SURGERY FOR INVASIVE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary tumor or local and regional metastases may invade the strap muscles, trachea, recurrent laryngeal nerves, larynx, esophagus, thoracic duct, or carotid sheath. Careful preoperative and intraoperative evaluation, including laryngoscopy and symptom-guided imaging studies, is essential [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conservative procedures, such as vertical hemilaryngectomy for unilateral laryngeal cartilage invasion or circumferential tracheal resection for subglottic invasion, may allow maintenance of function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/50\">",
"     50",
"    </a>",
"    ]. However, extensive intraluminal invasion may occasionally necessitate total laryngectomy. While attempting to preserve normal organ function is important, gross resection of all visible tumor, if possible, should be the goal of surgical intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid surgery is associated with risk for metabolic complications, of which hypoparathyroidism is the most common, and anatomic complications, including damage to the laryngeal nerves. Both complications are more likely to occur after total thyroidectomy combined with lymph node dissection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hypoparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoparathyroidism is the most frequent complication of near-total thyroidectomy. Transient hypoparathyroidism occurs in up to 20 percent of patients after surgery for thyroid cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/51,52\">",
"     51,52",
"    </a>",
"    ] and permanent hypoparathyroidism occurs in 0.8 to 3 percent of patients after total thyroidectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/51,53-56\">",
"     51,53-56",
"    </a>",
"    ] and is more common when the goiter is extensive and anatomic landmarks are displaced and obscured. Chvostek's and Trousseau's signs are indicative of neuromuscular irritability due to hypocalcemia. Current requirements for short hospital stays argue for early treatment of hypocalcemia. We generally use the following regimen (",
"    <a class=\"graphic graphic_table graphicRef59019 \" href=\"mobipreview.htm?28/57/29596\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with symptomatic hypocalcemia (circumoral and distal extremity paresthesias) or a serum calcium concentration below 7.8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.0",
"      <span class=\"nowrap\">",
"       mmol/L,",
"      </span>",
"      with correction for any abnormality in the serum albumin concentration) should be treated with calcitriol 0.5 mcg twice daily and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/32/42504?source=see_link\">",
"       calcium carbonate",
"      </a>",
"      500 mg four times daily. For patients who absorb calcium carbonate poorly,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38628?source=see_link\">",
"       calcium citrate",
"      </a>",
"      may be used.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/46/37604?source=see_link\">",
"       Calcium glubionate",
"      </a>",
"      is available as a liquid, although calcium carbonate can be crushed and mixed with water to form a drinkable slurry.",
"     </li>",
"     <li>",
"      Patients with more severe symptoms (muscle cramps) or a serum calcium concentration below 7.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.9",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      should",
"      <strong>",
"       also",
"      </strong>",
"      receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18616?source=see_link\">",
"       calcium gluconate",
"      </a>",
"      by continuous intravenous drip for 24 to 36 hours or until the serum calcium concentration rises and is maintained above 8.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.0",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      Details on preparing the intravenous calcium solution are found elsewhere (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/37/44632?source=see_link&amp;anchor=H4#H4\">",
"       \"Treatment of hypocalcemia\", section on 'Intravenous calcium'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Emergency therapy is indicated in patients with tetany, seizures, laryngospasm or markedly prolonged QT intervals on the electrocardiogram. Treatment is initiated with the intravenous administration of one 10 mL ampule of 10 percent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18616?source=see_link\">",
"       calcium gluconate",
"      </a>",
"      over 5 to 10 minutes, followed by the intravenous infusion suggested in the prior paragraph.",
"     </li>",
"     <li>",
"      If the vitamin D and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/32/42504?source=see_link\">",
"       calcium carbonate",
"      </a>",
"      cannot be tapered and then discontinued over the next two to eight weeks, the hypoparathyroidism may be permanent. Measurement of serum parathyroid hormone concentrations when serum calcium is low can confirm the permanent need for treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An alternative approach is to treat all patients undergoing thyroidectomy with calcitriol and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    starting the day before surgery in an effort to avoid the post-operative hypocalcemia with a plan to taper and eventually discontinue these medications over the next few weeks. The role of recombinant human PTH (teriparatide) is under investigation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Recurrent and superior laryngeal nerve injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Permanent injury to a recurrent laryngeal nerve occurs in approximately 1 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/51,52\">",
"     51,52",
"    </a>",
"    ], but up to 6 percent have temporary paresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/52,58\">",
"     52,58",
"    </a>",
"    ]. Intraoperative monitoring of recurrent laryngeal nerve function may reduce this complication, but data are conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. No randomized trials have compared the outcome in monitored and non-monitored patients.",
"   </p>",
"   <p>",
"    As a result of unilateral injury, the ipsilateral vocal cord is typically paralyzed in the paramedian position, causing a hoarse or breathy voice and a tendency toward aspiration. Most patients have improvement in these symptoms in the next year, due to recovery of nerve function or to gradual movement of the paralyzed cord more medially to provide better alignment with the contralateral cord. When the injury is permanent (or severe enough to permit aspiration), surgical procedures such as laryngoplasty and arytenoid adduction are available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41064/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, bilateral recurrent nerve injury can be immediately life-threatening, causing stridor and dyspnea. Reintubation and tracheostomy may be required when the stridor is severe. Although spontaneous recovery is possible, most patients require permanent tracheostomy. Phonation can be achieved through arytenoidectomy or nerve reinnervation procedures, and tracheostomy tubes that allow phonation are also available.",
"   </p>",
"   <p>",
"    Superior laryngeal nerve injury typically causes mild hoarseness, decreased voice projection, or loss of voice pitch control. Laryngoscopy may show shortening of the cord ipsilateral to the injury, allowing discrimination from recurrent nerve injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE THYROID HORMONE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;After thyroid surgery, patients require postoperative thyroid hormone therapy both to replace normal hormone production and to suppress regrowth of tumor.",
"   </p>",
"   <p>",
"    For patients who are to undergo postoperative radioiodine imaging and ablation of any remaining thyroid tissue, short-term thyroid hormone replacement can be initiated postoperatively with triiodothyronine, 25 mcg two to three times daily. After two to three weeks, triiodothyronine is discontinued and imaging is performed once the patient's serum thyrotropin concentration is above 25 to 30",
"    <span class=\"nowrap\">",
"     mU/L.",
"    </span>",
"    Another alternative is simply to withhold any thyroid hormone therapy until the patient's serum thyrotropin concentration is above 30",
"    <span class=\"nowrap\">",
"     mU/L.",
"    </span>",
"    These options are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/13/34010?source=see_link\">",
"     \"Radioiodine treatment of differentiated thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with minimal disease in whom radioiodine imaging is not planned and those patients who will be getting RAI ablation with recombinant thyrotropin alfa (rhTSH) can be started immediately post-operatively on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    , 1.5 to 2",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day. The long-term goal of thyroxine therapy for this patient subgroup is minimal suppression of the serum thyrotropin concentration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/17/44313?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the management of differentiated thyroid cancer\", section on 'Thyroid hormone suppression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary therapy for differentiated (papillary and follicular) thyroid cancer is surgery. Surgical options include",
"    <span class=\"nowrap\">",
"     total/near-total",
"    </span>",
"    thyroidectomy and unilateral lobectomy with isthmusectomy. The choice of surgical procedure is based upon tumor size and extent of disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest preoperative ultrasound evaluation of the central and lateral neck lymph nodes for all patients with malignant cytological findings on the fine needle aspiration.",
"     </li>",
"     <li>",
"      For most patients with papillary or follicular cancer, we recommend total thyroidectomy if the primary tumor is 1.0 cm in diameter or greater, there is extrathyroidal extension of tumor, metastases, or if there is a history of exposure to ionizing radiation of the head and neck (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Total thyroidectomy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      While there are no prospective clinical trials, considerable retrospective data supports this recommendation. However, it is recognized that if an experienced thyroid surgeon is unavailable, and the patient cannot be referred elsewhere, a near-total thyroidectomy or a hemithyroidectomy may be preferable to a more complete operation complicated by bilateral nerve damage.",
"     </li>",
"     <li>",
"      We recommend that subtotal thyroidectomy not be performed in patients with thyroid cancer (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). It is an inadequate procedure and is associated with a higher complication rate if subsequent surgery is required (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Total thyroidectomy'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      We suggest unilateral lobectomy and isthmusectomy when the tumor is less than 1.0 cm in diameter and confined to one lobe of the gland (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The 30-year survival rate for this subgroup of patients approaches 100 percent. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Unilateral lobectomy and isthmusectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend therapeutic regional neck dissection in patients with papillary cancer only if there is clinical evidence (on exam or preoperative ultrasound) of nodal involvement (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest against prophylactic dissection except in patients with large primary tumors (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Approach to neck dissection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of the high risk of hypocalcemia after thyroidectomy, serum calcium concentration should be measured the evening and first morning after thyroidectomy. Treatment of postoperative hypocalcemia should be tailored to the severity and expected duration of parathyroid deficiency (",
"      <a class=\"graphic graphic_table graphicRef59019 \" href=\"mobipreview.htm?28/57/29596\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Hypoparathyroidism'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/1\">",
"      Solorzano CC, Carneiro DM, Ramirez M, et al. Surgeon-performed ultrasound in the management of thyroid malignancy. Am Surg 2004; 70:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/2\">",
"      Shimamoto K, Satake H, Sawaki A, et al. Preoperative staging of thyroid papillary carcinoma with ultrasonography. Eur J Radiol 1998; 29:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/3\">",
"      Stulak JM, Grant CS, Farley DR, et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg 2006; 141:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/4\">",
"      Kouvaraki MA, Shapiro SE, Fornage BD, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 2003; 134:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/5\">",
"      Leboulleux S, Girard E, Rose M, et al. Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer. J Clin Endocrinol Metab 2007; 92:3590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/6\">",
"      DeGroot LJ, Kaplan EL, Straus FH, Shukla MS. Does the method of management of papillary thyroid carcinoma make a difference in outcome? World J Surg 1994; 18:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/7\">",
"      Soh EY, Clark OH. Surgical considerations and approach to thyroid cancer. Endocrinol Metab Clin North Am 1996; 25:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/8\">",
"      Ark N, Zemo S, Nolen D, et al. Management of locally invasive well-differentiated thyroid cancer. Surg Oncol Clin N Am 2008; 17:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/9\">",
"      SMITH RR, FRAZELL EL, CAULK R, et al. THE AMERICAN JOINT COMMITTEE'S PROPOSED METHOD OF STAGE CLASSIFICATION AND END-RESULT REPORTING APPLIED TO 1,320 PHARYNX CANCERS. Cancer 1963; 16:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/10\">",
"      Katoh R, Sasaki J, Kurihara H, et al. Multiple thyroid involvement (intraglandular metastasis) in papillary thyroid carcinoma. A clinicopathologic study of 105 consecutive patients. Cancer 1992; 70:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/11\">",
"      Pacini F, Elisei R, Capezzone M, et al. Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients. Thyroid 2001; 11:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/12\">",
"      Kim ES, Kim TY, Koh JM, et al. Completion thyroidectomy in patients with thyroid cancer who initially underwent unilateral operation. Clin Endocrinol (Oxf) 2004; 61:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/13\">",
"      Shattuck TM, Westra WH, Ladenson PW, Arnold A. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N Engl J Med 2005; 352:2406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/14\">",
"      TOLLEFSEN HR, DECOSSE JJ. PAPILLARY CARCINOMA OF THE THYROID. RECURRENCE IN THE THYROID GLAND AFTER INITIAL SURGICAL TREATMENT. Am J Surg 1963; 106:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/15\">",
"      Silverberg SG, Hutter RV, Foote FW Jr. Fatal carcinoma of the thyroid: histology, metastases, and causes of death. Cancer 1970; 25:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/16\">",
"      Hay ID. Papillary thyroid carcinoma. Endocrinol Metab Clin North Am 1990; 19:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/17\">",
"      DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990; 71:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/18\">",
"      Samaan NA, Schultz PN, Hickey RC, et al. The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. J Clin Endocrinol Metab 1992; 75:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/19\">",
"      Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/20\">",
"      Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 2007; 246:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/21\">",
"      Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006; 16:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/22\">",
"      Ross DS, Litofsky D, Ain KB, et al. Recurrence after treatment of micropapillary thyroid cancer. Thyroid 2009; 19:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/23\">",
"      Barney BM, Hitchcock YJ, Sharma P, et al. Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head Neck 2011; 33:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/24\">",
"      Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988; 104:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/25\">",
"      Wanebo H, Coburn M, Teates D, Cole B. Total thyroidectomy does not enhance disease control or survival even in high-risk patients with differentiated thyroid cancer. Ann Surg 1998; 227:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/26\">",
"      Hay ID, Grant CS, Bergstralh EJ, et al. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery 1998; 124:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/27\">",
"      Schroder DM, Chambors A, France CJ. Operative strategy for thyroid cancer. Is total thyroidectomy worth the price? Cancer 1986; 58:2320.",
"     </a>",
"    </li>",
"    <li>",
"     British Thyroid Association and Royal College of Physicians. Guidelines for the management of thyroid cancer in adults, London 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/29\">",
"      Cobin RH, Gharib H, Bergman DA, et al. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract 2001; 7:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/30\">",
"      Sherman SI, Angelos P, Ball DW, et al. Thyroid carcinoma. J Natl Compr Canc Netw 2007; 5:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/31\">",
"      American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/32\">",
"      Fogelfeld L, Wiviott MB, Shore-Freedman E, et al. Recurrence of thyroid nodules after surgical removal in patients irradiated in childhood for benign conditions. N Engl J Med 1989; 320:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/33\">",
"      Kwak JY, Kim EK, Youk JH, et al. Extrathyroid extension of well-differentiated papillary thyroid microcarcinoma on US. Thyroid 2008; 18:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/34\">",
"      Tyler DS, Winchester DJ, Caraway NP, et al. Indeterminate fine-needle aspiration biopsy of the thyroid: identification of subgroups at high risk for invasive carcinoma. Surgery 1994; 116:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/35\">",
"      DeGroot LJ, Kaplan EL. Second operations for \"completion\" of thyroidectomy in treatment of differentiated thyroid cancer. Surgery 1991; 110:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/36\">",
"      Tielens ET, Sherman SI, Hruban RH, Ladenson PW. Follicular variant of papillary thyroid carcinoma. A clinicopathologic study. Cancer 1994; 73:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/37\">",
"      American Thyroid Association Surgery Working Group, American Association of Endocrine Surgeons,, American Academy of Otolaryngology-Head and Neck Surgery, et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid 2009; 19:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/38\">",
"      Ito Y, Tomoda C, Uruno T, et al. Ultrasonographically and anatomopathologically detectable node metastases in the lateral compartment as indicators of worse relapse-free survival in patients with papillary thyroid carcinoma. World J Surg 2005; 29:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/39\">",
"      Stojadinovic A, Ghossein RA, Hoos A, et al. H&uuml;rthle cell carcinoma: a critical histopathologic appraisal. J Clin Oncol 2001; 19:2616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/40\">",
"      Scheumann GF, Gimm O, Wegener G, et al. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg 1994; 18:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/41\">",
"      Tuttle, RM, Fagin, JA. Can risk-adapted treatment recommendations replace the 'one size fits all' approach for early-stage thyroid cancer patients?. Oncology (Williston Park) 2009; 23:592,.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/42\">",
"      Zetoune T, Keutgen X, Buitrago D, et al. Prophylactic central neck dissection and local recurrence in papillary thyroid cancer: a meta-analysis. Ann Surg Oncol 2010; 17:3287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/43\">",
"      Shan CX, Zhang W, Jiang DZ, et al. Routine central neck dissection in differentiated thyroid carcinoma: a systematic review and meta-analysis. Laryngoscope 2012; 122:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/44\">",
"      Shindo M, Stern A. Total thyroidectomy with and without selective central compartment dissection: a comparison of complication rates. Arch Otolaryngol Head Neck Surg 2010; 136:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/45\">",
"      White ML, Gauger PG, Doherty GM. Central lymph node dissection in differentiated thyroid cancer. World J Surg 2007; 31:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/46\">",
"      Chisholm EJ, Kulinskaya E, Tolley NS. Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone. Laryngoscope 2009; 119:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/47\">",
"      Mekel M, Nucera C, Hodin RA, Parangi S. Surgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules. Am J Surg 2010; 200:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/48\">",
"      Bonnet S, Hartl D, Leboulleux S, et al. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab 2009; 94:1162.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/50\">",
"      Ballantyne AJ. Resections of the upper aerodigestive tract for locally invasive thyroid cancer. Am J Surg 1994; 168:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/51\">",
"      Hundahl SA, Cady B, Cunningham MP, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer 2000; 89:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/52\">",
"      Flynn MB, Lyons KJ, Tarter JW, Ragsdale TL. Local complications after surgical resection for thyroid carcinoma. Am J Surg 1994; 168:404.",
"     </a>",
"    </li>",
"    <li>",
"     Kaplan, EL, Sugimoto, J, Yang, H, Fredland, A. Postoperative hypoparathyroidism: Diagnosis and management. In: Surgery of the Thyroid and Parathyroid Glands, Kaplan, EL (Ed), Churchill Livingstone, New York, 1983. p. 262.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/54\">",
"      Serpell JW, Phan D. Safety of total thyroidectomy. ANZ J Surg 2007; 77:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/55\">",
"      Rafferty MA, Goldstein DP, Rotstein L, et al. Completion thyroidectomy versus total thyroidectomy: is there a difference in complication rates? An analysis of 350 patients. J Am Coll Surg 2007; 205:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/56\">",
"      Richmond BK, Eads K, Flaherty S, et al. Complications of thyroidectomy and parathyroidectomy in the rural community hospital setting. Am Surg 2007; 73:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/57\">",
"      Castellano, K, Plantalech, L. Post surgical hypoparathyroidism (HP): Treatment with teriparatide (TP). Bone 2006; 38:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/58\">",
"      Lo CY, Kwok KF, Yuen PW. A prospective evaluation of recurrent laryngeal nerve paralysis during thyroidectomy. Arch Surg 2000; 135:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/59\">",
"      Marcus B, Edwards B, Yoo S, et al. Recurrent laryngeal nerve monitoring in thyroid and parathyroid surgery: the University of Michigan experience. Laryngoscope 2003; 113:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/60\">",
"      Dralle H, Sekulla C, Haerting J, et al. Risk factors of paralysis and functional outcome after recurrent laryngeal nerve monitoring in thyroid surgery. Surgery 2004; 136:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/61\">",
"      Chan WF, Lang BH, Lo CY. The role of intraoperative neuromonitoring of recurrent laryngeal nerve during thyroidectomy: a comparative study on 1000 nerves at risk. Surgery 2006; 140:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41064/abstract/62\">",
"      Hartl DM, Travagli JP, Leboulleux S, et al. Clinical review: Current concepts in the management of unilateral recurrent laryngeal nerve paralysis after thyroid surgery. J Clin Endocrinol Metab 2005; 90:3084.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7821 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-AB2AAAC1E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_6_41064=[""].join("\n");
var outline_f40_6_41064=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IMPORTANCE OF PREOPERATIVE STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SURGICAL OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Total thyroidectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Unilateral lobectomy and isthmusectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Choice of procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      APPROACH TO THYROIDECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Parathyroid glands",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      APPROACH TO NECK DISSECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Nomenclature",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Therapeutic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Prophylactic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SURGERY FOR INVASIVE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hypoparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Recurrent and superior laryngeal nerve injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      POSTOPERATIVE THYROID HORMONE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7821\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7821|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/57/29596\" title=\"table 1\">",
"      Management of hypocalcemia after thyroid surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/17/39191?source=related_link\">",
"      External beam radiotherapy in the treatment of thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/57/31642?source=related_link\">",
"      Initial and reoperative thyroidectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/17/44313?source=related_link\">",
"      Overview of the management of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/49/1818?source=related_link\">",
"      Radiation-induced thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/13/34010?source=related_link\">",
"      Radioiodine treatment of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/23/29045?source=related_link\">",
"      Surgical anatomy of the parathyroid glands",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/37/44632?source=related_link\">",
"      Treatment of hypocalcemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_6_41065="Use of glucocorticoids in the treatment of rheumatoid arthritis";
var content_f40_6_41065=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Use of glucocorticoids in the treatment of rheumatoid arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/6/41065/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/6/41065/contributors\">",
"     James R O'Dell, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/6/41065/contributors\">",
"     Eric L Matteson, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/6/41065/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/6/41065/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/6/41065/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/6/41065/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/6/41065/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the early 1950s, Hench and colleagues earned a Nobel Prize in medicine and physiology for discovering the dramatic beneficial effect of cortisone on a patient incapacitated by rheumatoid arthritis (RA). Since that time, the exact role of glucocorticoids in the treatment of RA has generated considerable debate.",
"   </p>",
"   <p>",
"    Glucocorticoids exert both antiinflammatory and immunosuppressive effects via several mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28249?source=see_link\">",
"     \"Glucocorticoid effects on the immune system\"",
"    </a>",
"    .) Among those pertinent to patients with RA are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inhibition of prostaglandin and leukotriene synthesis",
"     </li>",
"     <li>",
"      Reductions in macrophage phagocytosis, IL-1 secretion, and the number of circulating monocytes",
"     </li>",
"     <li>",
"      Inhibition of the release of collagenase and lysosomal enzymes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These effects are mediated by intracellular glucocorticoid receptors that interact with transcription factors and, thus, affect gene transcription. Glucocorticoids effects may also be mediated by post-transcriptional and post-translational mechanisms, physicochemical interactions with biologic membranes, and binding to membrane bound glucocorticoid receptors.",
"   </p>",
"   <p>",
"    Among patients with RA, glucocorticoids may be administered via several different modalities. These include oral (short-term, chronic, and pulse), intramuscular, intravenous, and intraarticular routes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23208?source=see_link\">",
"     \"Pharmacologic use of glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the use of glucocorticoids given both short-term and chronically in low doses, acutely in intravenous pulses, or via the intraarticular route in the treatment of RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/2\">",
"     2",
"    </a>",
"    ]. An overview of the management of RA is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFICACY OF SHORT-TERM USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In sicker patients with active RA,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is frequently added for a short period to the treatment regimen to rapidly minimize disease activity while awaiting a clinical response to a slower acting disease-modifying antirheumatic drug (DMARD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. When used for a period of one month or less, glucocorticoids are more effective than either a placebo or nonsteroidal antiinflammatory drug (NSAID).",
"   </p>",
"   <p>",
"    Support for the value of short-term (ie, within the first month of therapy) steroid therapy comes from a year 2003 meta-analysis that included 10 studies utilizing random assignment of 320 patients with RA to groups that received glucocorticoids (equivalent to 15 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    or less per day) and either a placebo or a NSAID [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/7\">",
"     7",
"    </a>",
"    ]. The significant main results were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       Prednisolone",
"      </a>",
"      reduced joint tenderness more than placebo or NSAIDs.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       Prednisolone",
"      </a>",
"      reduced pain more than placebo or NSAIDs.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       Prednisolone",
"      </a>",
"      increased grip strength more than placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Short-term use of glucocorticoids in doses less than the equivalent of 15 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    per day is seldom associated with serious adverse effects. However, mood disorders and hyperglycemia may be seen with daily treatment at these relatively low doses, although short-term treatment of early RA with even high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    has not been associated with long-term worsening of glucose tolerance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several clinical trials have suggested salutary benefits of high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    therapy in early RA. The COBRA and BeST studies demonstrated that higher-dose oral prednisone (60",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    tapering to 7.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    by week 6 and then stopping after week 12) in combination with other conventional DMARDs substantially inhibits the progression of radiographic joint damage, and this effect is sustained over many years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. No studies have evaluated a more intermediate starting dose, such as 20",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p>",
"    Clinical experience suggests that glucocorticoids continue to be effective for periods up to six months. Longer-term use is more controversial because of waning effectiveness in controlling symptoms and increasing risk of adverse events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Efficacy of chronic use'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Short-term use of glucocorticoids has not been directly compared with biologic DMARDs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3384?source=see_link\">",
"     \"Overview of biologic agents in the rheumatic diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/35/566?source=see_link\">",
"     \"Miscellaneous novel therapies in rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/0/9223?source=see_link&amp;anchor=H5#H5\">",
"     \"T cell targeted therapies for rheumatoid arthritis\", section on 'Abatacept'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many clinicians employ NSAIDs, glucocorticoids, a traditional DMARD such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and, if needed, a biologic agent for patients with moderate to severe RA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFICACY OF CHRONIC USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence is conflicting regarding the benefits of chronic glucocorticoid therapy for patients with RA. We generally do not use glucocorticoids on a chronic basis without concurrent therapy with a disease-modifying antirheumatic drug (DMARD) or DMARD combinations (eg, a nonbiologic traditional DMARD and a biologic agent). The main conclusion from randomized trials in which patients received 7.5 to 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or equivalent was that there is initial symptomatic benefit, which may be sustained for up to two years at the initial dose, and that radiologic progression is reduced with such doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/12-19\">",
"     12-19",
"    </a>",
"    ]. These conclusions were best demonstrated in three randomized trials.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial included 128 patients with RA of less than two years&rsquo; duration who were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      therapy (7.5",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo; other DMARDs could also be prescribed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/13\">",
"       13",
"      </a>",
"      ]. Prednisolone was beneficial compared with placebo for pain at up to six months and for disability at up to 15 months. At two years, prednisolone therapy resulted in significantly fewer hand erosions (22 versus 46 percent). Among those initially administered prednisolone, an increase in erosions was seen one year after drug withdrawal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a randomized trial involving 81 DMARD-na&iuml;ve patients with RA for less than one year, who were assigned to receive either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo, greater clinical improvement in multiple measures was seen at six months in the patients treated with prednisone; however, the benefit was sustained only for joint tenderness at 24 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/15\">",
"       15",
"      </a>",
"      ]. Radiographic progression was less in the prednisone treated group, and this advantage persisted for at least three years following the completion of two years of prednisone treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/20\">",
"       20",
"      </a>",
"      ]. Vertebral compression fractures occurred in five and two of the prednisone and placebo treated patients, respectively.",
"     </li>",
"     <li>",
"      Another trial documented radiographic benefit of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      in patients treated with a tight-control strategy. In this trial, 236 patients with early RA who had not received therapy with either DMARDs or glucocorticoids were randomly assigned to receive prednisone (10",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (MTX) or placebo plus MTX beginning within one year of disease onset and continuing for two years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/19\">",
"       19",
"      </a>",
"      ]. Disease activity was assessed monthly to determine whether the dose of MTX should be increased. A second DMARD was added if control was inadequate at a maximum MTX dose of 30",
"      <span class=\"nowrap\">",
"       mg/week",
"      </span>",
"      (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      for the patients initially entered in the trial or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      for the majority of the patients who were subsequently entered in the trial after a change in trial protocol).",
"      <br/>",
"      <br/>",
"      After two years, radiologic scores in the patients receiving prednisone showed a statistically significant lower amount of progression compared with those given placebo, although the absolute difference was small (difference in Sharp-van der Heijde score of 0.87 units). The prednisone group had more symptomatic benefit during the first three months; this difference was sustained but was not significantly different at the end of two years. In the group receiving prednisone plus MTX, there was less need for the additional DMARD (15 versus 41 percent, including cyclosporine in 2 versus 7 patients and adalimumab in 16 versus 42 patients). The prednisone-treated patients experienced fewer adverse events, particularly gastrointestinal upset and elevated liver enzymes, possibly due to the lower average maximal dose of MTX in this group (19.7 versus 23.4",
"      <span class=\"nowrap\">",
"       mg/week).",
"      </span>",
"      No vertebral fractures were noted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is less clear whether similar efficacy to that seen with 7.5 to 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    can be achieved with doses of 5 to 7",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial of low-dose glucocorticoid therapy (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      5",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      compared with placebo found that the benefits of chronic glucocorticoid therapy were temporary; improvement in the number of painful joints with prednisone was observed at 12 weeks but not at 24 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/24\">",
"       24",
"      </a>",
"      ]. Abrupt discontinuation of glucocorticoids resulted in a significant exacerbation of the disease for a period of eight weeks.",
"     </li>",
"     <li>",
"      A dose of 7 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      daily was no better than placebo in preventing radiographic damage in a trial that randomly assigned 167 patients with RA of less than three years&rsquo; duration (mean of 12 months),to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      , with either low-dose glucocorticoid therapy or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/18\">",
"       18",
"      </a>",
"      ]. There were no significant differences at two years between the two groups in the proportions of patients who developed new erosions or in the rate of joint space narrowing. The authors of the study speculated that the standardized use of a DMARD (sulfasalazine) and of alternative DMARDs in those who did not have a good clinical response in either group may have &ldquo;outweighed any prednisolone effect.&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a nonrandomized prospective study of over 800 patients,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    doses of 5 mg per day (or less) did not dramatically affect the rate of radiographic progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even lower doses, such as 1 to 4",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    continued indefinitely, may be effective in some patients. This was shown in a trial in which 31 patients were randomly assigned to continued maintenance therapy of 1 to 4",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or to slow dose reduction, decreasing the daily dose by 1 mg every four weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/25\">",
"     25",
"    </a>",
"    ]. At study entry, patients were clinically stable, and practically all were receiving disease modifying antirheumatic drugs. Withdrawal from the study for lack of efficacy was significantly less frequent in patients maintained on their initial stable prednisone dose (3 of 13 patients versus 11 of 15 patients).",
"   </p>",
"   <p>",
"    In an analysis of the National Data Bank for Rheumatic Diseases&rsquo; longitudinal study in the United States of long-term outcomes in RA in which patients completed questionnaires every six months, the pattern of glucocorticoid use was examined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/26\">",
"     26",
"    </a>",
"    ]. The study included 12,749 patients, 66 percent of whom had used glucocorticoids to treat their RA at some point in their disease course. The following findings were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      36 percent of patients were current users of glucocorticoids.",
"     </li>",
"     <li>",
"      Among current users, persistent use (more than five years) occurred in approximately one-third of the patients.",
"     </li>",
"     <li>",
"      Among the pool of patients who were current glucocorticoid users, 24 percent discontinued this medication each year.",
"     </li>",
"     <li>",
"      One quarter of patients in remission or with minimal disease activity continued taking glucocorticoids.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effects of chronic glucocorticoid use in combination with effective therapy for RA with a nonbiologic or biologic DMARD remains to be determined. An effective DMARD or DMARD combinations (including conventional and biological DMARDs) may provide sufficient improvement so that the maintenance dose of the glucocorticoid may be decreased or discontinued to minimize the potential for adverse effects related to the glucocorticoid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H720849417\">",
"    <span class=\"h2\">",
"     Low-dose chronotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A limited number of randomized trials have suggested that a modified form of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , which delays release of the drug until approximately four hours after nighttime oral administration, is more effective than standard immediate-release prednisone taken in the morning in reducing morning stiffness, while having similar effects on other measures of disease activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The role of the delayed-release form in clinical practice, for which it is available in some countries, remains uncertain. The modified-release form of the drug was developed in an effort to more effectively reduce morning symptoms by countering the effects of proinflammatory cytokines, including interleukin-6, that are produced late at night [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/29\">",
"     29",
"    </a>",
"    ]. Use of this agent has been termed chronotherapy because of its deliberate timing to address circadian rhythms associated with symptoms and the production of such inflammatory mediators [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of this agent was examined in a 12-week randomized trial involving 350 patients with active RA, most of whom were receiving traditional DMARDs (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/28\">",
"     28",
"    </a>",
"    ]; treatment with the modified-release form of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (5 mg) at night resulted in significantly greater clinical improvement in composite measures of disease activity compared with placebo (ACR20 of 48 versus 29 percent, ACR50 of 22 versus 10 percent) and a greater relative reduction from baseline in morning stiffness (55 versus 35 percent).",
"   </p>",
"   <p>",
"    Further research will be required to establish the value of using delayed-release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    over the longer duration of glucocorticoid therapy frequently employed in patients with RA, particularly given its substantially greater cost [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/30\">",
"     30",
"    </a>",
"    ]. The relative efficacy, risk, and cost-benefit of chronic use remain to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISKS OF CHRONIC USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chronic use of low-dose glucocorticoids in RA can cause multiple adverse events. These include an increased risk for osteoporosis and skeletal fractures, gastrointestinal bleeding, peptic ulcer disease, diabetes mellitus, infections, cataracts, and impaired hypothalamic-pituitary-adrenal axis response. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In an analysis of serious adverse events following",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    therapy in RA, the complications were dose-dependent, primarily occurring at doses greater than or equal to 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/31\">",
"     31",
"    </a>",
"    ]. By comparison, there was no difference in the occurrence of such events between patients taking less than 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and the control group. An average prednisone dose between 10 and 15",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    correlated most strongly with the development of an adverse event. The relationship between adverse events and cumulative dose (rather than the daily dose) was much weaker. This study was flawed because it used historic matched controls who were never treated with glucocorticoids. However, multiple other studies also found evidence consistent with a dose-response relationship between steroid use and adverse effects, particularly with respect to bone loss.",
"   </p>",
"   <p>",
"    A prospective, randomized, controlled trial of low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    in patients with RA found that patients receiving 10 mg of prednisone per day lost approximately 7 percent of lumbar trabecular bone mineral density (BMD) over 20 weeks versus no change in the placebo group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/32\">",
"     32",
"    </a>",
"    ]. In another study of 65 patients treated with an average of 5.6",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    BMD in the lumbar spine and trochanter fell at a rate of 2 and 0.9 percent per year, respectively; these changes were prevented with calcium and vitamin D supplementation (see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/33\">",
"     33",
"    </a>",
"    ]. Doses above 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    also may be associated with an increased long-term risk of fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/34\">",
"     34",
"    </a>",
"    ]. Doses of less than 2.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    may still confer some increased risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/35\">",
"     35",
"    </a>",
"    ]. Significant loss of BMD can occur in as little as three months of glucocorticoid use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/54/42855?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis\", section on 'Effect of low-dose glucocorticoid therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bone loss in RA is also proportional to the degree of disability and is inversely proportional to the amount of weight-bearing exercise an individual can tolerate. Although difficult to prove, it is likely that the direct effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    to induce bone loss is partially attenuated if the patient also has greater mobility.",
"   </p>",
"   <p>",
"    A major goal for patients with RA treated chronically with glucocorticoids is to minimize adverse events. The following factors should be part of the regimen (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limiting the dose to a maximum of 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      when treating articular disease and preferably less than 5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"     <li>",
"      Using other measures to minimize bone loss such as calcium and vitamin D supplementation and, in patients in whom long-term use is anticipated, considering bisphosphonate therapy (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link\">",
"       \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy of calcium (1000",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and vitamin D (400 to 800 international",
"    <span class=\"nowrap\">",
"     units/day)",
"    </span>",
"    supplementation was demonstrated in a controlled trial in which 65 patients treated with a mean of 5.6",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    were randomized to supplementation or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/33\">",
"     33",
"    </a>",
"    ]. Bone mineral density in the lumbar spine and trochanter fell at a rate of 2 and 0.9 percent per year, respectively, with placebo but increased by 0.72 and 0.85 percent per year, respectively, with calcium and vitamin D.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PULSE GLUCOCORTICOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulse therapy consists of the administration of high doses of glucocorticoids over a short period of time. No studies exist that directly compare this mode of therapy with a regimen of chronic low-dose oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . The available studies examining pulse glucocorticoids have been poorly controlled and have consisted of only a small number of patients. As a result, pulse glucocorticoids remain a modality of last resort for the treatment of RA.",
"   </p>",
"   <p>",
"    The utility of pulse glucocorticoid therapy among patients with RA has been limited to the following settings (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The treatment of acute flares",
"     </li>",
"     <li>",
"      A therapeutic bridge between the initiation of and response to disease modifying antirheumatic drugs (DMARDs)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The average duration of response to pulse therapy alone is six to eight weeks, with a significantly prolonged response when combined with DMARDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The minimum effective dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    is unknown. The standard &ldquo;pulse&rdquo; dose has traditionally been 1000 mg IV daily for three consecutive days once monthly, but some evidence suggests that lower doses may be as effective. One study, for example, randomized 36 patients with active RA to standard pulse therapy or 100 mg IV daily for three consecutive days once monthly; there was no statistically significant difference in initial response or sustained clinical improvement between the two regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although intravenous administration is the most popular route for pulse therapy, pulse glucocorticoid therapy can also be given orally or by intramuscular (IM) injection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. These modes of administration may have variable durations of efficacy. One trial compared patients treated with three doses of 500 mg of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    plus placebo injection or 120 mg of IM methylprednisolone plus a placebo tablet at four-week intervals. IM therapy resulted in better disease remission from weeks 2 to 12, but no significant difference was seen at week 16 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/40\">",
"     40",
"    </a>",
"    ]. In contrast, another study comparing 1000 mg of IV methylprednisolone, 320 mg of IV methylprednisolone, and 320 mg of IM methylprednisolone found no significant differences with respect to the duration of benefits among the three groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/41\">",
"     41",
"    </a>",
"    ]. Thus, the IV and IM routes may be equivalent.",
"   </p>",
"   <p>",
"    Serious adverse events have been reported with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    infusion. These include cardiovascular collapse, hypokalemia, myocardial infarction, and severe infection, principally occurring in patients with compromised cardiovascular or immune systems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INTRAARTICULAR THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraarticular glucocorticoids are an important mainstay of the treatment of symptomatic synovitis in patients with RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/42\">",
"     42",
"    </a>",
"    ]; such therapy is palliative rather than disease modifying. Different glucocorticoid preparations may vary in their durations of efficacy, due in part to differences in solubility. One study of steroid injections into affected knees found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    hexacetonide provided longer-lasting local pain relief than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    succinate or triamcinolone acetonide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30951?source=see_link\">",
"     \"Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although many investigators do not recommend a formal rest period following joint injection, some studies suggest that rest may be beneficial. In one study of patients with inflammatory knee arthritis, those treated with 24 hours of bed rest following intraarticular steroid injection had, when compared with patients treated in the ambulatory setting, greater improvement at 12 weeks postinjection in the pain score, stiffness score, knee circumference, 50 foot walking time, and serum C-reactive protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intraarticular injections of multiple joints may have advantages over intramuscular injections for patients experiencing a disease flare. In a randomized controlled trial of short-term therapy, polyarticular intraarticular injections were more effective than intramuscular injections in attaining improvement by American College of Rheumatology criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/45\">",
"     45",
"    </a>",
"    ]; they were also associated with fewer adverse events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Adverse events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although rare, risks associated with intraarticular injection include tendon rupture, osteonecrosis, acute synovitis (transient postinfection flare which usually resolves within 48 hours), septic arthritis, and systemic effects (",
"    <a class=\"graphic graphic_table graphicRef74660 \" href=\"mobipreview.htm?14/25/14747\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/43,44,46\">",
"     43,44,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28564?source=see_link\">",
"     \"Joint aspiration or injection in adults: Complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An early study reviewed 18 years of experience with intraarticular steroid injections among 8000 patients who received a total of 235,000 injections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/46\">",
"     46",
"    </a>",
"    ]. There were 79 cases of osteonecrosis. These events were associated with weight-bearing joints that had been injected with large doses of glucocorticoids more frequently than once per month for extended periods of time. As a result, recommendations are that individual joints usually receive no more than four injections yearly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/42\">",
"     42",
"    </a>",
"    ]. However, monthly injections may initially be warranted in patients with very active synovitis. In such patients, the benefit from suppressing joint inflammation may compensate for the increased risk of toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28564?source=see_link\">",
"     \"Joint aspiration or injection in adults: Complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids remain an important therapeutic option in the treatment of RA; however, widely accepted criteria for the initiation of glucocorticoid therapy have not been established. Current studies suggest that glucocorticoids should be used as a bridge between the initiation of traditional (nonbiologic) and biologic disease-modifying antirheumatic drugs (DMARDs) and therapeutic effect of these slower acting agents",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the treatment of acute synovitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/48\">",
"     48",
"    </a>",
"    ]. Glucocorticoids may also be used at lower doses in combination with traditional (nonbiologic) and biologic DMARDs to maintain function and prevent degradation of joints in patients with rheumatoid arthritis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/3/31802?source=see_link&amp;anchor=H3695299#H3695299\">",
"     \"Initial treatment of moderately to severely active rheumatoid arthritis in adults\", section on 'Oral glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When deciding whether to initiate steroid therapy, the following clinical features which increase the risk of toxicity should be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Established hypertension or diabetes mellitus",
"     </li>",
"     <li>",
"      Preexisting cataract(s) or glaucoma",
"     </li>",
"     <li>",
"      Significant risk factors for osteoporosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients should be informed about the risks and benefits of glucocorticoid therapy, and the danger of abrupt cessation of the medication after long-term use. Whether the benefits of therapy with glucocorticoids outweigh the risks associated with these agents ultimately rests upon the judgment of the individual clinician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chronic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, most adverse effects of chronic steroid therapy are typically seen at doses of 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or higher, with risk of bone loss at lower doses. Thus, when chronic use is anticipated, the dose of glucocorticoids should be tapered as quickly as possible to the lowest effective dose, usually 5 to 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or its equivalent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/42,50,51\">",
"     42,50,51",
"    </a>",
"    ]. Patients with RA, particularly those on disease modifying antirheumatic drugs, usually do not require higher daily doses for synovitis control. Even lower doses, such as less than 5",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    may be adequate in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To minimize interference with the normal diurnal hormonal pattern, glucocorticoids are best administered in the morning.",
"   </p>",
"   <p>",
"    Concurrent initiation of a nonbiologic or biologic disease-modifying antirheumatic drug (DMARD) may permit tapering of the glucocorticoid once the patient begins to respond to the DMARD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/42\">",
"     42",
"    </a>",
"    ]. Once the patient has improved further or after addition of other effective agents, glucocorticoid therapy should be slowly tapered over a period of months as tolerated. If symptoms return upon tapering, it can be assumed that the particular DMARD or combination is inadequate, and a higher dose or alternative therapies should be utilized. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/37/22103?source=see_link\">",
"     \"Glucocorticoid withdrawal\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/6/42090?source=see_link\">",
"     \"Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic therapy using monthly IM glucocorticoid injections does not appear to offer any advantage over daily use. This was illustrated in a study that randomly assigned 91 patients with RA and an inadequate response to a DMARD to either IM depomedrone (120 mg) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/52\">",
"     52",
"    </a>",
"    ]. Typical glucocorticoid adverse events were more frequent in the depomedrone group and improved disease activity seen with depomedrone during the first year of treatment diminished subsequently; there was no significant difference in disease activity at the end of two years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Flares",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a flare of RA occurs it should be recognized that the underlying DMARD therapy may not be adequate and steps should be taken to optimize the treatment. Flares of disease may be treated by an increase in the dose of oral glucocorticoid, with the intention of reducing the dose once the flare is under control. Alternatively, pulse intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    therapy, usually consisting of three separate infusions of up to 1000 mg of methylprednisolone given at weekly intervals, may rarely be used and may lead to marked temporary disease suppression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Monitoring parameters",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for baseline studies to monitor toxicity varies among patients. The following are generally recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/49,53\">",
"     49,53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum glucose",
"     </li>",
"     <li>",
"      Lipid profile",
"     </li>",
"     <li>",
"      Bone mineral density (BMD), preferably of the spine, should be measured if it is anticipated that a patient will be treated with glucocorticoids for more than six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/54\">",
"       54",
"      </a>",
"      ]. Dual photon X-ray absorptiometry (DXA) is an accurate method for assessing BMD. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42583?source=see_link\">",
"       \"Overview of dual-energy x-ray absorptiometry\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bone mineral density (BMD) testing and prophylactic measures have been underutilized in patients at risk for glucocorticoid-induced osteoporosis. This was illustrated in a review of the medical records of 212 patients who received one year of oral glucocorticoid therapy. Only 21 percent of these patients had documented evidence of BMD testing and only 31 percent were receiving medication for osteoporosis prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study showed that patients aged &gt; 50 years with RA sustained more hip fractures than other groups but were least likely to have effective fracture prevention therapy prescribed. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/56\">",
"     56",
"    </a>",
"    ]. More attention to the prevention and monitoring of possible adverse events of long-term glucocorticoid therapy is warranted. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Osteoporosis prevention counseling has been underutilized in patients taking glucocorticoids. This was illustrated in a survey-based study in which patients taking oral glucocorticoids were asked to recall whether or not they received osteoporosis prevention counseling, and to identify factors associated with the intake of calcium and vitamin D and the assessment of bone mineral density [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/57\">",
"     57",
"    </a>",
"    ]. Only 36 percent reported receiving osteoporosis prevention counseling. Slightly more than one-half of the study participants were obtaining the recommended amount of calcium. One-third were obtaining the recommended amount of vitamin D and a similar proportion had received a test of BMD within the preceding year. Effective strategies need to be developed to educate patients about this potential complication and how to prevent it.",
"   </p>",
"   <p>",
"    Once steroid therapy is initiated, the following should be assessed or performed at each patient visit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The presence of polydipsia, edema, shortness of breath, or visual changes",
"     </li>",
"     <li>",
"      Weight gain",
"     </li>",
"     <li>",
"      Blood pressure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All patients on chronic therapy (more than six months) at a dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    above 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/54\">",
"     54",
"    </a>",
"    ] (or 7.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for more than three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/53\">",
"     53",
"    </a>",
"    ]) should be treated with calcium (1000",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and vitamin D (400 to 800",
"    <span class=\"nowrap\">",
"     IU/day)",
"    </span>",
"    supplementation. The BMD should be repeated yearly for as long as the steroid therapy is continued, and the serum glucose and lipid profile should be periodically reassessed. Patients who continue to lose bone may benefit from the addition of a bisphosphonate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/53,58\">",
"     53,58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to monitoring for the development of toxicities, patients should be assessed for therapeutic benefits from these agents with alterations based upon clinical response. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Patient attitude",
"    </span>",
"    &nbsp;&mdash;&nbsp;The attitudes of 148 patients with RA to oral glucocorticoid treatment were surveyed and the factors influencing these views and their likely clinical impact were assessed in a study published in 2003 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/59\">",
"     59",
"    </a>",
"    ]. The majority (68 percent) of the patients were not willing to be treated with an oral glucocorticoid. The patients who were willing to be treated were older, had a higher mean erythrocyte sedimentation rate, worse function and greater use of disease-modifying anti-rheumatic drugs. Many patients refused to participate due to their high level of concern about the events of glucocorticoid treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41065/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/61/21463?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/44/24264?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/40/27266?source=see_link\">",
"       \"Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/29/39378?source=see_link\">",
"       \"Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4992891\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We primarily use glucocorticoids as a bridge between the initiation and therapeutic effect of DMARDs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      for the treatment of acute synovitis, and at lower doses in combination with traditional and biologic disease-modifying antirheumatic drugs (DMARDs) when needed to maintain function and prevent degradation of joints. We generally do not use glucocorticoids in the absence of concurrent DMARD therapy. Clinical features which increase the risk of toxicity should be considered when deciding whether to initiate steroid therapy. Patients should be informed about the risks and benefits of glucocorticoid therapy and the danger of abrupt cessation of the medication after long-term use. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glucocorticoids, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , are frequently added for a short period to the treatment regimen to minimize disease activity in patients with active rheumatoid arthritis (RA), while awaiting a clinical response to a disease-modifying antirheumatic drug (DMARD, traditional and biologic). When used for a period of one month or less, glucocorticoids are more effective than either a placebo or nonsteroidal antiinflammatory drug (NSAID), and clinical experience suggests that glucocorticoids continue to be effective for periods up to 24 months. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Efficacy of short-term use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evidence is conflicting regarding the benefits of chronic glucocorticoid therapy for patients with RA. In trials in which patients received 7.5 to 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or equivalent there was initial symptomatic benefit that was not sustained at the initial dose, but with these doses, radiologic progression may be slowed. It is less clear whether similar efficacy can be achieved with doses of 5 to 7",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      but even lower doses, such as 1 to 4",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      continued indefinitely, may be effective in some patients. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Efficacy of chronic use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The chronic use of low dose glucocorticoids in RA can cause multiple adverse events, including an increased risk for osteoporosis and skeletal fractures, gastrointestinal bleeding, peptic ulcer disease, diabetes mellitus, infections, cataracts, and impaired hypothalamic-pituitary-adrenal axis response. A major goal for patients with RA treated chronically with glucocorticoids is to minimize adverse events. We try to limit the dose to a maximum of 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and preferably less than 5",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      and use other measures to minimize bone loss. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risks of chronic use'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"       \"Major side effects of systemic glucocorticoids\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link\">",
"       \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulse therapy consists of the administration of high doses of glucocorticoids over a short period of time; pulse glucocorticoids remain a modality of last resort for the treatment of RA. The available studies examining pulse glucocorticoids are very limited, and serious cardiovascular adverse events and infections may occur. The utility of pulse glucocorticoid therapy among patients with RA has been limited to the treatment of acute flares, and as a therapeutic bridge between the initiation of and response to disease modifying antirheumatic drugs. The average duration of response to pulse therapy alone is six to eight weeks. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pulse glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intraarticular glucocorticoids are frequently helpful in the treatment of symptomatic synovitis in patients with RA; such therapy is palliative rather than disease modifying. Intraarticular injections of multiple joints may have advantages over intramuscular injections for patients experiencing a disease flare. Although rare, risks associated with intraarticular injection include tendon rupture, osteonecrosis, acute synovitis (transient postinfection flare which usually resolves within 48 hours), septic arthritis, and systemic effects (",
"      <a class=\"graphic graphic_table graphicRef74660 \" href=\"mobipreview.htm?14/25/14747\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Intraarticular therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Adverse events'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30951?source=see_link\">",
"       \"Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28564?source=see_link\">",
"       \"Joint aspiration or injection in adults: Complications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The dose of glucocorticoids should be tapered as quickly as possible to the lowest effective dose when chronic use is anticipated. Glucocorticoids are best administered in the morning to minimize interference with the normal diurnal hormonal pattern. Glucocorticoid therapy should be slowly tapered over a period of months, as tolerated, once the patient has improved further or after addition of other effective agents. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Chronic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We obtain baseline studies to monitor toxicity, including serum glucose, a lipid profile, and appropriate studies for the prevention and treatment of glucocorticoid-induced osteoporosis. We monitor patients for the presence of polydipsia, edema, shortness of breath, visual changes, weight gain, and changes in blood pressure at each visit following the initiation of glucocorticoids. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Monitoring parameters'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link\">",
"       \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/1\">",
"      Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 2004; 50:3408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/2\">",
"      Moreland LW, O'Dell JR. Glucocorticoids and rheumatoid arthritis: back to the future? Arthritis Rheum 2002; 46:2553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/3\">",
"      Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996; 39:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/4\">",
"      American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002; 46:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/5\">",
"      Smolen JS, Aletaha D, Keystone E. Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction? Arthritis Rheum 2005; 52:2975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/6\">",
"      McInnes IB, O'Dell JR. State-of-the-art: rheumatoid arthritis. Ann Rheum Dis 2010; 69:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/7\">",
"      G&oslash;tzsche PC, Johansen HK. Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. BMJ 1998; 316:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/8\">",
"      den Uyl D, van Raalte DH, Nurmohamed MT, et al. Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. Arthritis Rheum 2012; 64:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/9\">",
"      Landew&eacute; RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002; 46:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/10\">",
"      Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52:3381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/11\">",
"      Bijlsma JW, Boers M, Saag KG, Furst DE. Glucocorticoids in the treatment of early and late RA. Ann Rheum Dis 2003; 62:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/12\">",
"      Million R, Kellgren JH, Poole P, Jayson MI. Long-term study of management of rheumatoid arthritis. Lancet 1984; 1:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/13\">",
"      Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995; 333:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/14\">",
"      Strand V. Steroid withdrawal favours joint erosion in rheumatoid arthritis. Clin Exp Rheumatol 1999; 17:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/15\">",
"      van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 2002; 136:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/16\">",
"      McDougall R, Sibley J, Haga M, Russell A. Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. J Rheumatol 1994; 21:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/17\">",
"      Morrison E, Capell HA. Corticosteroids in the management of early and established rheumatoid disease. Rheumatology (Oxford) 2006; 45:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/18\">",
"      Capell HA, Madhok R, Hunter JA, et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis 2004; 63:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/19\">",
"      Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 2012; 156:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/20\">",
"      Jacobs JW, van Everdingen AA, Verstappen SM, Bijlsma JW. Followup radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo. Arthritis Rheum 2006; 54:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/21\">",
"      Paulus HE, Di Primeo D, Sanda M, et al. Progression of radiographic joint erosion during low dose corticosteroid treatment of rheumatoid arthritis. J Rheumatol 2000; 27:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/22\">",
"      Svensson B, Boonen A, Albertsson K, et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 2005; 52:3360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/23\">",
"      Wassenberg S, Rau R, Steinfeld P, Zeidler H. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52:3371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/24\">",
"      Harris ED Jr, Emkey RD, Nichols JE, Newberg A. Low dose prednisone therapy in rheumatoid arthritis: a double blind study. J Rheumatol 1983; 10:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/25\">",
"      Pincus T, Swearingen CJ, Luta G, Sokka T. Efficacy of prednisone 1-4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial. Ann Rheum Dis 2009; 68:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/26\">",
"      Caplan L, Wolfe F, Russell AS, Michaud K. Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. J Rheumatol 2007; 34:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/27\">",
"      Buttgereit F, Doering G, Schaeffler A, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 2008; 371:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/28\">",
"      Buttgereit F, Mehta D, Kirwan J, et al. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis 2013; 72:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/29\">",
"      Perry MG, Kirwan JR, Jessop DS, Hunt LP. Overnight variations in cortisol, interleukin 6, tumour necrosis factor alpha and other cytokines in people with rheumatoid arthritis. Ann Rheum Dis 2009; 68:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/30\">",
"      Delayed-release prednisone (Rayos). Med Lett Drugs Ther 2012; 54:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/31\">",
"      Saag KG, Koehnke R, Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994; 96:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/32\">",
"      Laan RF, van Riel PL, van de Putte LB, et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med 1993; 119:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/33\">",
"      Buckley LM, Leib ES, Cartularo KS, et al. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 125:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/34\">",
"      Michel BA, Bloch DA, Fries JF. Predictors of fractures in early rheumatoid arthritis. J Rheumatol 1991; 18:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/35\">",
"      Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/36\">",
"      Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990; 112:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/37\">",
"      Smith MD, Ahern MJ, Roberts-Thomson PJ. Pulse methylprednisolone therapy in rheumatoid arthritis: unproved therapy, unjustified therapy, or effective adjunctive treatment? Ann Rheum Dis 1990; 49:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/38\">",
"      Iglehart IW 3rd, Sutton JD, Bender JC, et al. Intravenous pulsed steroids in rheumatoid arthritis: a comparative dose study. J Rheumatol 1990; 17:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/39\">",
"      Corkill MM, Kirkham BW, Chikanza IC, et al. Intramuscular depot methylprednisolone induction of chrysotherapy in rheumatoid arthritis: a 24-week randomized controlled trial. Br J Rheumatol 1990; 29:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/40\">",
"      Choy EH, Kingsley GH, Corkill MM, Panayi GS. Intramuscular methylprednisolone is superior to pulse oral methylprednisolone during the induction phase of chrysotherapy. Br J Rheumatol 1993; 32:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/41\">",
"      Radia M, Furst DE. Comparison of three pulse methylprednisolone regimens in the treatment of rheumatoid arthritis. J Rheumatol 1988; 15:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/42\">",
"      Weiss MM. Corticosteroids in rheumatoid arthritis. Semin Arthritis Rheum 1989; 19:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/43\">",
"      Blyth T, Hunter JA, Stirling A. Pain relief in the rheumatoid knee after steroid injection. A single-blind comparison of hydrocortisone succinate, and triamcinolone acetonide or hexacetonide. Br J Rheumatol 1994; 33:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/44\">",
"      Chakravarty K, Pharoah PD, Scott DG. A randomized controlled study of post-injection rest following intra-articular steroid therapy for knee synovitis. Br J Rheumatol 1994; 33:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/45\">",
"      Furtado RN, Oliveira LM, Natour J. Polyarticular corticosteroid injection versus systemic administration in treatment of rheumatoid arthritis patients: a randomized controlled study. J Rheumatol 2005; 32:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/46\">",
"      HOLLANDER JL, JESSAR RA, BROWN EM Jr. Intra-synovial corticosteroid therapy: a decade of use. Bull Rheum Dis 1961; 11:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/47\">",
"      Roberts WN, Babcock EA, Breitbach SA, et al. Corticosteroid injection in rheumatoid arthritis does not increase rate of total joint arthroplasty. J Rheumatol 1996; 23:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/48\">",
"      Jain R, Lipsky PE. Treatment of rheumatoid arthritis. Med Clin North Am 1997; 81:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/49\">",
"      Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996; 39:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/50\">",
"      Conn DL. Resolved: Low-dose prednisone is indicated as a standard treatment in patients with rheumatoid arthritis. Arthritis Rheum 2001; 45:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/51\">",
"      Strand V, Simon LS. Low dose glucocorticoids in early rheumatoid arthritis. Clin Exp Rheumatol 2003; 21:S186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/52\">",
"      Choy EH, Kingsley GH, Khoshaba B, et al. A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs. Ann Rheum Dis 2005; 64:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/53\">",
"      Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007; 66:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/54\">",
"      Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. American College of Rheumatology Task Force on Osteoporosis Guidelines. Arthritis Rheum 1996; 39:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/55\">",
"      Hougardy DM, Peterson GM, Bleasel MD, Randall CT. Is enough attention being given to the adverse effects of corticosteroid therapy? J Clin Pharm Ther 2000; 25:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/56\">",
"      Chantler IW, Davie MW, Evans SF, Rees JS. Oral corticosteroid prescribing in women over 50, use of fracture prevention therapy, and bone densitometry service. Ann Rheum Dis 2003; 62:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/57\">",
"      Blalock SJ, Norton LL, Patel RA, Dooley MA. Patient knowledge, beliefs, and behavior concerning the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 2005; 53:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/58\">",
"      Yilmaz L, Ozoran K, G&uuml;nd&uuml;z OH, et al. Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids. Rheumatol Int 2001; 20:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41065/abstract/59\">",
"      Morrison E, Crosbie D, Capell HA. Attitude of rheumatoid arthritis patients to treatment with oral corticosteroids. Rheumatology (Oxford) 2003; 42:1247.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7520 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-B4DFEB0FC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_6_41065=[""].join("\n");
var outline_f40_6_41065=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4992891\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFICACY OF SHORT-TERM USE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFICACY OF CHRONIC USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H720849417\">",
"      Low-dose chronotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISKS OF CHRONIC USE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PULSE GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INTRAARTICULAR THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Adverse events",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chronic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Flares",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Monitoring parameters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Patient attitude",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4992891\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7520\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7520|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/25/14747\" title=\"table 1\">",
"      Intraarticular steroid toxicity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28249?source=related_link\">",
"      Glucocorticoid effects on the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/37/22103?source=related_link\">",
"      Glucocorticoid withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/3/31802?source=related_link\">",
"      Initial treatment of moderately to severely active rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30951?source=related_link\">",
"      Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28564?source=related_link\">",
"      Joint aspiration or injection in adults: Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/35/566?source=related_link\">",
"      Miscellaneous novel therapies in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42583?source=related_link\">",
"      Overview of dual-energy x-ray absorptiometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/54/42855?source=related_link\">",
"      Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/29/39378?source=related_link\">",
"      Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/40/27266?source=related_link\">",
"      Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/61/21463?source=related_link\">",
"      Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/44/24264?source=related_link\">",
"      Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23208?source=related_link\">",
"      Pharmacologic use of glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/0/9223?source=related_link\">",
"      T cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/6/42090?source=related_link\">",
"      Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_6_41066="Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis";
var content_f40_6_41066=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/6/41066/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/6/41066/contributors\">",
"     Jochen Reiser, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/6/41066/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/6/41066/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/6/41066/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/6/41066/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/6/41066/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal segmental glomerulosclerosis (FSGS) is a histologic lesion, rather than a disease, that is commonly found to underlie the nephrotic syndrome in adults and children, particularly in the United States, Brazil, and many other countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/1-6\">",
"     1-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The focal nature of the glomerulosclerosis means that some mild cases of FSGS will be missed on renal biopsy due to sampling error and will be misclassified as minimal change disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34601?source=see_link&amp;anchor=H661039280#H661039280\">",
"     \"Etiology, clinical features, and diagnosis of minimal change disease in adults\", section on 'Primary MCD versus primary FSGS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology, classification, and pathogenesis of FSGS will be reviewed in this topic. The treatment of both primary FSGS and recurrent disease in the renal transplant are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=see_link\">",
"     \"Treatment of primary focal segmental glomerulosclerosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/59/33722?source=see_link\">",
"     \"Focal segmental glomerulosclerosis in the transplanted kidney\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5530119\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A survey of renal biopsies performed in the United States from 1995 to 1997 for idiopathic nephrotic syndrome in adults found that focal segmental glomerulosclerosis (FSGS) was the most common lesion seen, accounting for 35 percent of all cases and over 50 percent of cases among blacks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9804961\">",
"     'FSGS in African Americans'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    According to data from the United States Renal Data System (USRDS) collected over 21 years, FSGS is the most common pathology identified in patients with end-stage renal disease (ESRD) in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/3\">",
"     3",
"    </a>",
"    ]. The prevalence of FSGS as a lesion associated with ESRD has risen. In 1980, FSGS was the cause of ESRD in only 0.2 percent of patients; by 2000, it was responsible for 2.3 percent of cases (excluding patients with HIV), an 11-fold increase. The risk of ESRD was fourfold higher in black patients compared with white and Asian patients and 1.5- to twofold higher in males compared with females.",
"   </p>",
"   <p>",
"    By comparison, some other countries have found that FSGS is a less common lesion associated with the nephrotic syndrome. Among 2000 patients between 15 and 65 years of age with nephrotic syndrome noted in the glomerulonephritis registry of Spain, the most common histologic lesion was membranous nephropathy (24 percent), minimal change disease (16 percent), lupus (14 percent), and then FSGS (12 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiologic classification of focal segmental glomerulosclerosis (FSGS) is complicated and somewhat confusing, with some degree of overlap observed among the different categories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. One classification is based upon the known",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    postulated causes of this histologic pattern:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary or idiopathic FSGS, which most often presents with the nephrotic syndrome. (See",
"      <a class=\"local\" href=\"#H306776363\">",
"       'Clinical features'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Secondary FSGS, which most often presents with non-nephrotic proteinuria and, commonly, some degree of renal insufficiency. This category most commonly refers to FSGS thought to represent an adaptive response to glomerular hypertrophy or hyperfiltration. This includes disorders associated with a reduced renal mass",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      renal vasodilation, such as unilateral renal agenesis. In addition, a nonspecific pattern of secondary FSGS can result from scarring produced by a previous injury (due to a variety of conditions, including active IgA nephropathy, vasculitis, and lupus nephritis). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Secondary FSGS'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Other known causes of FSGS include infections (particularly HIV), toxins (including heroin, interferon,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      ), genetic abnormalities, and renal atheroembolic disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/3/2104?source=see_link\">",
"       \"HIV-associated nephropathy (HIVAN)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/13/13528?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical presentation, evaluation, and treatment of renal atheroemboli\", section on 'Evaluation and diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HISTOLOGIC VARIANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several morphologic variants of focal segmental glomerulosclerosis (FSGS) as observed on light microscopy have been defined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/11\">",
"     11",
"    </a>",
"    ]. This schema assumes that renal scarring due to other primary glomerular diseases has been excluded as a diagnostic possibility.",
"   </p>",
"   <p>",
"    Since this system is based upon sampling from a renal biopsy, the number of glomeruli that are available for accurate classification is often limited, resulting in some degree of uncertainty [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/9\">",
"     9",
"    </a>",
"    ]. Expertise of the pathologist in reading renal biopsies is essential.",
"   </p>",
"   <p>",
"    These histologic variants, which can be found with primary as well as some other forms of FSGS, include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/8,12\">",
"     8,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Classic FSGS, also called FSGS NOS (",
"      <strong>",
"       n",
"      </strong>",
"      ot",
"      <strong>",
"       o",
"      </strong>",
"      therwise",
"      <strong>",
"       s",
"      </strong>",
"      pecified), is the most common form.",
"     </li>",
"     <li>",
"      Collapsing variant, although some argue that this should be considered a separate entity rather than a variant of FSGS.",
"     </li>",
"     <li>",
"      Tip variant.",
"     </li>",
"     <li>",
"      Perihilar variant.",
"     </li>",
"     <li>",
"      Cellular variant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the appearance of the glomerulus on light microscopy, by definition, differs among these forms, they all share ultrastructural findings of podocyte alterations. The factors responsible for these different histologic variants are unknown.",
"   </p>",
"   <p>",
"    Support for this classification is best provided by the observation that the histology of those with recurrent disease after kidney transplantation is most commonly the same as that observed prior to transplantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/59/33722?source=see_link\">",
"     \"Focal segmental glomerulosclerosis in the transplanted kidney\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Classic FSGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;To make the histologic diagnosis of classic FSGS, the collapsing, tip, perihilar, and cellular variants must be excluded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On light microscopy, classic FSGS (or FSGS NOS) is characterized by segmental areas of mesangial collapse and sclerosis in some, but not all, glomeruli (hence the name focal) (",
"    <a class=\"graphic graphic_picture graphicRef67677 graphicRef63456 \" href=\"mobipreview.htm?42/20/43338\">",
"     picture 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/8\">",
"     8",
"    </a>",
"    ]. Sclerotic changes occur first in juxtamedullary glomeruli and therefore may be missed in superficial biopsies that only contain cortex. Mild mesangial hypercellularity and partial occlusion of the capillary lumens by hyaline deposits are commonly seen. The latter represent the insudation of plasma proteins into the abnormally permeable glomerular capillary wall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/8,13\">",
"     8,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Careful light microscopic examination is more compatible for the diffuse nature of the glomerular injury. In one study, 32 percent of glomeruli had sclerotic lesions on single sections; when serial sections were evaluated, the number of affected glomeruli increased to 48 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunofluorescence microscopy usually reveals no immune deposits, except for what may represent nonspecific binding of IgM and complement (C3 and variably C1) in sclerotic lesions (",
"    <a class=\"graphic graphic_picture graphicRef59969 \" href=\"mobipreview.htm?14/40/14991\">",
"     picture 2",
"    </a>",
"    ). Very weak mesangial deposition of IgM may also be observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/47/41717?source=see_link\">",
"     \"Minimal change variants: Mesangial proliferation; IgM nephropathy; C1q nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Electron microscopy shows diffuse fusion of the epithelial cell foot processes, similar to that seen in minimal change disease (",
"    <a class=\"graphic graphic_picture graphicRef79479 \" href=\"mobipreview.htm?42/25/43416\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/8\">",
"     8",
"    </a>",
"    ]. By comparison, secondary FSGS is associated with lesser degrees of foot process effacement. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Secondary FSGS'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Collapsing variant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Collapsing FSGS, which may be induced by HIV infection or other disorders, is distinguished from classic FSGS by collapse and sclerosis of the entire glomerular tuft, rather than segmental injury (",
"    <a class=\"graphic graphic_picture graphicRef81601 \" href=\"mobipreview.htm?17/19/17721\">",
"     picture 4",
"    </a>",
"    ). Given its unique pathology, some investigators feel that this variant should be called collapsing glomerulopathy and",
"    <strong>",
"     not",
"    </strong>",
"    be considered a form of FSGS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/3/2104?source=see_link\">",
"     \"HIV-associated nephropathy (HIVAN)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/31/43512?source=see_link\">",
"     \"Collapsing focal segmental glomerulosclerosis not associated with HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Collapsing FSGS often presents with more severe nephrotic syndrome than classic FSGS. Affected patients are frequently resistant to therapy and often have a rapid downhill course. Collapsing FSGS is most commonly seen in patients of African ancestry, which may contribute to the worse prognosis. (See",
"    <a class=\"local\" href=\"#H9804961\">",
"     'FSGS in African Americans'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Tip variant",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tip variant is characterized by epithelial cell injury and foam cell accumulation that occur",
"    <em>",
"    </em>",
"    at the \"tip\" of the glomerulus near the origin of the proximal tubule (",
"    <a class=\"graphic graphic_picture graphicRef66716 \" href=\"mobipreview.htm?8/53/9050\">",
"     picture 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/8\">",
"     8",
"    </a>",
"    ]. Immunofluorescence microscopy may show positive staining for IgM and C3 in the sclerotic lesion and in the mesangium.",
"   </p>",
"   <p>",
"    The tip lesion may identify a subset of patients who are more likely to present abruptly with the nephrotic syndrome and are more likely to respond to glucocorticoid therapy than patients with the other FSGS variants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. In a report of 47 patients with tip lesions, glucocorticoid therapy led to complete remission in 59 percent and partial remission in 14 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/9/31898?source=see_link&amp;anchor=H445388988#H445388988\">",
"     \"Treatment of minimal change disease in adults\", section on 'Immunosuppressive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients with the tip variant undergo spontaneous remission without immunosuppressive therapy. In a series from Sweden of 20 patients with FSGS (13 of whom had the tip variant, most of whom received ACE inhibitor therapy), 70 percent had a partial remission within a median of ten months, and complete remission subsequently ensued in 11 patients (55 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=see_link\">",
"     \"Treatment of primary focal segmental glomerulosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Insight into the pathologic and clinical evolution of the glomerular tip lesion was reported in a retrospective study of two series of patients with FSGS who had more than one renal biopsy over time (sometimes including autopsy kidneys) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 24 patients with an initial tip lesion who underwent a second biopsy for persistent or relapsing proteinuria, 17 subsequently had findings of classic FSGS, while seven continued to only have the tip lesion.",
"     </li>",
"     <li>",
"      Among patients with an original diagnosis of FSGS prior to transplantation, recurrent nephrotic syndrome was noted in seven renal allografts; six revealed the tip lesion.",
"     </li>",
"     <li>",
"      Patients with a tip lesion at initial presentation were more likely, compared with those with classic FSGS at initial biopsy, to have a complete response to glucocorticoids and to not progress to end-stage renal disease (ESRD).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given these findings, the authors speculated that, rather than being unique, the tip lesion may be an early form of classic FSGS in some cases and a variant of minimal change disease in others. Further study in larger numbers of patients is required to determine the histologic and prognostic significance of this lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Perihilar variant",
"    </span>",
"    &nbsp;&mdash;&nbsp;The perihilar variant consists of perihilar sclerosis and hyalinosis in more than 50 percent of segmentally sclerotic glomeruli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/8\">",
"     8",
"    </a>",
"    ]. Immunofluorescence and electron microscopic findings with the perihilar variant are similar to those observed with classic FSGS.",
"   </p>",
"   <p>",
"    Although the perihilar form can occur with primary FSGS, it is frequently observed with secondary FSGS due to processes associated with increased glomerular capillary pressure, such as renal agenesis. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Nephron loss'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cellular variant",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cellular variant is characterized by the presence of at least one glomerulus with segmental endocapillary hypercellularity that occludes the capillary lumen. Other glomeruli may exhibit findings consistent with classic FSGS. Diffuse foot process effacement is typically seen on electron microscopy. The tip and collapsing variants must be excluded histologically to make a diagnosis of the cellular variant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some claim that the cellular variant is characterized by severe proteinuria. At least some such cases may represent collapsing FSGS in which sampling limitations result in an inability to detect at least one glomerulus with collapsing changes. The combination of severe nephrotic syndrome and acute kidney injury (AKI) would strongly suggest collapsing FSGS. Some pathologists think that the cellular and collapsing variants are the same lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Prognostic relevance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognostic and therapeutic decision-making value of the histologic variants of FSGS is debated, and further prospective controlled studies are necessary to resolve the controversy. In one study, there was no difference in response to therapy among patients with the different biopsy findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/21\">",
"     21",
"    </a>",
"    ]. However, other studies suggest that the histologic classification can predict outcomes. This was illustrated in a retrospective analysis of 197 patients with biopsy-proven FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/18\">",
"     18",
"    </a>",
"    ]. Three percent had the cellular variant, 11 percent collapsing, 17 percent tip lesion, 26 percent perihilar, and 42 percent classic. At a median follow-up of 1.8 years, 23 percent were on dialysis.",
"   </p>",
"   <p>",
"    The following additional observations were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with the collapsing and tip variants had more proteinuria.",
"     </li>",
"     <li>",
"      Patients with the tip lesion had the least tubulointerstitial injury and best renal function, and almost 50 percent achieved complete remission with glucocorticoid therapy.",
"     </li>",
"     <li>",
"      Patients with the collapsing variant had the worst outcomes, with lower rates of renal survival at both one year (74 versus 86 percent for the remaining patients) and three years (33 versus 67 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study supports a more favorable prognosis associated with the tip variant and a more unfavorable prognosis associated with the collapsing variant. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Tip variant'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5\">",
"     'Collapsing variant'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, this study did not have a sufficient number of patients with the cellular variant to determine whether their outcomes differed significantly from the other types. A larger number of patients with the cellular variant were studied in separate review of 225 patients with biopsy-proven FSGS, in which 22 patients had the cellular lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/22\">",
"     22",
"    </a>",
"    ]. Follow-up was available on 18 of these patients. At a mean follow-up of 17 months, five (28 percent) progressed to ESRD, eight had a complete or partial remission following therapy, and five had persistent proteinuria or a progressive increase in the serum creatinine. The rates of remission and ESRD among these patients were similar to those who had the classic variant and were intermediate between the tip and collapsing variant. Thus, this study does not support the claim that the cellular and collapsing variants are the same.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PRIMARY FSGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some have theorized that primary focal segmental glomerulosclerosis (FSGS) and minimal change disease are related entities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/12\">",
"     12",
"    </a>",
"    ], demonstrating certain clinical and histologic similarities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/23\">",
"     23",
"    </a>",
"    ]. As an example of the former, occasional patients with FSGS follow a frequently relapsing, steroid-responsive course similar to that in minimal change disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/24\">",
"     24",
"    </a>",
"    ]. This is particularly likely in patients with focal global (as opposed to segmental) sclerosis in whom steroid-resistance and progressive renal failure appear to be uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/25\">",
"     25",
"    </a>",
"    ]; why focal global sclerosis has a more benign prognosis is unclear. In addition, some patients with biopsy-proven minimal change disease later progress to FSGS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34601?source=see_link\">",
"     \"Etiology, clinical features, and diagnosis of minimal change disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, it is also possible that, due to the focal nature of FSGS, some patients who appear to \"progress\" from minimal change disease to FSGS had primary FSGS all along, but, possibly due to sampling error, characteristic sclerotic lesions were missed on the initial biopsy. If sampling error in a patient with FSGS produces a histologic specimen devoid of sclerotic lesions in the glomeruli, the only potential clue to the presence of FSGS would be regions of tubular atrophy and interstitial fibrosis. In addition, the pathogenesis of primary FSGS is increasingly seen as being distinct from that of minimal change disease. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Pathogenesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Primary FSGS must also be distinguished from secondary FSGS, which can be clinically challenging. (See",
"    <a class=\"local\" href=\"#H1498484543\">",
"     'Distinguishing between primary and secondary FSGS'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injury to the visceral epithelial cell or podocyte, which attaches to the glomerular basement membrane by discrete foot processes, appears to be the primary problem in most forms of FSGS as it is in minimal change disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/13,26,27\">",
"     13,26,27",
"    </a>",
"    ]. However, involvement of parietal epithelial cells, independent of podocyte involvement, has also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the majority of patients with primary FSGS, injury to glomerular cells may occur as a consequence of a circulating factor. As an example, elevated circulating blood levels of the soluble urokinase plasminogen activator receptor (suPAR) are found in approximately 55 percent of pediatric patients with FSGS and in greater than two-thirds of adult patients with the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Evidence supporting a pathogenic role for suPAR is discussed below. (See",
"    <a class=\"local\" href=\"#H166292499\">",
"     'Soluble urokinase receptor'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Clinical observations that support a key role for a circulating factor such as suPAR in primary FSGS (and posttransplant FSGS) include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rapidity and relatively high incidence of disease recurrence after renal transplantation in patients with primary FSGS within hours or months after transplantation. In addition, serum from some patients with recurrent FSGS after transplantation increases the permeability of isolated glomeruli to albumin. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/59/33722?source=see_link&amp;anchor=H1045081412#H1045081412\">",
"       \"Focal segmental glomerulosclerosis in the transplanted kidney\", section on 'Epidemiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Transmission from a pregnant woman to the fetus. One woman, for example, developed the nephrotic syndrome in the thirteenth week of gestation that was found to be FSGS on renal biopsy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/31\">",
"       31",
"      </a>",
"      ]. At delivery, the child had proteinuria (935",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      and hypoalbuminemia that rapidly resolved within a few days. Serum suPAR levels were elevated in both the infant and mother at the time of birth, suggesting that transmission of suPAR from the mother to the child produced transient proteinuria in the otherwise healthy infant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H166292499\">",
"    <span class=\"h3\">",
"     Soluble urokinase receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased circulating levels of soluble urokinase receptor (suPAR) may be a common causative factor of primary FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. The following illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a detailed analysis of 148 patients (78 with primary FSGS, 25 with minimal change disease, 7 with preeclampsia, 16 with membranous nephropathy, and 22 normal controls), suPAR was significantly elevated in sera from patients with FSGS compared with normal controls and patients with other proteinuric glomerular diseases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/33\">",
"       33",
"      </a>",
"      ]. The highest serum suPAR levels were in pretransplant sera of patients who developed recurrent FSGS after transplantation, suggesting an association of suPAR with recurrent FSGS. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/59/33722?source=see_link\">",
"       \"Focal segmental glomerulosclerosis in the transplanted kidney\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum suPAR using a commercially available assay was measured in a cohort comprised of 70 adult and 94 pediatric patients with biopsy-proven primary FSGS and an estimated glomerular filtration rate (eGFR) greater than 40",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/30\">",
"       30",
"      </a>",
"      ]. Levels greater than 3000",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      were found in 84 percent of adults and 55 percent of children. In contrast, elevated suPAR was detected in only 6 percent of healthy controls. Patients treated with immunosuppression had lower suPAR levels, and a reduction in suPAR with immunosuppressive therapy was associated with a reduction in proteinuria and a higher likelihood of achieving complete remission.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, suPAR testing may not reliably identify primary FSGS in patients with end-stage renal disease (ESRD) because suPAR can accumulate due to lack of urinary excretion.",
"   </p>",
"   <p>",
"    Support for a causal role of suPAR in primary FSGS was provided by the selective expression of suPAR in mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/33\">",
"     33",
"    </a>",
"    ]. The mice developed albuminuria and a progressive glomerulopathy characterized by effacement of foot processes, hypercellularity, mesangial expansion, mesangiolysis, and tuft adhesions. suPAR acts via activation of podocyte alphaVbeta3 integrin, which plays an important role both in the dynamic regulation of mature foot processes and the controlled adhesion to the glomerular basement membrane [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/29,34\">",
"     29,34",
"    </a>",
"    ]. Additional mechanisms are involved in the genetic diseases associated with the development of FSGS. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Genetic disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the study cited above, serum from patients with recurrent FSGS, but not from those with nonrecurrent FSGS or normal controls, activated beta3 integrin activity",
"    <em>",
"     in vitro",
"    </em>",
"    , while inhibition of suPAR reduced beta3 integrin activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/33\">",
"     33",
"    </a>",
"    ]. In addition, plasmapheresis, which is commonly used to treat recurrent FSGS following transplantation, induced clinical remission and decreased both serum suPAR levels and beta3 integrin activity in a subset of patients with recurrent FSGS. In animal studies, the expression of non-integrin-binding mutant forms of suPAR did not induce glomerular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/59/33722?source=see_link&amp;anchor=H2#H2\">",
"     \"Focal segmental glomerulosclerosis in the transplanted kidney\", section on 'Etiology and pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It appears that, with the commercially available test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/33\">",
"     33",
"    </a>",
"    ], roughly one-third of patients with primary FSGS do not have elevated serum suPAR concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/33\">",
"     33",
"    </a>",
"    ]. This suggests that other circulating factors may contribute to the pathogenesis of primary FSGS, although fluctuations in suPAR concentrations, relative insensitivity of the assay, and individual variability in the response to the effects of suPAR may also play a role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with primary FSGS may present with acute or insidious onset of proteinuria and can eventually exhibit features of the nephrotic syndrome, as manifested by peripheral edema, hypoalbuminemia, and nephrotic range proteinuria. However, some patients have non-nephrotic or nephrotic range proteinuria without overt clinical manifestations. Patients with FSGS also commonly have hypertension, and many have microscopic hematuria. The level of kidney function is variable.",
"   </p>",
"   <p>",
"    The frequency of the following clinical features at either presentation or time of biopsy have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/21,35-38\">",
"     21,35-38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nephrotic range proteinuria &ndash; 60 to 75 percent",
"     </li>",
"     <li>",
"      Microscopic hematuria with variable degrees of proteinuria &ndash; 30 to 50 percent",
"     </li>",
"     <li>",
"      Hypertension &ndash; 45 to 65 percent",
"     </li>",
"     <li>",
"      Renal insufficiency &ndash; 25 to 50 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SECONDARY FSGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to occurring in primary idiopathic focal segmental glomerulosclerosis (FSGS), FSGS can be observed in a variety of secondary settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/8,13\">",
"     8,13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Classification'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In our view, the glomerulosclerosis of secondary FSGS usually results from an adaptive response to glomerular hypertrophy and hyperfiltration, from scarring due to previous injury (eg, healed lesions of lupus or vasculitis), or from direct toxic injury to podocytes. In the above context, hyperfiltration refers to an adaptive but abnormal increase in single-nephron glomerular filtration that increases the total glomerular filtration rate (GFR) above the level expected from the reduced number of glomeruli. The settings in which adaptive glomerular hypertrophy and hyperfiltration occur include the many diseases associated with either nephron loss",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    renal vasodilatation with an initially normal number of nephrons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important clinically to distinguish secondary from primary FSGS since the treatment of secondary FSGS consists of angiotensin inhibition but not immunosuppressive therapy. How this distinction is made is discussed below. (See",
"    <a class=\"local\" href=\"#H1498484543\">",
"     'Distinguishing between primary and secondary FSGS'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=see_link\">",
"     \"Treatment of primary focal segmental glomerulosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Podocyte injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary site of injury in secondary FSGS, as in primary FSGS, is the glomerular epithelial cell or podocyte [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/39-47\">",
"     39-47",
"    </a>",
"    ]. A variety of factors have been postulated to cause injury to glomerular cells, including circulating cytokines (such as transforming growth factor-beta [TGF-beta]), angiotensin II, macrophage infiltration and other mediators of inflammation, direct effects of intraglomerular hypertension, toxins, and viral infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/42-44,48-50\">",
"     42-44,48-50",
"    </a>",
"    ]. The renoprotective effects of angiotensin inhibition may be partly due to protecting podocytes from further injury. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=see_link&amp;anchor=H3#H3\">",
"     \"Secondary factors and progression of chronic kidney disease\", section on 'Intraglomerular hypertension and glomerular hypertrophy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/30/18921?source=see_link&amp;anchor=H2#H2\">",
"     \"Mechanisms of immune injury of the glomerulus\", section on 'Noninflammatory mechanisms of immune glomerular injury'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9304?source=see_link&amp;anchor=H7#H7\">",
"     \"Biology of glomerular podocytes\", section on 'Direct podocyte injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Proteinuria in secondary FSGS, as in primary FSGS, is a manifestation of podocyte injury, but the mechanism is different. The visceral epithelial cells are unable to replicate. In the presence of the hypertrophic response to nephron loss or direct epithelial cell injury, it is postulated that the inability of these cells to replicate leads to decreased podocyte density and focal areas of denudation from the glomerular basement membrane. As a result, the barrier to filtration normally provided by the slit diaphragms between the foot processes is lost in these areas. The ensuing increase in flux of small solutes and water through these sites carries albumin along by solvent drag [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/13,27\">",
"     13,27",
"    </a>",
"    ]. Larger macromolecules (such as IgM and fibrinogen and complement metabolites) are unable to cross the glomerular basement membrane but can form large subendothelial hyaline deposits.",
"   </p>",
"   <p>",
"    Glomerular cell proliferation, macrophage infiltration, and the progressive accumulation of extracellular matrix components all may contribute to the development of the sclerotic lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/51\">",
"     51",
"    </a>",
"    ]. How these changes occur is not well understood, but cytokines, such as transforming growth factor beta, may be responsible for at least part of the matrix accumulation. Transforming growth factor beta accelerates podocyte damage by changing transcriptional activity to allow for expression of cytosolic cathepsin L [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/52\">",
"     52",
"    </a>",
"    ]. Cytosolic cathepsin L in podocytes cleaves the large GTPase dynamin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/53\">",
"     53",
"    </a>",
"    ], synaptopodin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/54\">",
"     54",
"    </a>",
"    ], as well as the as CD2AP establishing the ultrastructural changes in podocytes seen in FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Healing of prior inflammatory injury'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Nephron loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;FSGS induced by the adaptive response to nephron loss occurs with many causes of chronic kidney disease (CKD), including nonglomerular disorders such as reflux nephropathy and ischemia in benign hypertensive nephrosclerosis. It can also occur when there is a marked reduction in renal mass due to congenital absence or surgical removal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/42/6824?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of hypertensive nephrosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In these settings, compensatory intraglomerular hypertension and hypertrophy in the remaining glomeruli will lead to an increase in the nephron filtration rate that will initially tend to maintain the total GFR. Over a period of years, however, \"hypertensive\" injury associated with intraglomerular hypertension can lead to FSGS and a decline in GFR. The protective effect of angiotensin inhibitors is mediated in part by the associated reduction in glomerular capillary pressure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=see_link&amp;anchor=H3#H3\">",
"     \"Secondary factors and progression of chronic kidney disease\", section on 'Intraglomerular hypertension and glomerular hypertrophy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/57/13206?source=see_link&amp;anchor=H2#H2\">",
"     \"Antihypertensive therapy and progression of chronic kidney disease: Experimental studies\", section on 'Preferential effect of ACE inhibitors on renal hemodynamics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Dose-dependence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of developing secondary FSGS after nephron loss is dose-dependent or there may be a threshold effect, with surgical studies suggesting that loss of more than 50 percent of nephrons is required in adults. This was illustrated in a long-term follow-up of adults undergoing partial nephrectomy for renal cancer in a solitary kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/56\">",
"     56",
"    </a>",
"    ]. Patients who lost more than 75 percent of their total renal mass were at greatest risk for developing proteinuria, glomerulosclerosis, and, in some cases, progressive renal failure. Clinically evident disease was usually delayed for at least five years after the surgery.",
"   </p>",
"   <p>",
"    In comparison, long-term renal outcomes are generally excellent after loss of one kidney (50 percent nephron loss). As an example, a benign clinical course after 45 years was noted in 62 men who had one kidney removed (ie, 50 percent nephron loss) due to trauma during World War II and in a literature review of 3124 patients with reduced renal mass, almost all of whom had undergone unilateral nephrectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. There was no evidence that nephrectomy was associated with an increased prevalence of renal dysfunction or hypertension, but there was a small increase in proteinuria and in the systolic blood pressure (2.4 mmHg initially and a further 1.1 mmHg per decade) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/58\">",
"     58",
"    </a>",
"    ]. Similarly, long-term renal outcomes are generally excellent in kidney donors for renal transplantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/62/30697?source=see_link&amp;anchor=H13#H13\">",
"     \"Evaluation of the living kidney donor and risk of donor nephrectomy\", section on 'Long-term risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although loss of 50 percent of renal mass may be associated with a minor long-term risk when it occurs in adults, unilateral renal agenesis is associated with an increased incidence of secondary FSGS. These patients often have structural disease (most often vesicoureteral reflux or partial urinary tract obstruction) in the solitary kidney, which may result in a greater degree of nephron loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/39,59\">",
"     39,59",
"    </a>",
"    ]. However, proteinuria and renal insufficiency can occur in patients with an apparently normal solitary kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/60\">",
"     60",
"    </a>",
"    ], suggesting that loss of 50 percent of renal mass beginning at birth is sufficient to induce hemodynamically mediated glomerular injury. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16296?source=see_link\">",
"     \"Prenatal diagnosis of renal agenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Renal vasodilatation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Segmental areas of glomerulosclerosis can be induced by intraglomerular hypertension resulting from primary renal vasodilatation as occurs in diabetic nephropathy, sickle cell anemia, familial autonomic insufficiency, and type I glycogen storage disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/13,61,62\">",
"     13,61,62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=see_link&amp;anchor=H3#H3\">",
"     \"Secondary factors and progression of chronic kidney disease\", section on 'Intraglomerular hypertension and glomerular hypertrophy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/63/30714?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of diabetic nephropathy\", section on 'Glomerular hyperfiltration'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6202?source=see_link&amp;anchor=H13#H13\">",
"     \"Renal manifestations of sickle cell disease\", section on 'Progressive renal failure and proteinuria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intraglomerular hypertension may also be responsible for FSGS associated with obesity, severe preeclampsia, anabolic steroid abuse, and treatment with interferon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Severe obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;FSGS has been described in occasional patients with severe (also called massive or extreme) obesity, a disorder that is increasingly common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/63-67\">",
"     63-67",
"    </a>",
"    ]. In one study, FSGS was present in 9 of 17 patients with severe obesity who underwent renal biopsy for marked proteinuria without an apparent systemic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/65\">",
"     65",
"    </a>",
"    ]. The frequency of FSGS was much higher than in 34 normal body weight controls matched for age and sex with a similar renal presentation (53 versus 6 percent). Most patients also have glomerulomegaly, but some patients (14 of 71 [20 percent] in one series) have glomerulomegaly without evidence of glomerulosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The term \"obesity-related glomerulopathy\" has been used to refer to FSGS associated with obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/63,68\">",
"     63,68",
"    </a>",
"    ]. However, some obese patients with moderate to heavy proteinuria have little or no glomerulosclerosis and no epithelial cell injury or foot process fusion on renal biopsy; they do have significant mesangial expansion and glomerular capillary loop enlargement (glomerulomegaly) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/63,68-71\">",
"     63,68-71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hemodynamic factors appear to be pathogenetically important in the association between severe obesity and FSGS as evidenced by studies in animals and humans:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obese dogs acutely fed a high-fat diet developed a marked increase in GFR with expansion of Bowman's capsule [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Caloric restriction in aging rats prevented the development of glomerular enlargement, proteinuria, and glomerulosclerosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Severe obesity in humans is associated with a marked increase in GFR. In one study, for example, the mean GFR in eight severely obese patients was 145",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    compared with 90",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    in nine healthy controls. After marked weight loss in the obese patients (32 percent reduction in body mass index), the mean GFR fell to 110",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/72\">",
"     72",
"    </a>",
"    ].These findings are compatible with a role for intraglomerular hypertension in the pathogenesis of the proteinuria and sclerotic lesions in obesity-related FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/63,65-67\">",
"     63,65-67",
"    </a>",
"    ]. Decreased serum levels of an adipose-derived hormone, adiponectin, have been associated with proteinuria in obese patients and may play a pathogenetic role in the development of glomerulosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical and pathologic findings that distinguish obesity-related from primary FSGS are similar to those that distinguish other forms of secondary FSGS from primary FSGS. The data are presented below. (See",
"    <a class=\"local\" href=\"#H1498484543\">",
"     'Distinguishing between primary and secondary FSGS'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Some patients with severe obesity have",
"    <strong>",
"     subclinical",
"    </strong>",
"    disease, which is defined as sclerotic lesions in a few glomeruli in patients with little or mild proteinuria and a normal GFR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/63,65,74,75\">",
"     63,65,74,75",
"    </a>",
"    ]. The best data come from a series of 95 patients with severe obesity and no clinical evidence of renal disease in whom intraoperative renal biopsy was performed during bariatric surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/74\">",
"     74",
"    </a>",
"    ]. Forty patients undergoing nephrectomy who were neither obese nor hypertensive served as controls. FSGS was observed in approximately 5 percent of the obese patients compared with none of the nonobese patients (median body mass index 52 versus 25",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ).",
"    </span>",
"    Increased mesangial matrix, mesangial cell proliferation, and podocyte hypertrophy occurred in 73 and 5 percent of obese and nonobese patients, respectively. Body mass index was independently associated with these glomerular lesions in the entire cohort. It is not known if these observations would also apply to the merely obese population (BMI = 30 to 45",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ).",
"    </span>",
"   </p>",
"   <p>",
"    In some reports, obesity-related glomerulopathy has been attributed to coexistent sleep apnea, with its reversal leading to complete resolution of the proteinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/69,76\">",
"     69,76",
"    </a>",
"    ]. However, a subsequent well-designed study of patients with varying degrees of sleep apnea found no correlation between proteinuria and the presence or severity of the sleep apnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/77\">",
"     77",
"    </a>",
"    ]. Although the reasons for these discrepant findings are unclear, previous reports failed to exclude possible confounding factors, particularly decompensated heart failure. In the biopsy study cited above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/74\">",
"     74",
"    </a>",
"    ], sleep apnea was associated with glomerulomegaly (in the absence of proteinuria) in the extremely obese cohort.",
"   </p>",
"   <p>",
"    Both weight loss and the administration of an angiotensin inhibitor can dramatically reduce protein excretion (up to 80 to 85 percent) in patients with obesity-related FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/66,72,78,79\">",
"     66,72,78,79",
"    </a>",
"    ]. The efficacy of weight loss was demonstrated in a study of 63 patients with biopsy-proven FSGS who participated in a weight loss program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/79\">",
"     79",
"    </a>",
"    ]. Mean protein excretion was 1.5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    and mean baseline estimated GFR was 104",
"    <span class=\"nowrap\">",
"     ml/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    . At six months, mean protein excretion decreased from 1.6 to 1.1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    in the 27 patients who lost weight in comparison with no reduction in proteinuria in patients who had a stable (n = 21) or increased (n = 8) body mass index. The findings were similar at 24 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H306772923\">",
"    <span class=\"h3\">",
"     Severe preeclampsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;FSGS is an occasional finding in pregnant women with severe preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. Affected women tend to have both marked hypertension and larger glomeruli, suggesting that hemodynamic factors may be of primary importance. The typical although not uniform disappearance of proteinuria after delivery is compatible with the hypothesis that the FSGS was induced by pregnancy and preeclampsia rather than representing a preexisting or concurrent disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/80,81\">",
"     80,81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Anabolic steroid abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;FSGS and proteinuria were associated with the long-term use of anabolic steroids in a cohort of ten patients identified from the archives of the Columbia Renal Pathology Laboratory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/82\">",
"     82",
"    </a>",
"    ]. All patients engaged in weightlifting for the purpose of bodybuilding or strength competitions and used at least one anabolic androgenic steroid for a number of years (range 8 to 20 years). Most patients also used dietary supplements such as creatine monohydrate and a high-protein diet. The following characteristics were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Six patients were hypertensive on presentation.",
"     </li>",
"     <li>",
"      Mean protein excretion was 10.1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      (range 1.3 to 26.3",
"      <span class=\"nowrap\">",
"       g/day),",
"      </span>",
"      eight patients had nephrotic range proteinuria even when corrected for the unusually large body surface area, and three patients had the nephrotic syndrome. The average creatinine clearance was 96",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      (range 17",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      to 196",
"      <span class=\"nowrap\">",
"       mL/min).",
"      </span>",
"      The mean serum creatinine was much higher (3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [265",
"      <span class=\"nowrap\">",
"       micromol/L])",
"      </span>",
"      than usually expected from the near-normal mean creatinine clearance, which presumably reflects the marked increase in muscle mass and therefore creatinine production.",
"     </li>",
"     <li>",
"      Nine patients had FSGS on biopsy, three with collapsing features. Four patients had glomerulomegaly in addition to FSGS, and one patient had glomerulomegaly without evidence of glomerulosclerosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Eight of the ten patients were followed for a mean of 2.2 years. Of these, one patient who had cortical scarring at the time of biopsy progressed to end-stage disease within one month. Seven patients were started on an angiotensin receptor blocker (ARB)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    renin inhibitor and encouraged to discontinue anabolic steroids and supplements and to reduce their exercise regimen. All had improvement in or stabilization of the serum creatinine and a decrease in protein excretion. One patient who restarted steroids and dietary supplements had an increase in serum creatinine and urine protein within six weeks.",
"   </p>",
"   <p>",
"    Renal hemodynamic factors and possibly a direct nephrotoxic effect of anabolic steroids probably underlie this association.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Treatment with interferon",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of interferon (IFN)-alpha has been associated with both FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/83,84\">",
"     83,84",
"    </a>",
"    ] and minimal change disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/85\">",
"     85",
"    </a>",
"    ]. In addition, 11 cases of collapsing FSGS associated with therapeutic doses of IFN-alpha (6), IFN beta (3) and IFN-gamma (2) were identified from the archives of the Columbia Renal Pathology Laboratory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/86\">",
"     86",
"    </a>",
"    ]. The following characteristics were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ten of 11 patients were African-American, and one was Hispanic.",
"     </li>",
"     <li>",
"      The mean serum creatinine at the time of biopsy was 3.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      and 10 of 11 patients had renal insufficiency. The mean 24-hour urine protein was 9.7",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      and 9 of 11 patients had nephrotic range proteinuria. Ten patients had hypoalbuminemia.",
"     </li>",
"     <li>",
"      Five patients had microhematuria, and one patient had leukocyturia, but no red cell casts were observed.",
"     </li>",
"     <li>",
"      Among ten patients for whom follow-up was available, 9 had a decrease in serum creatinine from a mean of 3.9 to 1.9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      following cessation of IFN therapy, and four patients returned to normal renal function. All seven patients for whom follow-up measurements of urinary protein excretion were obtained showed a decline in protein excretion from a mean of 9.9 to 3",
"      <span class=\"nowrap\">",
"       g/day.",
"      </span>",
"     </li>",
"     <li>",
"      Six patients were treated with glucocorticoids and one with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      plus glucocorticoids. Immunosuppressive therapy failed to provide any significant benefit.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Healing of prior inflammatory injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;FSGS can occur during the healing phase of any focal glomerular injury due, for example, to active IgA nephropathy, small vessel vasculitis, or lupus nephritis. In these settings and perhaps in other renal diseases as well, release of transforming growth factor-beta (TGF-beta) from platelets and glomerular cells may play a role in progressive renal injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TGF-beta stimulates extracellular matrix production, inhibits matrix degradation, and facilitates the adhesion of inflammatory cells to the matrix; each of these changes can promote the development of glomerulosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/88\">",
"     88",
"    </a>",
"    ]. TGF-beta expression and type 1 collagen are increased in animal models of chronic renal injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/89-91\">",
"     89-91",
"    </a>",
"    ], while the administration of TGF-beta antibodies or inhibitors decreases matrix accumulation and the severity of glomerular scarring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/90,92\">",
"     90,92",
"    </a>",
"    ]. In addition, the suppressed expression of TGF-beta via the administration of other cytokines, such as hepatocyte growth factor, significantly limits renal fibrosis in mouse models of chronic renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The applicability of these findings to humans is unproven. A further discussion related to the wide variety of factors associated with progression of renal injury, including glomerulosclerosis, can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=see_link\">",
"     \"Secondary factors and progression of chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1498484543\">",
"    <span class=\"h1\">",
"     DISTINGUISHING BETWEEN PRIMARY AND SECONDARY FSGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differentiating primary and secondary focal segmental glomerulosclerosis (FSGS) clearly has important therapeutic implications but, as stated above, it remains controversial whether differentiation of the primary forms of FSGS into subcategories (eg, FSGS NOS [",
"    <strong>",
"     n",
"    </strong>",
"    ot",
"    <strong>",
"     o",
"    </strong>",
"    therwise",
"    <strong>",
"     s",
"    </strong>",
"    pecified] versus cellular variant) is useful in making treatment decisions.",
"   </p>",
"   <p>",
"    About 50 to 60 percent of patients with primary FSGS respond to immunosuppressive agents such as glucocorticoids, while secondary FSGS is best treated with modalities aimed at lowering the intraglomerular pressure, such as angiotensin inhibitors. This distinction can usually be made from the history (such as one of the disorders associated with secondary disease) and from the clinical and histologic findings at diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=see_link\">",
"     \"Treatment of primary focal segmental glomerulosclerosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H79962422#H79962422\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Renin-angiotensin system inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H306776363\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to patients with secondary FSGS who present with slowly increasing proteinuria and renal insufficiency over time, patients with primary FSGS most commonly present with the acute or subacute onset of the nephrotic syndrome and the associated features of peripheral edema, hypoalbuminemia, and usually high-grade (&gt;3.5",
"    <span class=\"nowrap\">",
"     g/d)",
"    </span>",
"    proteinuria. By comparison, the proteinuria in patients with secondary FSGS is often in the non-nephrotic range, serum albumin levels are usually normal, and often, there is no peripheral edema, even when protein excretion exceeds 3 to 4",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/63,64,94,95\">",
"     63,64,94,95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest series evaluating the clinical differences between secondary and primary FSGS included 71 patients with obesity-related secondary FSGS and 50 patients with idiopathic FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/63\">",
"     63",
"    </a>",
"    ]. The patients with obesity-related disease had the following significant differences: a lesser degree of proteinuria (4.1 versus 6.9",
"    <span class=\"nowrap\">",
"     g/day),",
"    </span>",
"    lower prevalence of the nephrotic syndrome (6 versus 54 percent), a higher serum albumin (3.9 versus 2.9",
"    <span class=\"nowrap\">",
"     g/dL),",
"    </span>",
"    a lower serum cholesterol (229 versus 335",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    5.9 versus 8.7",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and a lower rate of edema (35 versus 68 percent).",
"   </p>",
"   <p>",
"    The relationships among hypoalbuminemia, peripheral edema, and primary and secondary FSGS were also evaluated in a study of 37 patients with biopsy-proven FSGS and nephrotic range proteinuria (&gt;3.5",
"    <span class=\"nowrap\">",
"     g/day),",
"    </span>",
"    of whom 19 had a serum albumin below 3",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/95\">",
"     95",
"    </a>",
"    ]. Primary FSGS was defined as idiopathic disease (rather than by histologic criteria), while secondary FSGS was thought to result from the presence of massive obesity, vesicoureteral reflux, or renal mass reduction. Only 2 of 18 patients with a normal serum albumin concentration compared with all with hypoalbuminemia had primary FSGS. In addition, all patients with, but none without, hypoalbuminemia had peripheral edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H306776377\">",
"    <span class=\"h2\">",
"     Pathologic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histologic findings are generally different in primary and secondary FSGS, although there is some overlap. Primary FSGS is associated with diffuse foot process fusion; in comparison, this abnormality tends to be focal in the secondary forms, being largely limited to the sclerotic areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/8,13,63\">",
"     8,13,63",
"    </a>",
"    ]. In a systematic histologic study, the mean percentage of the glomerular surface area affected by foot process fusion was 65 percent in primary FSGS versus 25 percent in FSGS due to reflux nephropathy and 20 percent in obesity-related disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/8\">",
"     8",
"    </a>",
"    ]. Foot process fusion was greatest (82 to 89 percent) in the most severe form, collapsing FSGS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/31/43512?source=see_link&amp;anchor=H12#H12\">",
"     \"Collapsing focal segmental glomerulosclerosis not associated with HIV infection\", section on 'Pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar findings were noted in the above report comparing obesity-related and idiopathic (primary) FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/63\">",
"     63",
"    </a>",
"    ]. The following significant differences were noted in the patients with obesity-related disease: fewer glomeruli had segmental sclerotic lesions (10 versus 39 percent), glomerulomegaly was much more common (100 versus 10 percent), and foot process fusion was less extensive (40 versus 75 percent).",
"   </p>",
"   <p>",
"    There are also pathologic findings that permit healed vasculitis to be distinguished from idiopathic FSGS or that are due to nephron loss. With healed vasculitis, the obsolescent segment of the capillary tuft is usually incorporated into scar tissue that is typically composed of collagens type I and III and that may fragment the tuft. On PAS stain, this scar tissue stains significantly less intensely than the strongly PAS-positive segment of collapsed capillary basement membrane material in primary FSGS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     GENETIC DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of genetic forms of focal segmental glomerulosclerosis (FSGS) have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/76,96-104\">",
"     76,96-104",
"    </a>",
"    ] and may account for a significant proportion of patients with steroid-resistant disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/105,106\">",
"     105,106",
"    </a>",
"    ]. In some cases, the genetic forms of FSGS appear to be transmitted in an autosomal dominant pattern with variable penetrance, while autosomal recessive inheritance has been observed in other families.",
"   </p>",
"   <p>",
"    As described in the following sections, suspect gene loci have been identified at multiple sites including chromosome 19q13 (coincidentally near the region that contains the nephrin gene [NPHS1] that is mutated in the congenital nephrotic syndrome of the Finnish type) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/76,99,100\">",
"     76,99,100",
"    </a>",
"    ], chromosome 11 (which harbors the gene for the canonical transient receptor potential 6 [TRPC6] ion channel), chromosome 1 (which harbors the NPHS2 gene and may harbor other suspect genes), and chromosome 14q (which harbors the INF2 gene that encodes the formin family of actin-regulatory proteins) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/98,104,107-111\">",
"     98,104,107-111",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/36/7753?source=see_link\">",
"     \"Congenital and infantile nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/15/28922?source=see_link\">",
"     \"Treatment of idiopathic nephrotic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some series, chromosome 11 was the most frequently implicated genetic locus for familial disease. Among nine affected families in an Australian study, for example, FSGS segregated with loci on chromosomes 11 and 1 in four and two families, respectively, with no suspect genetic loci uncovered in three families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/108\">",
"     108",
"    </a>",
"    ]. Suspect genes in some of these loci have now been identified.",
"   </p>",
"   <p>",
"    In general, the genes involved encode for proteins that are integral for proper glomerular basement membrane formation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    glomerular podocyte differentiation and function. These include the gene(s) for podocin, nephrin, alpha-actinin-4, the TRPC6 ion channel, CD2AP (which interacts at the slit diaphragm with both podocin and nephrin), and the formin family of actin-regulatory proteins.",
"   </p>",
"   <p>",
"    Podocin affects the expression and location of nephrin, a principal component of the slit diaphragm. Some mutant forms of these genes appear to result in intracellular retention of the abnormal proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/112,113\">",
"     112,113",
"    </a>",
"    ]. This suggests that drugs that ameliorate processing defects may provide therapeutic benefits in these disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Commercial tests are available to detect NPHS1 and NPHS2 mutations but not the alpha-actinin-4, TRPC6, or CD2AP genes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     NPHS1 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the gene for nephrin, called NPHS1, cause congenital nephrotic syndrome of Finnish type. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/36/7753?source=see_link&amp;anchor=H3#H3\">",
"     \"Congenital and infantile nephrotic syndrome\", section on 'CNS of Finnish type'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NPHS1 mutations have also been identified in older children with steroid-resistant nephrotic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/114,115\">",
"     114,115",
"    </a>",
"    ] and in at least one adult who presented with FSGS at age 27 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/115\">",
"     115",
"    </a>",
"    ]. This patient was identified as part of study in which 97 patients from 89 unrelated families with steroid-resistant nephrotic syndrome",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    FSGS on biopsy were screened by direct DNA sequencing. Compound heterozygous or homozygous NPHS1 mutations were detected in five familial and seven sporadic cases of FSGS, including the adult patient described above and four children ages 8 months, 1 year, 6 years and 7 years; two of the children were from the same family. The detection rate of NPHS1 mutations among familial cases was 38 percent (5 of 13) and 10 percent (7 of 76) among sporadic cases. There were also two patients ages 27 and 29 years who had single NPHS1 variants of unknown effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     NPHS2 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causative gene for an autosomal recessive form of familial FSGS was cloned using a positional cloning technique directed at the chromosomal area 1q25-31 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/101,116\">",
"     101,116",
"    </a>",
"    ]. This gene, called NPHS2, encodes podocin, which is found exclusively in glomerular podocytes. Patients with FSGS due to mutations in NPHS2 usually present with early-onset nephrotic syndrome (age six years or less). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/36/7753?source=see_link&amp;anchor=H9#H9\">",
"     \"Congenital and infantile nephrotic syndrome\", section on 'CNS and NPHS2 mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, some affected patients have milder disease and present in adolescence or young adulthood. This was shown in a study of 30 families with apparent autosomal recessive late-onset FSGS (with an average age of onset of 21 years) and 91 individuals with non-familial or sporadic primary FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/117\">",
"     117",
"    </a>",
"    ]. Mutations in NPHS2 cosegregated with the disease in nine families, while no likely disease-causing mutations were observed in 21. Affected individuals from six families were compound heterozygotes, and those from one family were homozygous for a specific nonconservative amino acid substitution in NPHS2. Allele frequency of this mutation, named R229Q, was 6 and 3.6 percent in those with non-familial disease and a non-disease control population, respectively, a difference that was not statistically significant. The presence of R229Q is associated with microalbuminuria in the non-disease general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of the R229Q variant has been assessed among various FSGS patient populations with discordant results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/119-122\">",
"     119-122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, screening for known mutations in NPHS2 was performed in 87 adults with idiopathic FSGS identified through the Toronto Glomerulonephritis Registry database [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/119\">",
"       119",
"      </a>",
"      ]. Of these, 15, 63, and 9 had steroid-sensitive (average age 41 years old), steroid-resistant (38 years old), and familial disease (23 years old), respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/119\">",
"       119",
"      </a>",
"      ]. No homozygous mutations were found, and only one patient had compound heterozygous mutations (R229Q and Q285fsX302).",
"     </li>",
"     <li>",
"      In a study of 377 biopsy-proven cases of FSGS and 919 controls, the role of NPHS2 polymorphisms was evaluated by sequencing exons and intron-exon junctions of the gene [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/120\">",
"       120",
"      </a>",
"      ]. There was no increase in frequency of the R229Q mutation among patients with FSGS compared to the control population.",
"     </li>",
"     <li>",
"      By contrast, one large study suggested that compound heterozygosity for R229Q is associated with steroid-resistant adult-onset FSGS among patients from European or South America [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/121\">",
"       121",
"      </a>",
"      ]. Among 546 patients from 455 ethnically diverse families with FSGS, 36 patients from 27 families were compound heterozygous for the R229Q variant and one pathogenic mutation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/121\">",
"       121",
"      </a>",
"      ]. Of the 27 families with compound heterozygosity, 11 were from Europe and 14 from South America. Furthermore, an analysis of the frequency of the R229Q allele in specific ethnic populations revealed highly significant differences in distribution among European and South American patients (mostly of Spanish descent) compared to controls of similar ethnic backgrounds, but no difference was observed among similarly controlled individuals from the Middle East or North Africa. Limitations in sample size prevented comparisons among other ethnic groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of the mutation R138Q in only one NPHS2 allele is also associated with a markedly increased risk of FSGS. In the study cited above of 377 biopsy-proven cases of FSGS, carriers of the R138Q mutation were four- to fivefold more frequent among those with FSGS than among the control population. In addition, three carriers were steroid-resistant, suggesting an increased risk for this prognostic feature. No homozygote or compound heterozygotes were noted for any missense mutation.",
"   </p>",
"   <p>",
"    In addition, mutations in both NPHS2 alleles have been described in approximately 10 to 25 percent of cases of apparently sporadic steroid-resistant FSGS in children from Europe and the Middle East. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/15/28922?source=see_link\">",
"     \"Treatment of idiopathic nephrotic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although one might expect that patients with NPHS2 mutations would not develop recurrent disease in the transplant, recurrence has been described. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/59/33722?source=see_link\">",
"     \"Focal segmental glomerulosclerosis in the transplanted kidney\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1498485774\">",
"    <span class=\"h2\">",
"     Alpha-actinin-4 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the alpha-actinin-4 gene on chromosome 19q13 are associated with an autosomal dominant form of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/99,123\">",
"     99,123",
"    </a>",
"    ]. The mutant form of alpha-actinin-4 binds to actin more strongly than the wild type protein, suggesting that the disease might be due to an alteration in the actin cytoskeleton of the glomerular podocytes.",
"   </p>",
"   <p>",
"    FSGS resulting from mutations in the alpha-actinin-4 gene may be associated with unique ultrastructural features on kidney biopsy. In one study of five patients with alpha-actinin-4 mutations, electron-dense podocyte aggregates were observed in all kidney biopsies, while a segmental and irregular immunofluorescent pattern for alpha-actinin-4 was noted in the four biopsies available for staining [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/124\">",
"     124",
"    </a>",
"    ]. These observations were not found in the biopsies from patients with FSGS not due to an abnormal alpha-actinin-4 gene. Although intriguing, further study in a larger number of patients is required to better characterize these findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     TRPC6 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, chromosome 11 harbors a suspect genetic locus for FSGS, which is also the location for the gene for the canonical transient receptor potential 6 (TRPC6) ion channel. This receptor is expressed in podocytes and is a member of a family of calcium-permeable cation channels. TRPC6 also colocalizes to the slit diaphragm with nephrin, podocin, and CD2AP; in addition, alterations in TRPC6 calcium currents appear to underlie proper podocyte structure and function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These features pointed toward defects in the TRPC6 gene as a cause of familial FSGS. FSGS mutations have now been documented in individuals with both familial and non-familial FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/110,111,125\">",
"     110,111,125",
"    </a>",
"    ]. In a study of 71 families with FSGS, mutations in the TRPC6 gene segregated with FSGS in five families with autosomal dominant disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/110\">",
"     110",
"    </a>",
"    ]. Mutation analysis in 130 patients from 115 families identified TRPC6 mutations in two patients with clinically non-familial FSGS and one with familial disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     INF2 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations of the INF2 gene, which encodes a member of the formin family of actin-regulating proteins, were initially identified in two large families with autosomal dominant FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/126\">",
"     126",
"    </a>",
"    ]. Similar INF2 mutations were subsequently detected in nine additional probands with familial FSGS and shown to be present in affected family members (with biopsy-proven FSGS, end-stage renal disease (ESRD) or significant proteinuria without another cause); but not in control individuals who had no features of proteinuric kidney disease. In a subsequent study, INF2 mutations were identified in 28 of 78 patients (17 percent) with known autosomal dominant FSGS, but in only 1 of 84 patients with sporadic FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/127\">",
"     127",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon the phenotype of individuals with identified mutations, INF2-associated FSGS appears to present at a later age (adolescence or early adulthood) compared to FSGS caused by NPHS1 and NPHS2 mutations who typically present at a very early age. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'NPHS1 gene'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H27\">",
"     'NPHS2 gene'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1787233\">",
"    <span class=\"h2\">",
"     Myo1e gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;A recent study identified two mutations in the",
"    <em>",
"     Myo1e",
"    </em>",
"    gene, which are linked to a childhood-onset and glucocorticoid-resistant form of FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/128\">",
"     128",
"    </a>",
"    ]. Whole-genome linkage analysis was used to discover and sequence these mutations in 52 unrelated patients with FSGS. It was demonstrated that MYO1E is highly enriched in human podocytes, and the mutations A159P and Y695X were linked with decreased motile behavior of human podocytes and mislocalized expression of the MYO1E protein in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Other genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;CD2AP is a glomerular protein found at the slit diaphragm. Mutations in the gene for CD2AP have been described in two patients with primary FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/129\">",
"     129",
"    </a>",
"    ]. Two mutations in the gene MY01E, which encodes a nonmuscle class I myosin, myosin 1E, have been closely associated with autosomal recessive FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other genetic disorders are also associated with FSGS on kidney biopsy as well as other renal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extrarenal lesions. These include adult-onset cystinosis, nail-patella syndrome, Denys-Drash syndrome, Frasier syndrome, Charcot-Marie-Tooth disease, and glucose-6-phosphatase deficiency. These disorders are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/18/12584?source=see_link\">",
"     \"Cystinosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/59/1973?source=see_link\">",
"     \"Nail-patella syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/48/16136?source=see_link&amp;anchor=H21#H21\">",
"     \"Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)\", section on 'Renal disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/59/24506?source=see_link&amp;anchor=H4#H4\">",
"     \"Evaluation of the infant with ambiguous genitalia\", section on 'Genes involved in gonadal development'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1708984\">",
"    <span class=\"h2\">",
"     Distinguishing genetic from idiopathic FSGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distinguishing familial or genetic FSGS from idiopathic disease can be difficult, and familial disease may account for a significant proportion of patients with steroid-resistant FSGS, at least in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/105,106\">",
"     105,106",
"    </a>",
"    ]. Genetic disorders can lead to a wide range of clinical disease, ranging from minimal change disease to adult-onset FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Findings suggestive, but not diagnostic, of familial FSGS include a family history of FSGS and disease onset in infancy or early childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/104\">",
"     104",
"    </a>",
"    ]. Thus, a detailed family history is of paramount importance in the evaluation of such patients.",
"   </p>",
"   <p>",
"    Steroid resistance is a consistent finding that also may be seen in primary FSGS. Although steroid-resistant FSGS is due to familial disease in many children, its predictive value in adults is uncertain. In addition, some adults who have FSGS-associated mutations may respond to glucocorticoid therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/15/28922?source=see_link&amp;anchor=H22#H22\">",
"     \"Treatment of idiopathic nephrotic syndrome in children\", section on 'Steroid-resistant nephrotic syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Morphologic characteristics seen on kidney biopsy cannot usually distinguish genetic and non-genetic forms of primary FSGS. Exceptions include the distinctive features associated with NPHS1 and alpha-actinin-4 gene mutations. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'NPHS1 gene'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1498485774\">",
"     'Alpha-actinin-4 gene'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Genetic screening may identify patients who have familial disease. Among patients with congenital or infantile FSGS, genetic screening should be performed prior to initiating treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/36/7753?source=see_link&amp;anchor=H24#H24\">",
"     \"Congenital and infantile nephrotic syndrome\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9804961\">",
"    <span class=\"h1\">",
"     FSGS IN AFRICAN AMERICANS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative frequency of the different causes of nephrotic proteinuria varies with race, with the largest difference between blacks and whites being the frequency of focal segmental glomerulosclerosis (FSGS). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27130?source=see_link&amp;anchor=H49245340#H49245340\">",
"     \"Differential diagnosis and evaluation of glomerular disease\", section on 'Effect of race'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with nephrotic proteinuria, two studies from the United States found that blacks had a higher prevalence of FSGS than whites, an effect that may be increasing over time. The following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 358 adults who underwent renal biopsy for nephrotic syndrome between 1976 and 1979 and between 1995 and 1997, the frequency of FSGS as the cause was two to three times higher in black compared with white patients in both time periods and increased to a similar degree in both blacks and whites from the earlier to the later time period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/1\">",
"       1",
"      </a>",
"      ]. Between 1995 and 1997, FSGS accounted for more than 50 percent of cases of unexplained nephrotic syndrome in black adults and for more than 67 percent in black adults younger than 45 years. There were only seven cases of collapsing FSGS, making it unlikely that the increase in prevalence was due to HIV infection.",
"     </li>",
"     <li>",
"      In a report of 340 patients who underwent renal biopsy (mean age 43 years) for nephrotic proteinuria over a 20-year period from 1975 to 1994, FSGS accounted for 57 percent of cases in blacks and 23 percent in whites [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/6\">",
"       6",
"      </a>",
"      ]. Furthermore, the prevalence of FSGS in blacks increased significantly from 39 percent in 1975 to 1984 to 64 percent in 1985 to 1994. The distribution did not vary with gender or age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Blacks also account for the overwhelming majority of patients with HIV-associated FSGS (88 percent in a report from the United States Renal Data System [USRDS]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/130\">",
"     130",
"    </a>",
"    ]. In addition, black patients with this disorder have an increased incidence of a family history of end-stage renal disease. This was illustrated in a study that compared 201 black patients with HIV-associated collapsing FSGS with a control group of 50 HIV-infected black patients without renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/131\">",
"     131",
"    </a>",
"    ]. The patients with FSGS had a much higher percentage of first and second degree relatives with end-stage renal disease (ESRD) (24 versus 6 percent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/3/2104?source=see_link\">",
"     \"HIV-associated nephropathy (HIVAN)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2383433\">",
"    <span class=\"h2\">",
"     APOL1",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increased susceptibility of blacks to FSGS may be explained, at least in part, by genetic factors, although socioeconomic and environmental factors may also play a role. Polymorphisms in a region of chromosome 22, which are strongly linked with African ancestry, are highly associated with an increased risk of developing FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/132,133\">",
"     132,133",
"    </a>",
"    ]. The MYH9 gene that is located within this region encodes for kidney podocyte nonmuscle myosin IIA and contains multiple noncoding polymorphisms that were initially shown to be closely linked with both idiopathic and HIV-associated FSGS. The specific haplotype that confers the highest risk for FSGS is common in African-Americans but rare in European Americans (60 and 4 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/132,134\">",
"     132,134",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Variants in the apolipoprotein L1 (APOL1) gene, which resides in close proximity to MYH9 on chromosome 22, have since been shown to be even more closely associated with nondiabetic nephropathy in African Americans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/135,136\">",
"     135,136",
"    </a>",
"    ]. In fact, a strong linkage disequilibrium (in which multiple loci are non-randomly associated) exists in this chromosomal region, such that the MYH9 haplotype that was initially implicated in kidney disease may simply reflect APOL1 variation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/135\">",
"     135",
"    </a>",
"    ]. It is possible that other variants in MYH9, APOL1, or other genes in this region of chromosome 22 are involved in kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/137\">",
"     137",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Polymorphisms in APOL1 appear to be expressed exclusively in individuals of African descent and have not been identified in any individuals from Europe, Japan, or China [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/135\">",
"     135",
"    </a>",
"    ]. APOL1 polymorphisms are associated with FSGS in African Americans:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An analysis that compared African Americans with non-familial biopsy-proven FSGS to African Americans without FSGS identified two APOL1 variants that are expressed more frequently in patients with FSGS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/135\">",
"       135",
"      </a>",
"      ]. The association of APOL1 variants with renal disease was confirmed in a second larger cohort of African American patients with hypertension-associated end-stage kidney disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/135\">",
"       135",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      APOL1 genotypes were compared among 271 African American cases of FSGS, 168 European American cases of FSGS, and 939 control subjects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/138\">",
"       138",
"      </a>",
"      ]. APOL1 variants conferred a 17-fold higher odds (95% CI, 11-26) for FSGS and twenty-ninefold higher odds (95% CI, 13-68) for HIV-associated nephropathy (HIVAN). Individuals with two APOL1 risk alleles had an earlier age of onset and faster progression to ESRD but a similar sensitivity to steroids compared with other subjects. Positive selective forces likely underlie this linkage disequilibrium, suggesting that a biological advantage is conferred by the inheritance of these variants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/137\">",
"       137",
"      </a>",
"      ]. Although this hypothesis is speculative, in vitro studies suggest that the APOL1 gene variants that predispose to kidney disease may provide superior defense against a subspecies of Trypanosomes, which would provide a selective advantage to carriers of these variants against sleeping sickness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/135\">",
"       135",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13895?source=see_link&amp;anchor=H6#H6\">",
"       \"Epidemiology, pathogenesis, and prevention of African trypanosomiasis\", section on 'Innate immunity'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     HEROIN NEPHROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heroin abuse may be associated with focal segmental glomerulosclerosis (FSGS), including in patients who are HIV-negative. Disorders other than FSGS also can occur in heroin abusers, including secondary amyloidosis due to chronic suppurative subcutaneous infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/139\">",
"     139",
"    </a>",
"    ], membranous nephropathy due to hepatitis B virus infection, and membranoproliferative glomerulonephritis due to hepatitis C virus infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/140\">",
"     140",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Heroin-associated FSGS has a predilection for black patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/139,141\">",
"     139,141",
"    </a>",
"    ]. Slow progression to renal failure can occur, usually over a period of several years rather than several months as in HIV-induced disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/3/2104?source=see_link\">",
"     \"HIV-associated nephropathy (HIVAN)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis of heroin nephropathy is uncertain. It has been proposed that glomerular epithelial cell injury may be induced by an exogenous toxin given with the heroin. Compatible with this hypothesis is the observation that heroin nephropathy has largely disappeared in large urban centers at a time when the purity of street heroin has markedly increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/142\">",
"     142",
"    </a>",
"    ]. An alternate explanation is that drug abusers have become HIV-positive and either die earlier or develop HIV nephropathy, or that heroin nephropathy represented a variety of renal disorders that are now recognized to be associated with other conditions (eg, hepatitis C).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     OTHER CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal segmental glomerulosclerosis (FSGS) can be seen in a number of other disorders in which the pathogenesis is uncertain. Included in this group are chronic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    therapy and malignancy, particularly Hodgkin and non-Hodgkin lymphomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/6/41066/abstract/143,144\">",
"     143,144",
"    </a>",
"    ]. The course of the glomerular disease parallels that of the malignancy. A discussion of the association between malignancy and nephrotic syndrome is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/40/4744?source=see_link\">",
"     \"Overview of renal disease associated with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1230754994\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Focal segmental glomerulosclerosis (FSGS) is a histologic lesion, rather than a disease, that is commonly found to underlie the nephrotic syndrome in adults and children. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the United States, FSGS is one of the most common histologic lesions associated with the idiopathic nephrotic syndrome in adults, accounting for 35 percent of all cases and over 50 percent of cases among blacks. By comparison, FSGS is a less common cause of the nephrotic syndrome in many other countries. (See",
"      <a class=\"local\" href=\"#H5530119\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      One FSGS classification scheme is based upon the known",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      postulated causes of the renal disease (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Primary or idiopathic FSGS, which typically presents with the nephrotic syndrome.",
"     </li>",
"     <li>",
"      Secondary FSGS, which typically presents with non-nephrotic proteinuria and often renal insufficiency. This category most commonly refers to FSGS thought to represent an adaptive response to glomerular hypertrophy or hyperfiltration (eg, reduced renal mass) or a nonspecific pattern of scarring due to a previous injury.",
"     </li>",
"     <li>",
"      FSGS due to infections (particularly HIV), toxins (including heroin, interferon,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      ), genetic abnormalities, and renal atheroembolic disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28008182\">",
"    <span class=\"h2\">",
"     Primary FSGS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several morphologic variants of primary (idiopathic) FSGS observed with light microscopy have been defined (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Histologic variants'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Classic FSGS, also called FSGS NOS (",
"      <strong>",
"       n",
"      </strong>",
"      ot",
"      <strong>",
"       o",
"      </strong>",
"      therwise",
"      <strong>",
"       s",
"      </strong>",
"      pecified), is the most common form. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Classic FSGS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Collapsing variant, although some experts argue that this should not be considered an FSGS variant. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Collapsing variant'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tip variant. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Tip variant'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Perihilar variant. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Perihilar variant'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cellular variant. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Cellular variant'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prognostic and therapeutic decision-making value of these histologic variants of FSGS is unclear. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Prognostic relevance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the majority of patients with primary FSGS (and posttransplant FSGS), injury to glomerular cells may occur as a consequence of a circulating factor. Clinical observations support a key role for a circulating factor such as the soluble urokinase plasminogen activator receptor (suPAR). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with primary FSGS may present with acute or insidious onset of the nephrotic syndrome, as manifested by peripheral edema, hypoalbuminemia, and nephrotic range proteinuria. The frequency of various clinical features at either presentation or time of biopsy have included (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Clinical manifestations'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Nephrotic range proteinuria &ndash; 60 to 75 percent",
"     </li>",
"     <li>",
"      Microscopic hematuria with variable degrees of proteinuria &ndash; 30 to 50 percent",
"     </li>",
"     <li>",
"      Hypertension &ndash; 45 to 65 percent",
"     </li>",
"     <li>",
"      Renal insufficiency &ndash; 25 to 50 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28008192\">",
"    <span class=\"h2\">",
"     Secondary FSGS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In our view, the glomerulosclerosis of secondary FSGS usually results from an adaptive response to one or more of the following mechanisms (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Secondary FSGS'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Podocyte injury, which may be due to, among other causes, inflammation, angiotensin II, toxins, and viral infection. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Podocyte injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior nephron loss due, for example, to reflux nephropathy, ischemia in benign hypertensive nephrosclerosis, and congenital absence or surgical removal of a kidney. In these settings, compensatory intraglomerular hypertension and hypertrophy in the remaining glomeruli can, over a period of years, lead to FSGS. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Nephron loss'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary renal vasodilatation and glomerular hypertension as occurs in diabetic nephropathy, sickle cell anemia, familial autonomic insufficiency, type I glycogen storage disease, severe obesity, preeclampsia, anabolic steroid abuse, and treatment with interferon. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Renal vasodilatation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Healing of a prior inflammatory injury due, for example, to IgA nephropathy, small vessel vasculitis, or lupus nephritis. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Healing of prior inflammatory injury'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Differentiating primary and secondary FSGS clearly has important therapeutic implications. About 50 to 60 percent of patients with primary FSGS respond to immunosuppressive agents such as glucocorticoids, while secondary FSGS is best treated with modalities aimed at lowering the intraglomerular pressure, such as angiotensin inhibitors. This distinction can usually be made from the history (such as one of the disorders associated with secondary disease) and from the clinical and histologic findings at diagnosis (see",
"      <a class=\"local\" href=\"#H1498484543\">",
"       'Distinguishing between primary and secondary FSGS'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with secondary FSGS usually present with slowly increasing proteinuria and renal insufficiency over time; patients with primary FSGS typically present with the acute or subacute onset of the nephrotic syndrome. Primary FSGS is also associated with peripheral edema, hypoalbuminemia, and usually nephrotic range proteinuria. By comparison, the proteinuria in secondary FSGS is often non-nephrotic, and both low serum levels of albumin and edema are unusual even when protein excretion exceeds 3 to 4",
"      <span class=\"nowrap\">",
"       g/day.",
"      </span>",
"     </li>",
"     <li>",
"      The histologic findings are generally different in primary and secondary FSGS, although there is some overlap. Primary FSGS is associated with diffuse foot process fusion; in comparison, this abnormality tends to be focal in the secondary forms, being largely limited to the sclerotic areas.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6242925\">",
"    <span class=\"h2\">",
"     Genetic disease",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A number of genetic forms of FSGS have been described and may account for a significant proportion of patients with steroid-resistant disease. In some cases, the genetic forms of FSGS appear to be transmitted in an autosomal dominant pattern with variable penetrance, while autosomal recessive inheritance has been observed in other families. In general, the involved genes encode proteins that are integral for proper glomerular basement membrane formation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      glomerular podocyte differentiation and function. These include the gene(s) for NPHS1, NPHS2, alpha-actinin-4, the TRPC6 ion channel, CD2AP (which interacts at the slit diaphragm with both podocin and nephrin), and the formin family of actin-regulatory proteins. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Genetic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Commercial tests are available to detect NPHS1 and NPHS2 mutations, but not the alpha-actinin-4, TRPC6, or CD2AP genes. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Distinguishing familial or genetic FSGS from idiopathic disease can be difficult, and familial disease may account for a significant proportion of patients with steroid-resistant FSGS, at least in children. Findings suggestive, but not diagnostic, of familial FSGS include a family history of FSGS and disease onset in infancy or early childhood. Morphologic characteristics seen on kidney biopsy cannot usually distinguish genetic and non-genetic forms of primary FSGS; exceptions include the distinctive features associated with NPHS1 and alpha-actinin-4 gene mutations. Genetic screening may identify some patients who have familial disease. (See",
"      <a class=\"local\" href=\"#H1708984\">",
"       'Distinguishing genetic from idiopathic FSGS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The increased susceptibility of blacks to FSGS may be explained, at least in part, by genetic factors, although socioeconomic and environmental factors may also play a role. Variants in the apolipoprotein L1 (APOL1) gene have been shown to be closely associated with nondiabetic nephropathy in African Americans. Polymorphisms in APOL1 appear to be expressed exclusively in individuals of African descent and have not been identified in any individuals from Europe, Japan, or China. (See",
"      <a class=\"local\" href=\"#H2383433\">",
"       'APOL1'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/1\">",
"      Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 1997; 30:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/2\">",
"      Braden GL, Mulhern JG, O'Shea MH, et al. Changing incidence of glomerular diseases in adults. Am J Kidney Dis 2000; 35:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/3\">",
"      Kitiyakara C, Eggers P, Kopp JB. Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis 2004; 44:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/4\">",
"      Bahiense-Oliveira M, Saldanha LB, Mota EL, et al. Primary glomerular diseases in Brazil (1979-1999): is the frequency of focal and segmental glomerulosclerosis increasing? Clin Nephrol 2004; 61:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/5\">",
"      Filler G, Young E, Geier P, et al. Is there really an increase in non-minimal change nephrotic syndrome in children? Am J Kidney Dis 2003; 42:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/6\">",
"      Korbet SM, Genchi RM, Borok RZ, Schwartz MM. The racial prevalence of glomerular lesions in nephrotic adults. Am J Kidney Dis 1996; 27:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/7\">",
"      Rivera F, L&oacute;pez-G&oacute;mez JM, P&eacute;rez-Garc&iacute;a R, Spanish Registry of Glomerulonephritis. Clinicopathologic correlations of renal pathology in Spain. Kidney Int 2004; 66:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/8\">",
"      D'Agati V. Pathologic classification of focal segmental glomerulosclerosis. Semin Nephrol 2003; 23:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/9\">",
"      Meyrier A. Nephrotic focal segmental glomerulosclerosis in 2004: an update. Nephrol Dial Transplant 2004; 19:2437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/10\">",
"      Greenberg A, Bastacky SI, Iqbal A, et al. Focal segmental glomerulosclerosis associated with nephrotic syndrome in cholesterol atheroembolism: clinicopathological correlations. Am J Kidney Dis 1997; 29:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/11\">",
"      D'Agati VD, Kaskel FJ, Falk RJ. Focal segmental glomerulosclerosis. N Engl J Med 2011; 365:2398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/12\">",
"      D'Agati VD, Fogo AB, Bruijn JA, Jennette JC. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis 2004; 43:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/13\">",
"      Rennke HG, Klein PS. Pathogenesis and significance of nonprimary focal and segmental glomerulosclerosis. Am J Kidney Dis 1989; 13:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/14\">",
"      Fogo A, Glick AD, Horn SL, Horn RG. Is focal segmental glomerulosclerosis really focal? Distribution of lesions in adults and children. Kidney Int 1995; 47:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/15\">",
"      Beaman M, Howie AJ, Hardwicke J, et al. The glomerular tip lesion: a steroid responsive nephrotic syndrome. Clin Nephrol 1987; 27:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/16\">",
"      Haas M, Yousefzadeh N. Glomerular tip lesion in minimal change nephropathy: a study of autopsies before 1950. Am J Kidney Dis 2002; 39:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/17\">",
"      Stokes MB, Markowitz GS, Lin J, et al. Glomerular tip lesion: a distinct entity within the minimal change disease/focal segmental glomerulosclerosis spectrum. Kidney Int 2004; 65:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/18\">",
"      Thomas DB, Franceschini N, Hogan SL, et al. Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int 2006; 69:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/19\">",
"      Deegens JK, Assmann KJ, Steenbergen EJ, et al. Idiopathic focal segmental glomerulosclerosis: a favourable prognosis in untreated patients? Neth J Med 2005; 63:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/20\">",
"      Howie AJ, Pankhurst T, Sarioglu S, et al. Evolution of nephrotic-associated focal segmental glomerulosclerosis and relation to the glomerular tip lesion. Kidney Int 2005; 67:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/21\">",
"      Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 2004; 15:2169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/22\">",
"      Stokes MB, Valeri AM, Markowitz GS, D'Agati VD. Cellular focal segmental glomerulosclerosis: Clinical and pathologic features. Kidney Int 2006; 70:1783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/23\">",
"      Clement LC, Avila-Casado C, Mac&eacute; C, et al. Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat Med 2011; 17:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/24\">",
"      Siegel NJ, Gaudio KM, Krassner LS, et al. Steroid-dependent nephrotic syndrome in children: histopathology and relapses after cyclophosphamide treatment. Kidney Int 1981; 19:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/25\">",
"      Nash MA, Greifer I, Olbing H, et al. The significance of focal sclerotic lesions of glomeruli in children. J Pediatr 1976; 88:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/26\">",
"      Laurens WE, Vanrenterghem YF, Steels PS, Van Damme BJ. A new single nephron model of focal and segmental glomerulosclerosis in the Munich-Wistar rat. Kidney Int 1994; 45:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/27\">",
"      Rennke HG. How does glomerular epithelial cell injury contribute to progressive glomerular damage? Kidney Int Suppl 1994; 45:S58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/28\">",
"      Dijkman H, Smeets B, van der Laak J, et al. The parietal epithelial cell is crucially involved in human idiopathic focal segmental glomerulosclerosis. Kidney Int 2005; 68:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/29\">",
"      Wei C, M&ouml;ller CC, Altintas MM, et al. Modification of kidney barrier function by the urokinase receptor. Nat Med 2008; 14:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/30\">",
"      Wei C, Trachtman H, Li J, et al. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 2012; 23:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/31\">",
"      Kemper MJ, Wolf G, M&uuml;ller-Wiefel DE. Transmission of glomerular permeability factor from a mother to her child. N Engl J Med 2001; 344:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/32\">",
"      Kemper MJ, Wei C, Reiser J. Transmission of glomerular permeability factor soluble urokinase plasminogen activator receptor (suPAR) from a mother to child. Am J Kidney Dis 2013; 61:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/33\">",
"      Wei C, El Hindi S, Li J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011; 17:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/34\">",
"      Shankland SJ, Pollak MR. A suPAR circulating factor causes kidney disease. Nat Med 2011; 17:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/35\">",
"      Rydel JJ, Korbet SM, Borok RZ, Schwartz MM. Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am J Kidney Dis 1995; 25:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/36\">",
"      Cattran DC, Rao P. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 1998; 32:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/37\">",
"      Pokhariyal S, Gulati S, Prasad N, et al. Duration of optimal therapy for idiopathic focal segmental glomerulosclerosis. J Nephrol 2003; 16:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/38\">",
"      Crook ED, Habeeb D, Gowdy O, et al. Effects of steroids in focal segmental glomerulosclerosis in a predominantly African-American population. Am J Med Sci 2005; 330:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/39\">",
"      Cascio S, Paran S, Puri P. Associated urological anomalies in children with unilateral renal agenesis. J Urol 1999; 162:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/40\">",
"      Henegar JR, Bigler SA, Henegar LK, et al. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 2001; 12:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/41\">",
"      Wiggins JE, Goyal M, Sanden SK, et al. Podocyte hypertrophy, \"adaptation,\" and \"decompensation\" associated with glomerular enlargement and glomerulosclerosis in the aging rat: prevention by calorie restriction. J Am Soc Nephrol 2005; 16:2953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/42\">",
"      Kriz W, Gretz N, Lemley KV. Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 1998; 54:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/43\">",
"      Ding G, Reddy K, Kapasi AA, et al. Angiotensin II induces apoptosis in rat glomerular epithelial cells. Am J Physiol Renal Physiol 2002; 283:F173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/44\">",
"      Durvasula RV, Petermann AT, Hiromura K, et al. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 2004; 65:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/45\">",
"      Pagtalunan ME, Miller PL, Jumping-Eagle S, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/46\">",
"      Meyer TW, Bennett PH, Nelson RG. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria. Diabetologia 1999; 42:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/47\">",
"      Lemley KV, Lafayette RA, Safai M, et al. Podocytopenia and disease severity in IgA nephropathy. Kidney Int 2002; 61:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/48\">",
"      Wu DT, Bitzer M, Ju W, et al. TGF-beta concentration specifies differential signaling profiles of growth arrest/differentiation and apoptosis in podocytes. J Am Soc Nephrol 2005; 16:3211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/49\">",
"      Yang HC, Ma LJ, Ma J, Fogo AB. Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis. Kidney Int 2006; 69:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/50\">",
"      Peters I, Tossidou I, Achenbach J, et al. IGF-binding protein-3 modulates TGF-beta/BMP-signaling in glomerular podocytes. J Am Soc Nephrol 2006; 17:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/51\">",
"      Floege J, Alpers CE, Burns MW, et al. Glomerular cells, extracellular matrix accumulation, and the development of glomerulosclerosis in the remnant kidney model. Lab Invest 1992; 66:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/52\">",
"      Yaddanapudi S, Altintas MM, Kistler AD, et al. CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival. J Clin Invest 2011; 121:3965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/53\">",
"      Sever S, Altintas MM, Nankoe SR, et al. Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease. J Clin Invest 2007; 117:2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/54\">",
"      Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008; 14:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/55\">",
"      Abdi R, Dong VM, Rubel JR, et al. Correlation between glomerular size and long-term renal function in patients with substantial loss of renal mass. J Urol 2003; 170:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/56\">",
"      Novick AC, Gephardt G, Guz B, et al. Long-term follow-up after partial removal of a solitary kidney. N Engl J Med 1991; 325:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/57\">",
"      Narkun-Burgess DM, Nolan CR, Norman JE, et al. Forty-five year follow-up after uninephrectomy. Kidney Int 1993; 43:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/58\">",
"      Kasiske BL, Ma JZ, Louis TA, Swan SK. Long-term effects of reduced renal mass in humans. Kidney Int 1995; 48:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/59\">",
"      Atiyeh B, Husmann D, Baum M. Contralateral renal abnormalities in patients with renal agenesis and noncystic renal dysplasia. Pediatrics 1993; 91:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/60\">",
"      Argueso LR, Ritchey ML, Boyle ET Jr, et al. Prognosis of patients with unilateral renal agenesis. Pediatr Nephrol 1992; 6:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/61\">",
"      Chen YT, Coleman RA, Scheinman JI, et al. Renal disease in type I glycogen storage disease. N Engl J Med 1988; 318:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/62\">",
"      Wesson DE. The initiation and progression of sickle cell nephropathy. Kidney Int 2002; 61:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/63\">",
"      Kambham N, Markowitz GS, Valeri AM, et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/64\">",
"      Praga M, Hern&aacute;ndez E, Morales E, et al. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant 2001; 16:1790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/65\">",
"      Kasiske BL, Crosson JT. Renal disease in patients with massive obesity. Arch Intern Med 1986; 146:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/66\">",
"      Praga M, Hern&aacute;ndez E, Andr&eacute;s A, et al. Effects of body-weight loss and captopril treatment on proteinuria associated with obesity. Nephron 1995; 70:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/67\">",
"      Fletcher EC. Obstructive sleep apnea and the kidney. J Am Soc Nephrol 1993; 4:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/68\">",
"      Chen HM, Liu ZH, Zeng CH, et al. Podocyte lesions in patients with obesity-related glomerulopathy. Am J Kidney Dis 2006; 48:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/69\">",
"      Sklar AH, Chaudhary BA. Reversible proteinuria in obstructive sleep apnea syndrome. Arch Intern Med 1988; 148:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/70\">",
"      Wesson DE, Kurtzman NA, Frommer JP. Massive obesity and nephrotic proteinuria with a normal renal biopsy. Nephron 1985; 40:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/71\">",
"      Chen HM, Li SJ, Chen HP, et al. Obesity-related glomerulopathy in China: a case series of 90 patients. Am J Kidney Dis 2008; 52:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/72\">",
"      Chagnac A, Weinstein T, Herman M, et al. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 2003; 14:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/73\">",
"      Sharma K, Ramachandrarao S, Qiu G, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008; 118:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/74\">",
"      Serra A, Romero R, Lopez D, et al. Renal injury in the extremely obese patients with normal renal function. Kidney Int 2008; 73:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/75\">",
"      D'Agati VD, Markowitz GS. Supersized kidneys: Lessons from the preclinical obese kidney. Kidney Int 2008; 73:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/76\">",
"      Mathis BJ, Kim SH, Calabrese K, et al. A locus for inherited focal segmental glomerulosclerosis maps to chromosome 19q13. Kidney Int 1998; 53:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/77\">",
"      Casserly LF, Chow N, Ali S, et al. Proteinuria in obstructive sleep apnea. Kidney Int 2001; 60:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/78\">",
"      Morales E, Valero MA, Le&oacute;n M, et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003; 41:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/79\">",
"      Shen WW, Chen HM, Chen H, et al. Obesity-related glomerulopathy: body mass index and proteinuria. Clin J Am Soc Nephrol 2010; 5:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/80\">",
"      Nochy D, Heudes D, Glotz D, et al. Preeclampsia associated focal and segmental glomerulosclerosis and glomerular hypertrophy: a morphometric analysis. Clin Nephrol 1994; 42:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/81\">",
"      Nishimoto K, Shiiki H, Nishino T, et al. Glomerular hypertrophy in preeclamptic patients with focal segmental glomerulosclerosis. A morphometric analysis. Clin Nephrol 1999; 51:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/82\">",
"      Herlitz LC, Markowitz GS, Farris AB, et al. Development of focal segmental glomerulosclerosis after anabolic steroid abuse. J Am Soc Nephrol 2010; 21:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/83\">",
"      Dressler D, Wright JR, Houghton JB, Kalra PA. Another case of focal segmental glomerulosclerosis in an acutely uraemic patient following interferon therapy. Nephrol Dial Transplant 1999; 14:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/84\">",
"      Coroneos E, Petrusevska G, Varghese F, Truong LD. Focal segmental glomerulosclerosis with acute renal failure associated with alpha-interferon therapy. Am J Kidney Dis 1996; 28:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/85\">",
"      Tovar JL, Buti M, Segarra A, et al. De novo nephrotic syndrome following pegylated interferon alfa 2b/ribavirin therapy for chronic hepatitis C infection. Int Urol Nephrol 2008; 40:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/86\">",
"      Markowitz GS, Nasr SH, Stokes MB, D'Agati VD. Treatment with IFN-{alpha}, -{beta}, or -{gamma} is associated with collapsing focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2010; 5:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/87\">",
"      Yoshioka K, Takemura T, Murakami K, et al. Transforming growth factor-beta protein and mRNA in glomeruli in normal and diseased human kidneys. Lab Invest 1993; 68:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/88\">",
"      Sharma K, Ziyadeh FN. The emerging role of transforming growth factor-beta in kidney diseases. Am J Physiol 1994; 266:F829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/89\">",
"      Wang W, Koka V, Lan HY. Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology (Carlton) 2005; 10:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/90\">",
"      Hou CC, Wang W, Huang XR, et al. Ultrasound-microbubble-mediated gene transfer of inducible Smad7 blocks transforming growth factor-beta signaling and fibrosis in rat remnant kidney. Am J Pathol 2005; 166:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/91\">",
"      Huang Y, Border WA, Noble NA. Perspectives on blockade of TGFbeta overexpression. Kidney Int 2006; 69:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/92\">",
"      Border WA, Noble NA, Yamamoto T, et al. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 1992; 360:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/93\">",
"      Mizuno S, Kurosawa T, Matsumoto K, et al. Hepatocyte growth factor prevents renal fibrosis and dysfunction in a mouse model of chronic renal disease. J Clin Invest 1998; 101:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/94\">",
"      Praga M, Borstein B, Andres A, et al. Nephrotic proteinuria without hypoalbuminemia: clinical characteristics and response to angiotensin-converting enzyme inhibition. Am J Kidney Dis 1991; 17:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/95\">",
"      Praga M, Morales E, Herrero JC, et al. Absence of hypoalbuminemia despite massive proteinuria in focal segmental glomerulosclerosis secondary to hyperfiltration. Am J Kidney Dis 1999; 33:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/96\">",
"      Faubert PF, Porush JG. Familial focal segmental glomerulosclerosis: nine cases in four families and review of the literature. Am J Kidney Dis 1997; 30:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/97\">",
"      Conlon PJ, Lynn K, Winn MP, et al. Spectrum of disease in familial focal and segmental glomerulosclerosis. Kidney Int 1999; 56:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/98\">",
"      Winn MP, Conlon PJ, Lynn KL, et al. Linkage of a gene causing familial focal segmental glomerulosclerosis to chromosome 11 and further evidence of genetic heterogeneity. Genomics 1999; 58:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/99\">",
"      Kaplan JM, Kim SH, North KN, et al. Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 2000; 24:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/100\">",
"      Vats A, Nayak A, Ellis D, et al. Familial nephrotic syndrome: clinical spectrum and linkage to chromosome 19q13. Kidney Int 2000; 57:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/101\">",
"      Boute N, Gribouval O, Roselli S, et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 2000; 24:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/102\">",
"      Vats AN, Ishwad C, Vats KR, et al. Steroid-resistant nephrotic syndrome and congenital anomalies of kidneys: evidence of locus on chromosome 13q. Kidney Int 2003; 64:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/103\">",
"      Kitamura A, Tsukaguchi H, Iijima K, et al. Genetics and clinical features of 15 Asian families with steroid-resistant nephrotic syndrome. Nephrol Dial Transplant 2006; 21:3133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/104\">",
"      Pollak MR. The genetic basis of FSGS and steroid-resistant nephrosis. Semin Nephrol 2003; 23:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/105\">",
"      Caridi G, Bertelli R, Carrea A, et al. Prevalence, genetics, and clinical features of patients carrying podocin mutations in steroid-resistant nonfamilial focal segmental glomerulosclerosis. J Am Soc Nephrol 2001; 12:2742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/106\">",
"      Ruf RG, Lichtenberger A, Karle SM, et al. Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 2004; 15:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/107\">",
"      Tsukaguchi H, Yager H, Dawborn J, et al. A locus for adolescent and adult onset familial focal segmental glomerulosclerosis on chromosome 1q25-31. J Am Soc Nephrol 2000; 11:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/108\">",
"      Rana K, Isbel N, Buzza M, et al. Clinical, histopathologic, and genetic studies in nine families with focal segmental glomerulosclerosis. Am J Kidney Dis 2003; 41:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/109\">",
"      Prakash S, Chung KW, Sinha S, et al. Autosomal dominant progressive nephropathy with deafness: linkage to a new locus on chromosome 11q24. J Am Soc Nephrol 2003; 14:1794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/110\">",
"      Reiser J, Polu KR, M&ouml;ller CC, et al. TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet 2005; 37:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/111\">",
"      Winn MP, Conlon PJ, Lynn KL, et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 2005; 308:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/112\">",
"      Liu XL, Don&eacute; SC, Yan K, et al. Defective trafficking of nephrin missense mutants rescued by a chemical chaperone. J Am Soc Nephrol 2004; 15:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/113\">",
"      Nishibori Y, Liu L, Hosoyamada M, et al. Disease-causing missense mutations in NPHS2 gene alter normal nephrin trafficking to the plasma membrane. Kidney Int 2004; 66:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/114\">",
"      Philippe A, Nevo F, Esquivel EL, et al. Nephrin mutations can cause childhood-onset steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2008; 19:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/115\">",
"      Sant&iacute;n S, Garc&iacute;a-Maset R, Ru&iacute;z P, et al. Nephrin mutations cause childhood- and adult-onset focal segmental glomerulosclerosis. Kidney Int 2009; 76:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/116\">",
"      Fuchshuber A, Mehls O. Familial steroid-resistant nephrotic syndromes: recent advances. Nephrol Dial Transplant 2000; 15:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/117\">",
"      Tsukaguchi H, Sudhakar A, Le TC, et al. NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele. J Clin Invest 2002; 110:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/118\">",
"      Pereira AC, Pereira AB, Mota GF, et al. NPHS2 R229Q functional variant is associated with microalbuminuria in the general population. Kidney Int 2004; 65:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/119\">",
"      He N, Zahirieh A, Mei Y, et al. Recessive NPHS2 (Podocin) mutations are rare in adult-onset idiopathic focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007; 2:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/120\">",
"      McKenzie LM, Hendrickson SL, Briggs WA, et al. NPHS2 variation in sporadic focal segmental glomerulosclerosis. J Am Soc Nephrol 2007; 18:2987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/121\">",
"      Machuca E, Hummel A, Nevo F, et al. Clinical and epidemiological assessment of steroid-resistant nephrotic syndrome associated with the NPHS2 R229Q variant. Kidney Int 2009; 75:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/122\">",
"      Tonna SJ, Needham A, Polu K, et al. NPHS2 variation in focal and segmental glomerulosclerosis. BMC Nephrol 2008; 9:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/123\">",
"      Weins A, Kenlan P, Herbert S, et al. Mutational and Biological Analysis of alpha-actinin-4 in focal segmental glomerulosclerosis. J Am Soc Nephrol 2005; 16:3694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/124\">",
"      Henderson JM, Alexander MP, Pollak MR. Patients with ACTN4 mutations demonstrate distinctive features of glomerular injury. J Am Soc Nephrol 2009; 20:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/125\">",
"      Sant&iacute;n S, Ars E, Rossetti S, et al. TRPC6 mutational analysis in a large cohort of patients with focal segmental glomerulosclerosis. Nephrol Dial Transplant 2009; 24:3089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/126\">",
"      Brown EJ, Schl&ouml;ndorff JS, Becker DJ, et al. Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis. Nat Genet 2010; 42:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/127\">",
"      Boyer O, Benoit G, Gribouval O, et al. Mutations in INF2 are a major cause of autosomal dominant focal segmental glomerulosclerosis. J Am Soc Nephrol 2011; 22:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/128\">",
"      Mele C, Iatropoulos P, Donadelli R, et al. MYO1E mutations and childhood familial focal segmental glomerulosclerosis. N Engl J Med 2011; 365:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/129\">",
"      Kim JM, Wu H, Green G, et al. CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility. Science 2003; 300:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/130\">",
"      Abbott KC, Hypolite I, Welch PG, Agodoa LY. Human immunodeficiency virus/acquired immunodeficiency syndrome-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival in the pre highly active antiretroviral therapy era. J Nephrol 2001; 14:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/131\">",
"      Freedman BI, Soucie JM, Stone SM, Pegram S. Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy. Am J Kidney Dis 1999; 34:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/132\">",
"      Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008; 40:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/133\">",
"      Pollak MR. Kidney disease and African ancestry. Nat Genet 2008; 40:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/134\">",
"      Kao WH, Klag MJ, Meoni LA, et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008; 40:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/135\">",
"      Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/136\">",
"      Genovese G, Tonna SJ, Knob AU, et al. A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9. Kidney Int 2010; 78:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/137\">",
"      Freedman BI, Kopp JB, Langefeld CD, et al. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J Am Soc Nephrol 2010; 21:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/138\">",
"      Kopp JB, Nelson GW, Sampath K, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 2011; 22:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/139\">",
"      Cunningham EE, Zielezny MA, Venuto RC. Heroin-associated nephropathy. A nationwide problem. JAMA 1983; 250:2935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/140\">",
"      do Sameiro Faria M, Sampaio S, Faria V, Carvalho E. Nephropathy associated with heroin abuse in Caucasian patients. Nephrol Dial Transplant 2003; 18:2308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/141\">",
"      Dubrow A, Mittman N, Ghali V, Flamenbaum W. The changing spectrum of heroin-associated nephropathy. Am J Kidney Dis 1985; 5:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/142\">",
"      Friedman EA, Tao TK. Disappearance of uremia due to heroin-associated nephropathy. Am J Kidney Dis 1995; 25:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/143\">",
"      Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 15-1983. A 24-year-old man with cervical lymphadenopathy and the nephrotic syndrome. N Engl J Med 1983; 308:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/6/41066/abstract/144\">",
"      Rault R, Holley JL, Banner BF, el-Shahawy M. Glomerulonephritis and non-Hodgkin's lymphoma: a report of two cases and review of the literature. Am J Kidney Dis 1992; 20:84.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3049 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-202.43.93.2-77D3A94D3A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_6_41066=[""].join("\n");
var outline_f40_6_41066=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1230754994\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5530119\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HISTOLOGIC VARIANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Classic FSGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Collapsing variant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Tip variant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Perihilar variant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cellular variant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Prognostic relevance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PRIMARY FSGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H166292499\">",
"      - Soluble urokinase receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SECONDARY FSGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Podocyte injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Nephron loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Dose-dependence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Renal vasodilatation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Severe obesity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H306772923\">",
"      - Severe preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Anabolic steroid abuse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Treatment with interferon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Healing of prior inflammatory injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1498484543\">",
"      DISTINGUISHING BETWEEN PRIMARY AND SECONDARY FSGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H306776363\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H306776377\">",
"      Pathologic features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      GENETIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      NPHS1 gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      NPHS2 gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1498485774\">",
"      Alpha-actinin-4 gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      TRPC6 gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      INF2 gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1787233\">",
"      Myo1e gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Other genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1708984\">",
"      Distinguishing genetic from idiopathic FSGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9804961\">",
"      FSGS IN AFRICAN AMERICANS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2383433\">",
"      APOL1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      HEROIN NEPHROPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      OTHER CAUSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1230754994\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28008182\">",
"      Primary FSGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28008192\">",
"      Secondary FSGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6242925\">",
"      Genetic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3049\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3049|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/19/9530\" title=\"picture 1A\">",
"      Mild FGS Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/9/8346\" title=\"picture 1B\">",
"      Moderate FGS Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/40/14991\" title=\"picture 2\">",
"      FGS IF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/25/43416\" title=\"picture 3\">",
"      FGS EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/19/17721\" title=\"picture 4\">",
"      Light micrograph showing collapsing FGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/53/9050\" title=\"picture 5\">",
"      Early FGS Tip lesion Light",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/57/13206?source=related_link\">",
"      Antihypertensive therapy and progression of chronic kidney disease: Experimental studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9304?source=related_link\">",
"      Biology of glomerular podocytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/42/6824?source=related_link\">",
"      Clinical features, diagnosis, and treatment of hypertensive nephrosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/13/13528?source=related_link\">",
"      Clinical presentation, evaluation, and treatment of renal atheroemboli",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/31/43512?source=related_link\">",
"      Collapsing focal segmental glomerulosclerosis not associated with HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/36/7753?source=related_link\">",
"      Congenital and infantile nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/18/12584?source=related_link\">",
"      Cystinosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13895?source=related_link\">",
"      Epidemiology, pathogenesis, and prevention of African trypanosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34601?source=related_link\">",
"      Etiology, clinical features, and diagnosis of minimal change disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/59/24506?source=related_link\">",
"      Evaluation of the infant with ambiguous genitalia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/62/30697?source=related_link\">",
"      Evaluation of the living kidney donor and risk of donor nephrectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/59/33722?source=related_link\">",
"      Focal segmental glomerulosclerosis in the transplanted kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/48/16136?source=related_link\">",
"      Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/3/2104?source=related_link\">",
"      HIV-associated nephropathy (HIVAN)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/30/18921?source=related_link\">",
"      Mechanisms of immune injury of the glomerulus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/47/41717?source=related_link\">",
"      Minimal change variants: Mesangial proliferation; IgM nephropathy; C1q nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/59/1973?source=related_link\">",
"      Nail-patella syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/63/30714?source=related_link\">",
"      Overview of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/40/4744?source=related_link\">",
"      Overview of renal disease associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16296?source=related_link\">",
"      Prenatal diagnosis of renal agenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6202?source=related_link\">",
"      Renal manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/15/28922?source=related_link\">",
"      Treatment of idiopathic nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/9/31898?source=related_link\">",
"      Treatment of minimal change disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=related_link\">",
"      Treatment of primary focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_6_41067="Categories of CRS";
var content_f40_6_41067=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F53734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F53734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Types of chronic rhinosinusitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Features",
"       </td>",
"       <td class=\"subtitle1\">",
"        AFRS",
"       </td>",
"       <td class=\"subtitle1\">",
"        CRS with NP",
"       </td>",
"       <td class=\"subtitle1\">",
"        CRS without NP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bilateral nasal polyps",
"       </td>",
"       <td>",
"        <span class=\"red\" style=\"color: #019e30;\">",
"         Yes (in most cases)",
"        </span>",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         Yes: Required for diagnosis*",
"        </span>",
"       </td>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         No: Exclusion of polyps is required for diagnosis",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allergic mucin",
"       </td>",
"       <td>",
"        <span style=\"color: #019e30;\">",
"         Yes: Required for diagnosis",
"        </span>",
"       </td>",
"       <td>",
"        May be present",
"       </td>",
"       <td>",
"        <span class=\"green\" style=\"color: #000000;\">",
"         May be present",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aspirin-associated respiratory disease",
"       </td>",
"       <td>",
"        May be present",
"       </td>",
"       <td>",
"        <p>",
"         Asthma present in ~40 percent",
"        </p>",
"        <p>",
"         Aspirin intolerance and asthma present in ~15 percent",
"        </p>",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evidence of IgE-mediated allergy to fungi",
"       </td>",
"       <td>",
"        <span style=\"color: #019e30;\">",
"         Yes: Required for diagnosis",
"        </span>",
"       </td>",
"       <td>",
"        May be present",
"       </td>",
"       <td>",
"        <span class=\"green\" style=\"color: #000000;\">",
"         May be present",
"        </span>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CRS: chronic rhinosinusitis; NP: nasal polyposis.",
"     <br>",
"      * Medical records documenting removal of bilateral NP during surgery would satisfy this requirement.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_6_41067=[""].join("\n");
var outline_f40_6_41067=null;
var title_f40_6_41068="Maternal opioid withdrawal symptoms";
var content_f40_6_41068=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Maternal opioid withdrawal symptoms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Opioid withdrawal signs and symptoms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Mild withdrawal signs and symptoms include",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Generalized anxiety, irritability",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Opioid craving",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Restlessness",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Slight aching of muscles, joints, and bones",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Lower back pain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Mild to moderate withdrawal signs and symptoms include",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Tension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Restless sleep",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Mydriasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Lethargy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Diaphoresis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Moderate withdrawal signs and symptoms include",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Chills alternating with flushing and diaphoresis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Nausea and/or stomach cramps",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Rhinorrhea",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Moderate aching of muscles, joints, and bones",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Lower back pain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Anorexia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Yawning",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Lacrimation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Goose flesh (earlier if client is in a cold, drafty room)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Elevated pulse and blood pressure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Moderate to severe withdrawal signs and symptoms include",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Diarrhea",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Vomiting",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Tremors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Tachycardia (pulse over 100 beats per minute)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Increased respiratory rate and depth",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Severe withdrawal signs and symptoms include",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Doubling over with stomach cramps",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Kicking movements",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Elevated temperature (usually low grade, less than 100&deg;F)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: Withdrawal signs and symptoms differ in their order of appearance from one individual to another. Some individuals may not exhibit certain withdrawal signs and symptoms. Signs may also include uterine irritability, increased fetal activity, or rarely, hypotension.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Alcohol and Other Drug Treatment Guidelines for Pregnant, Substance Using Women. In: Treatment Improvement Protocol Series 2: Pregnant, Substance-Using Women, Mitchell, JL (Ed), 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_6_41068=[""].join("\n");
var outline_f40_6_41068=null;
var title_f40_6_41069="Sensitivity analysis thrombolys";
var content_f40_6_41069=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    One-way sensitivity analysis (example for decision analysis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 408px; height: 355px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    One-way sensitivity analysis of the probability of a complication from thrombolytic therapy. As the likelihood of a complication (x-axis) rises, the expected value of the thrombolysis strategy declines. The point at which the probability of survival is equivalent between the two strategies is called the threshold.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Krumholz HM, Pasternak RC, Weinstein MC, et al. N Engl J Med 1992; 327:7.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_6_41069=[""].join("\n");
var outline_f40_6_41069=null;
var title_f40_6_41070="Kopliks spots in measles";
var content_f40_6_41070=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Koplik's spots",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 319px; height: 234px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Koplik's spots, seen as whitish elevations on an erythematous background opposite the molars (arrows), are pathognomic of measles.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright Dr. Michael Bennish; reproduced with his permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_6_41070=[""].join("\n");
var outline_f40_6_41070=null;
var title_f40_6_41071="Breaking adhesions circumcision";
var content_f40_6_41071=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Breaking up adhesions between foreskin and glans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David G Weismiller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_6_41071=[""].join("\n");
var outline_f40_6_41071=null;
